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ABSTRACT 
 
 The analysis of the rapid molecular evolution of enzymes provides insights into 
the remarkable adaptability of these sophisticated macromolecules and helps to 
elucidate the relationship between protein sequence, structure and function.  
	   A prominent example for rapid molecular evolution in response to changing 
environmental conditions is the	   phosphotriesterase from Pseudomonas diminuta 
(PTE), which hydrolyzes with remarkably catalytic efficiency synthetic 
organophosphates (OPs). Since OPs were invented only in the last century as 
agricultural insecticides and highly toxic chemical warfare agents, PTE is a relatively 
“young” enzyme. It has been postulated that it has evolved from members of the 
phosphotriesterase-like lactonase (PLL) family that show promiscuous 
organophosphate degrading activity. The goal of this thesis was to mimic this 
postulated evolutionary pathway from PLL to PTE in the laboratory by establishing 
OP hydrolysis activity on the scaffold of Dr0930, a PLL from the organism 
Deinococcus radiodurans R1. Dr0930 and PTE have a similar (βα)8-barrel fold and 
share crucial active site features including two catalytically essential bivalent metal 
ions.  
 In the first part of the thesis, steady-state kinetic parameters for D. radiodurans 
R1 Dr0930 were determined for the hydrolysis of δ-nonanoic lactone as well as the 
promiscuous hydrolysis of the OP insecticides methyl-paraoxon (MPXN) and ethyl-
paraoxon (EPXN) and the racemic p-nitrophenol (p-NP) analogues of OP nerve 
agents VX, sarin (GB), VR, soman (GD), and cyclosarin (GF). The promiscuous 
catalytic efficiencies for wild-type Co/Co-Dr0930 range from 2.1 M-1s-1 to        
6.1 × 102 M-1s-1 and are four (GD p-NP) to seven (GB p-NP and EPXN) orders of 
magnitude lowered when compared to wild-type Co/Co-PTE. Mutually, promiscuous 
activity of wild-type PTE for the hydrolysis of δ-nonanoic lactone was found to occur 
with a kcat/KM of 6.8 × 101 M-1s-1. 
 The low promiscuous OP degrading activity of wild-type Dr0930 was increased by 
an iterative process comprising several steps of rational protein design and random 
mutagenesis in combination with in vitro screening for the hydrolysis of EPXN and six 
additional tested OP compounds. Beneficial mutations identified in the different steps 
were successively combined, yielding the variant Dr0930_134. Dr0930_134 contains 
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seven amino acid exchanges (Y28L+D71N+Y97F+E101G+E179D+V235L+P274L) 
and its OP hydrolysis activity for GB p-NP, VR p-NP, and GF p-NP is elevated by 
four orders of magnitude compared to wild-type Dr0930. The catalytic efficiencies 
achieve absolute values of up to 105 M-1s-1. Most remarkably, Dr0930_134 shows a 
kcat/KM value of 104 M-1s-1 for the hydrolysis of GD p-NP, which comes close to the 
catalytic efficiency of wild-type PTE for this substrate. 
 The engineered Dr0930 variants were characterized for their residual native 
lactonase activities, the stereoselectivity of OP hydrolysis, and the ability to hydrolyze 
P-S in addition to P-O bonds. The results showed that the substantial increase in 
promiscuous OP hydrolysis activity is accompanied by an equally strong decrease of 
the native activity, with Dr0930_134 still achieving a catalytic efficiency of 
2.8 × 103 M-1s-1 for the hydrolysis of δ-nonanoic lactone. The increased OP 
hydrolysis activity of Dr0930_134 compared to wild-type Dr0930 comes along with an 
enhanced stereoselectivity for the less toxic RP enantiomers of the chiral OP 
substrates. The shift in the enantiomeric preference [ratio kcat/KM (RP) / kcat/KM (SP)] 
was as high as 4.3 × 102 in the case of VR p-NP. The highest enantiomeric 
preference of 1.5 × 104-fold was observed for GB p-NP. The engineered Dr0930 
variants were tested for their ability to hydrolyze the phosphorothiolate DEVX 
(Diethyl-VX), a close analogue of the nerve agent VX. In spite of their high catalytic 
efficiency for the hydrolysis of P-O bonds, the kcat/KM values for the hydrolysis of the 
P-S bond of DEVX were only 1 M-1s-1. 
 Structural and computational analysis was performed to identify the structural 
basis for the enhanced OP hydrolysis activities of the engineered Dr0930 variants. 
Three variants including Dr0930_134 were crystallized, and their X-ray structures 
were solved to a resolution of 1.8 - 2.1 Å. The variants exhibited only minor structural 
differences relative to wild-type Dr0930. The active site was enlarged and its 
hydrophobic character was increased, providing more space to accommodate the OP 
substrates. Moreover, additional flexibility was gained due to the elimination of a 
hydrogen bond between residues of the βα-loops 2 and 3. In order to identify the 
orientation of EPXN at the active site Dr0930_134, the substrate was docked using 
the RosettaLigand program. The best poses obtained were similar to the pose of 
EPXN when docked into the active site of P. diminuta PTE and confirm site-directed 
mutagenesis experiments that have indicated an important role of residues F26 and 
R228 for OP hydrolysis activity by Dr0930_134. 
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 Taken together, the results of this thesis show that laboratory evolution can 
readily establish high OP hydrolysis on the scaffold of Dr0930, providing strong 
evidence for the postulated natural evolution of PTE from members of the PLL family.  
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ZUSAMMENFASSUNG 
 
 Die Analyse der schnellen molekularen Evolution von Enzymen eröffnet Einblicke 
in die bemerkenswerte Anpassungsfähigkeit dieser komplexen Makromoleküle und 
trägt somit zum Verständnis der Beziehung zwischen Proteinsequenz, Struktur und 
Funktion bei. 
 Ein bekanntes Beispiel für schnelle molekulare Evolution in Anpassung an sich 
schnell verändernde Umweltbedingungen ist die Phosphotriesterase aus 
Pseudomonas diminuta (PTE), welche mit einer bemerkenswerten katalytischen 
Effizienz synthetische Organophosphate (OP) hydrolysiert. Da diese Verbindungen 
erstmals im letzten Jahrhundert als landwirtschaftliche Insektizide und hochgiftige 
chemische Kampfstoffe synthetisiert wurden, vermutet man an, dass PTE ein 
evolutionär relativ “junges“ Enzym ist. Es wird angenommen, dass sich die PTE aus 
der Familie der Phosphotriesterase-ähnlichen Lactonasen (PLL) entwickelt hat, 
welche promiskuitive OP hydrolytische Aktivität zeigt. Das Ziel dieser Arbeit war es, 
den postulierten Weg der natürlichen Evolution von PLL zu PTE im Labor 
nachzuvollziehen. Dazu sollte OP-Hydrolaseaktivität auf dem Proteingerüst von 
Dr0930, einer PLL aus dem Organismus Deinococcus radiodurans R1, etabliert 
werden. Dr0930 und PTE haben eine ähnliche (βα)8-Barrel Faltung und besitzen 
Gemeinsamkeiten im Bereich des aktiven Zentrums einschließlich zweier katalytisch 
essentieller zweiwertiger Metallionen. 
 Im ersten Teil dieser Arbeit wurden die enzymkinetischen Parameter von Dr0930 
aus D. radiodurans R1 für die Hydrolyse von δ-Nonalacton bestimmt. Darüber hinaus 
wurde die promiskuitive Hydrolyseaktivität von Dr0930 für die OP-Insektizide Methyl-
Paraoxon (MPXN) und Ethyl-Paraoxon (EPXN) sowie für die racemischen p-
Nitrophenol (p-NP) Analoga der OP-Nervenkampfstoffe VX, Sarin (GB), VR, Soman 
(GD) und Cyclosarin (GF) gemessen. Die katalytischen Effizienzen für das 
wildtypische Co/Co-Dr0930 Protein liegen im Bereich zwischen 2,1 M-1s-1 und 
6,1 × 102 M-1s-1. Damit sind sie um vier (GD p-NP) bis sieben (GB p-NP und EPXN) 
Größenordnungen niedriger als die katalytischen Effizienzen von wildtypischem 
Co/Co-PTE. Umgekehrt zeigt wildtypisches PTE promiskuitive Aktivität für die 
Hydrolyse von δ-Nonalacton mit einem kcat/KM von 6.8 × 101 M-1s-1. 
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 Die schwache promiskuitive OP-Hydrolyseaktivität von Dr0930 wurde in einem 
iterativen Prozess schrittweise gesteigert, wobei sowohl rationales Design als auch 
eine Kombination aus Zufallsmutagenese und in vitro Aktivitätsscreening verwendet 
wurden. Dabei wurde die Fähigkeit der erzeugten Mutanten zur Hydrolyse von EPXN 
und sechs weiterer OP-Verbindungen getestet. Die in den einzelnen Schritten 
identifizierten vorteilhaften Mutationen wurden in der Variante Dr0930_134 
kombiniert. Diese enthält 7 Austausche (Y28L+D71N+Y97F+E101G+E179D+V235L 
+P274L), die im Vergleich zum wildtypischen Dr0930 zu einer Erhöhung der OP-
hydrolytischen Aktivität für GB p-NP, VR p-NP und GF p-NP um vier 
Größenordnungen führen. Die Absolutwerte für die katalytischen Effizienzen 
erreichen Werte von bis zu 105 M-1s-1. Die Hydrolyse von GD p-NP durch 
Dr0930_134 erfolgt mit einem kcat/KM Wert von 104 M-1s-1, was im Bereich der 
katalytischen Effizienz von wildtypischem PTE für dieses Substrat liegt. 
 Die evolvierten Dr0930 Varianten wurden anschließend hinsichtlich ihrer nativen 
Lactonaseaktivität und bezüglich der Stereoselektivität der OP-Hydrolyse 
charakterisiert. Des Weiteren wurde ihre Fähigkeit überprüft, neben P-O Bindungen 
auch P-S Bindungen zu hydrolysieren. Die Ergebnisse zeigen, dass die beachtliche 
Verbesserung der promiskuitiven OP-Hydrolyseaktivität von einem vergleichbar 
starken Verlust der nativen Aktivität begleitet wird. Dennoch erreicht Dr0930_134 
immer noch eine katalytische Effizienz von 2.8 × 103 M-1s-1 für die Hydrolyse von δ-
Nonalacton. Die verbesserte OP-Hydrolyseaktivität von Dr0930_134 geht einher mit 
einer gesteigerten Stereoselektivität für das weniger giftige RP-Enantiomer der 
chiralen OP-Substrate. Die Verschiebung der enantiomeren Präferenz [Verhältnis 
kcat/KM (RP) / kcat/KM (SP)] lag für VR p-NP im Bereich von 4.3 × 102. Die höchste 
absolute enantiomere Präferenz beträgt 1.5 × 104 und wird für GB p-NP beobachtet. 
Die evolvierten Dr0930 Varianten wurden ebenfalls hinsichtlich der Fähigkeit zur 
Hydrolyse von Phosphorothiolat DEVX (Diethyl-VX), einem Analogon des 
Nervengases VX, getestet. Trotz der effizienten Hydrolyse von P-O Bindungen, lag 
der kcat/KM-Wert für die Hydrolyse der P-S Bindung von DEVX bei nur etwa 1 M-1s-1. 
 Zur Erklärung der hohen OP-Hydrolyseaktivität der evolvierten Dr0930 Varianten 
wurden Strukturanalysen und Dockingstudien mit Liganden durchgeführt. Drei 
Dr0930 Varianten, einschließlich Dr0930_134, wurden kristallisiert und die 
Röntgenstrukturen wurden mit einer Auflösung von 1,8 - 2,1 Å aufgeklärt. Die 
Varianten zeigen nur kleine strukturelle Änderungen im Vergleich zum wildtypischen 
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Dr0930 Protein. Das aktive Zentrum der Varianten wurde durch die Austausche 
etwas vergrößert und der hydrophobe Charakter gesteigert, wodurch mehr Platz und 
eine günstigere Umgebung für die Bindung der OP-Substrate geschaffen wurden. 
Darüber hinaus wurde zusätzliche Flexibilität durch die Eliminierung einer 
Wasserstoffbrückenbindung zwischen Resten der βα-loops 2 und 3 gewonnen. Um 
die Orientierung von EPXN im aktiven Zentrum von Dr0930_134 zu identifizieren, 
wurde das Substrat mit Hilfe des RosettaLigand Programms in das aktive Zentrum 
modelliert. Die besten Posen waren ähnlich zu den EPXN-Posen, die beim Docking 
von EPXN in das aktive Zentrum der PTE erhalten wurden. Zudem erklären die 
Ergebnisse die wichtige Rolle der Reste F26 und R228 für die OP-Hydrolyse,   
welche auf der Basis von gerichteter Mutagenese postuliert  wurde. 
 Zusammengefasst zeigen die Ergebnisse dieser Arbeit, dass es durch Evolution 
im Labor möglich ist, hohe OP-Hydrolyseaktivität auf dem Gerüst von Dr0930 zu 
etablieren, was einen starken Hinweis auf die postulierte natürliche Evolution von 
PTE aus Mitgliedern der PLL Familie liefert. 
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1 INTRODUCTION 
 
1.1 Enzyme promiscuity 
 Enzymes are exceptional catalysts that facilitate a wide variety of reactions under 
mild conditions, achieving high rate enhancements with excellent chemo-, regio- and 
stereoselectivities (Seelig & Szostak, 2007). The structural and functional diversity of 
enzymes has been generated by molecular evolution over billions of years (Todd et 
al., 2001). Three mechanisms of molecular evolution have been described by which 
the slow step of ab initio gene creation can be circumvented: Horizontal gene transfer 
(HGT), gene duplication, and gene recombination (Jain et al., 2003; Chothia et al., 
2003). In the past decades several examples of rapid and efficient molecular 
evolution of new enzymatic functions have been revealed that provide enzymes 
which degrade synthetic chemicals introduced to the biosystem during the last 
decades (Copley, 2009; Raushel & Holden, 2000; Janssen et al., 2005; Shapir et al., 
2007), enzymes associated with drug resistance (Hall, 2004; Wang et al., 2002; 
Weinreich et al., 2006), and enzymes in plant secondary metabolism (O’Maille et al., 
2008; Austin et al., 2008; Field & Osbourn, 2008; Khersonsky & Tawfik, 2010). It is 
plausible to assume that the recruitment of existing metabolic capabilities is 
responsible for such phenomena (Ochman et al., 2000; Jain et al., 2003; Chothia et 
al., 2003).  
 For example, promiscuous activities (weak secondary or side activities) serve as 
evolutionary starting points for the divergence of new functions, and broad-specificity 
enzymes served as progenitors for todays specialized enzymes (Jensen, 1976). Two 
cases of promiscuity can be distinguished: catalytic promiscuity and substrate 
ambiguity (Patrick & Matsumura, 2008; O’Brien & Herschlag, 1999; Khersonsky et 
al., 2011). For most cases, divergence of new enzyme functions is driven by 
substrate ambiguity, as key catalytic residues and reaction intermediates of transition 
states tend to be conserved throughout enzyme families and even highly diverse 
superfamilies (Gerlt & Babbitt, 1998). Mechanistically, promiscuity is often enabled by 
conformational flexibility as conformational changes enable the same enzyme to 
accommodate different substrates. In particular, the mobility of active site loops 
appears to play a key role in mediating promiscuity (Khersonsky & Tawfik, 2010; 
Khersonsky et al., 2006). To investigate rapid, adaptive molecular evolution of 
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homologous enzymes in the context of promiscuous activities, organophosphate 
hydrolyzing enzymes are studied in this work. 
 
1.2 Organophosphate compounds and organophosphate 
hydrolases (OPH)  
1.2.1 Organophosphate compounds 
 Organophosphates (OPs) are among the most toxic compounds that have been 
chemically synthesized. Since the discovery of their biological activity in the 1930s, 
these compounds have been widely used as broad-spectrum insecticides for 
agricultural and domestic applications (Raushel, 2011). Moreover, OPs have been 
developed as chemical warfare agents (CWAs) for military use (Munro et al., 1994). 
OPs are a large class of compounds with widely varied chemical structure. 
Organophosphate insecticides are primarily phosphotriesters, thiophosphotriesters, 
and phosphorothiolesters. OP nerve agents are chiral phosphonate compounds 
containing a direct P-C bond. The most noted types are the G-type (GA, GB, GD, 
GF) and V-type (VX, VR) nerve agents. G-type nerve agents contain either a cyanide 
leaving group (GA) or a fluoride leaving group (GB, GD, GF). V-type nerve agents 
exhibit a branched thiolate (N,N-dialkylaminoethylthiolate) leaving group, and are 
more toxic and persistent than G-type agents (Raushel, 2002; Bigley & Raushel, 
2012; Munro et al., 1994). 
 
 
Figure 1: Structures of organophosphate compounds. 
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A: General structure of OP compounds. X = oxygen, sulfur; Z = halogen, aliphatic, aromatic or 
heterocyclic substituents; R/R’ = ester linkage to an alkoxy or amino group. 
B: Organophosphate nerve agents: tabun (GA, O-ethyl-(N,N-dimethyl) phosphoroamidocyanidate), 
sarin (GB, O-isopropyl methylphosphonofluoridate), soman (GD; O-pinacolyl methyl-
phosphonofluoridate), cyclosarin (GF, O-cyclohexyl methylphosphonofluoridate), VX (O-ethyl-S-(2-
diisopropyl-aminoethyl) methylphosphonothiolate) and VR (O-isobutyl-S-(2-diethylaminoethyl) methyl-
phosphonothiolate).  
C: Common examples for OP insecticides. Ethyl-paraoxon (EPXN) and dichlorvos are 
phosphotriesters. Chlorpyrifos, parathion, and diazinon are thiophosphotriester. Malathion and 
phosmet are phosphorotiolates. Numerous insecticides, such as malathion and phosmet, contain both 
a thiophosphate and thiol-ester linkage. Lethal dosage values (LD50) were taken from Sigma-Aldrich 
MSDS (date: 1. April, 2012) and refer to oral intake in rats. 
 
 OPs are highly toxic because they rapidly inactivate the acetylcholinesterase 
(AChE), a key enzyme of the nervous system. AChE hydrolyzes the neurotransmitter 
acetylcholine at neural synapses that relays nerve pulses to mucles and other organs 
(Raushel, 2002). OPs react with AChE, resulting in an inactive enzyme with the 
nucleophilic serine residue in the active site being phosphorylated/phosphonylated. 
The subsequent build-up of acetylcholine blocks cholinegic nerve pulses, results in 
paralysis, suffocation and ultimately death (Raushel, 2011). Acute toxicity of OP 
nerve agents is three to four orders of magnitude greater than most of the chemically 
similar OP pesticides, with VX being the most potent nerve agent (Munro et al., 
1994). Moreover, chiral OP compounds differ greatly in their acute toxicity, with the 
depending on substituents and stereochemistry of the phosphorus center. The SP 
isomers of GB, GD, and GF inhibit the AChE >1000-fold faster than their respective 
RP isomers and can be >100-fold more toxic in vivo (Benschop & Dejong, 1988). 
Treatment with anti-cholinergic drugs is used to counteract acute OP-intoxication. 
Atropine, a competitive antagonist for muscarinic acetylcholine receptors, blocks the 
action of acetylcholine and thereby reduces the effective concentration of the 
neurotransmitter. It is used as an antidote, often in combination with oxime AChE 
reactivators such as pralidoxime. An alternative treatment is the human 
butyrylcholinesterase (BChE), which functions as stoichiometric catalytic scavenger 
for the nerve agents, as it reacts with OP in the same way as AChE (Raushel, 2011). 
 OP compounds are relatively easy to synthesize from readily available industrial 
chemicals; hence their use by international terrorist is a serious threat (Raushel, 
2011; Munro et al., 1994). Concerns over the health and environmental impact of 
OPs and their potential use for bioremediation lead to numerous efforts to identify 
enzymes capable of detoxifying them (Bigley & Raushel, 2010). 
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1.2.2 Organophosphate hydrolases (OPH) 
 Organophosphate hydrolyzing enzymes have been identified in archaea, bacteria 
and eukarya (Porzio et al., 2007; Tsai et al., 2010a). Common representatives of 
OPH enzymes are the bacterial phosphotriesterase (PTE), methyl parathion 
hydrolase (MPH), organophosphorus acid anhydrolase (OPAA), diisopropyl-
fluorophosphatase (DFPase), and paraoxonase 1 (PON1). These enzymes are 
metal-dependent hydrolases that contain a hydrophobic active site. Except for 
DFPase and PON1, that contain – besides a structural important metal – one single 
catalytic metal ion, OPH enzymes contain a binuclear metal center. In any case the 
divalent metal(s) coordinate the substrate for catalysis and activate the phosphorus 
center. The mechanistic details of hydrolysis differ among OPH enzymes with both 
direct attack of the nucleophilic hydroxide as well as covalent catalysis being 
observed, as in the case of DFPase and PON1. OPH enzymes differ widely in protein 
sequence and three-dimensional structure. OPH adopt numerous folds: TIM-barrel 
fold (PTE), β-lactamase fold (MPH), pita bread fold (OPAA) and β-propeller fold 
(DFPase and PON1) (Bigley & Raushel, 2012; see Figure 2 for illustration). Their 
substrate profile for the hydrolysis of OPs varies significantly. Moreover, most OPH 
enzymes catalyze various other reactions, such as the hydrolysis of esters, lactones 
and dipeptides. Bacterial PTE is most efficient for the hydrolysis of a broad range of 
phosphotriesters (Dumas et al., 1989), and promiscuous esterase activity has been 
reported (Roodveldt & Tawfik, 2005a; Afriat et al., 2006). Pseudomonas sp. WBC-3 
MPH hydrolyzes the insecticide methyl-parathion (Dong et al., 2005). OPAA from 
Alteromonas sp. JD6.5, a bacterial prolidase (X-Pro), efficiently hydrolyzes G-type 
nerve agents (DeFrank & Cheng, 1991; Cheng et al., 1997; Vyas et al., 2010). Logio 
vulgaris DFPase, of which the native activity remains unclear, hydrolyzes the fluoride 
containing diisopropylfluorophosphat (DFP), as well as the G-type nerve agents 
(Hartleib & Rüterjans, 2001; Blum et al., 2006). The mammalian serum PON1, a 
native lactonase, exhibits broad substrate specificity, hydrolyzing various γ- and δ-
lactones, aryl-esters, and a broad variety of OPs (Khersonsky & Tawfik, 2005). PON1 
is thought to function as a lactonase by inactivating toxic byproducts of lipid oxidation 
as part of the high-density lipoprotein (HDL) (Camps et al., 2009). 
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Figure 2: Three-dimensional structure of selected OPH enzymes: PTE, MPH, OPAA, and PON1. 
The α-helices are depicted in beige, β-strands in blue, and loops in grey. Catalytic important metal 
ions are depicted in green, structurally important metal ions in dark grey. 
A: Bacterial phosphotriesterase (PTE) adopts a TIM-barrel fold (PDB ID 1EZ2). B: Methyl parathion 
hydrolase (MPH) adopts a αβ/βα sandwich typical of the lactamase fold (PDB ID 1P9E). C: 
Organophosphorus acid anhydrolase comprises a pita bread C-terminal domain (OPAA) (PDB ID 
3L7G). D: Paraoxonase 1 (PON1) adopts a 6-bladed β-propeller fold containing one catalytic and one 
structural important calcium ion (PDB ID 1V04).  
 
 The organophosphate hydrolyzing enzyme PTE from Pseudomonas diminuta and 
enzymes homologous to PTE, adopting a (βα)8-barrel fold, are studied in this work. 
 
1.3 The (βα)8-barrel-fold 
 The (βα)8-barrel structure was first found in the triosephosphate isomerase (TIM) 
from Gallus gallus (Banner et al., 1975), and is therefore also known as TIM-barrel. 
The (βα)8-barrel fold is the most common enzyme fold: about 10% of all proteins with 
known three-dimensional structure contain at least one TIM-barrel domain 
(Sterner & Höcker, 2005). The current SCOP-database (Structural Classification of 
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Proteins, Version 1.75, latest update June 2009, Murzin et al., 1995) lists 33 
homologous superfamilies with this topology. With few notable exceptions, such as 
the storage proteins narbonin (Henning et al., 1992, 1995) and concavalin B 
(Henning et al., 1995), all known (βα)8-barrels are enzymes. 
 The canonical (βα)8-barrel contains at least 200 amino acids and is composed of 
eight units, each of which consists of a β-strand and an α-helix (Sterner & Höcker, 
2005). Within a unit, the C-terminus of a β-strand is linked to the N-terminus of the α-
helix by a βα-loop. The individual units are linked by αβ-loops, which connect the C-
terminus of α-helix I with the N-terminus of β-strand I+1. The resulting βα-super-
secondary structure is shown in Figure 3A. In the tertiary structure the eight β-stands 
form a central parallel β-sheet, which is surrounded by the eight amphipathic α-
helices (Figure 3B). Their hydrophilic faces are exposed to the solvent, whereas the 
hydrophobic faces interact with the β-strands. 
 
 
Figure 3: The (βα)8-barrel fold. 
A: Topologic depiction of the right-handed βα-super-secondary structure consisting of eight (βα)-units. 
β-strands and α-helices are depicted in blue and red, respectively; the connecting loops are depicted 
in grey. B: Side-view of a canonical (βα)8-barrel protein, with the central eight-stranded parallel β-
sheet (the barrel) surrounded by the eight α-helices. The active site is formed by residues at the C-
terminal ends of the β-strands and the βα-loops (catalytic face). The remainder of the fold, including 
the opposite face of the barrel with the αβ-loops, is important for conformational stability (stability 
face). The figure was taken from Sterner & Höcker (2005). 
 
 In all known (βα)8-barrel enzymes, the active site residues are located at the C-
terminal ends of the β-strands and in the βα-loops (catalytic face), while residues 
maintaining the stability of the fold are found in the core and on the opposite end of 
the barrel, which includes the αβ-loops (stability face). In general, αβ-loops are less 
flexible and shorter than βα-loops (Höcker et al., 2001). This arrangement gives the 
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functional groups structural independence, making it possible to change catalytic 
activities without compromising stability. Therefore, (βα)8-barrels are considered to 
be ideal tools for the study of enzyme evolution and the design of new catalytic 
activities (Sterner & Höcker, 2005; Höcker, 2005). 
 The (βα)8-barrel proteins cover all EC-classes, except ligases; the hydrolases are 
the dominating class, comprising about half of the known TIM-barrels. The broad 
distribution indicates that the (βα)8-barrel is, together with the P-loop-containing 
nucleoside triphosphate hydrolase fold and the DNA/RNA-binding three-helical 
bundle fold, one of the most ancestral folds (Caento-Anollés et al., 2007). 
Approximately one half of the characterized (βα)8-barrel enzymes require divalent 
metal ions for catalysis. A very common active site motif is the phosphate binding 
site, as about two-thirds of the (βα)8-barrels have substrates or cofactors with at least 
one phosphate group (Nagano et al., 2002). 
 Besides TIM, whose reaction rate is diffusion controlled (Knowles, 1991), one of 
the best known representatives of (βα)8-barrel enzymes is OMP-decarboxylase, 
which accelerates its reaction by a factor of 1017 and is therefore the most proficient 
biocatalyst known (Radzicka & Wolfenden, 1995). Another important (βα)8-barrel is 
ribulose-1,5-bisphosphate-carboxylase (RuBisCo), which is the most abundant 
enzyme in the biosphere (Cooper, 2000).  
 
1.4 The amidohydrolase superfamily (AHS) 
  The amidohydrolase superfamily (AHS) was identified on the basis of structural 
and mechanistic similarities among adenosine deaminase (ADA), phosphotriesterase 
(PTE), and urease (URE) (Holm & Sander, 1997). The number of documented 
members within this enzyme group exceeds 23,000 (Hobbs et al., 2012). To date 
more than 30 different chemical reactions are catalyzed by known members of this 
superfamily, including the hydrolysis of esters and amide bonds, the deamination of 
nucleic acids, the hydration of double bonds, aldose/ketose isomerizations, and 
decarboxylations (Xiang et al., 2010). AHS members have been identified in every 
organism sequenced to date (Nguyen et al., 2008). The broad spectrum of substrates 
and reaction characteristics of the diverse amidohydrolase superfamily 
(Seibert & Raushel, 2005; Roodveldt & Tawfik, 2005b) suggests that the active site is 
amenable to the efficient evolution of new substrate profiles (Xiang et al., 2009). 
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 The enzymes of the mechanistically diverse AHS (Gerlt & Babbitt, 2001) adopt a 
distorted (βα)8-barrel fold. Almost all structurally characterized superfamily members 
possess a mono- or binuclear metal center within the active site. For most of the 
AHS, the metal center functions to activate a water molecule for the nucleophilic 
attack, activates the scissile bond of the substrate for bond cleavage, and stabilizes 
the tetrahedral or trigonal bipyramidal transition state. The two metal ions are 
designated as α and β. The divalent cations are predominately bridged by a 
carbamate functional group of a post-translationally modified lysine residue from β-
strand 4, or less often by the carboxyl functional group of glutamate from β-strand 3 
or 4. The α-metal is mostly buried in the structure, whereas the β-metal is more 
solvent exposed. In the binuclear metal centers, the hydrolytic water molecule is 
activated for nucleophilic attack by interaction with the α-metal ion while the carbonyl 
and phosphoryl groups of the substrate are polarized through Lewis acid catalysis via 
complexation with the β-metal ion. In the mononuclear metal centers, the substrate is 
activated by proton transfer from the active site, and the water is activated by metal 
ligation and general base catalysis (Seibert & Raushel, 2005). The amidohydrolase 
superfamily members have been divided into eight subtypes, according to the 
complexation of their metal ions (Table 1). The most common metal center is 
subtype I. 
 
Table 1: Metal complexation in eight subtypes of the AHS. 
  β-strands 
subtype metals 1 2 3 4 5 6 7 8 
I α, β H-X-H   K H H  D 
II α, β H-X-H   E H H  D 
III α H-X-H    H hb  D 
IV β h-x-ha  E  H H  db 
V β h-x-ha C   H H  db 
VI α, β H-X-D  E  H H  db 
VII - H-X-H    H   D 
VIII - H-X-H   R Y H  D 
Metal coordinating amino acids are abbreviated by the 1-letter code. The abbreviation X in the 
conserved H-X-H motif in β-strand 1 corresponds to a random amino acid residue. In the case of two 
metal ions, the α-metal ion is coordinated by two histidines from β-strand 1 and an aspartate from β-
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strand 8, and the β-metal ion is coordinated by two histidines from β-strands 5 and 6. The bridging 
ligands originate from β-strands 3 or 4. 
a: The residues are in the active site, but do not appear to be ligated directly to the divalent cations. 
The specific function of these residues is uncertain. b: These residues are not directly ligated to the 
divalent cations, but are hydrogen bonded to the hydrolytic water molecule. 
Prominent representatives of the subtypes: subtype I: phosphotriesterase (PTE), dihydroorotase 
(DHO), isoaspartyl dipeptidas (IAD), urease (URE), hydantoinase (HYD); subtype II: PTE homology 
protein (PHP); subtype III: adenosine deaminase (ADA), cytosine deaminase (CDA); subtype IV: 
acetyl glucosamine-6-phosphate deacetylase (AGD); subtype V: D-amino acid deacetylase (DAA); 
subtype VI: renal dipeptidase (RDP); subtype VII: uronate isomerase (URI); subtype VIII: 2-pyrone-
4,6-dicarboxylate lactonase (LigI). 
LigI is a recently identified AHS member, where the divalent metal ion is not required for catalysis and 
active site residues differ from classical AHS members.  
Data from Seibert & Raushel, 2005; Williams et al., 2006; Hobbs et al., 2012.  
 
 The homologous H-X-H motif at the end of β-strand 1, the histidine residues at 
the ends of β-strands 5 and 6, and an aspartate residue at the end of β-strand 8 are 
conserved throughout the AHS. The preservation of an unusual carbamate group in 
members of subtype I indicates divergent evolution from a common ancestor 
(Seibert & Raushel, 2005; Gerlt & Babbitt, 2001).  
 The atoms that directly ligate the metal ions within the different AHS members 
superimpose with a r.m.s.d. of only 0.2-0.6 Å. Moreover, the Cα-atoms of the eight β-
strands of the amidohydrolase superfamily members superimpose well with a r.m.s.d. 
of 1.5 ± 0.3 Å. Despite these strong similarities the spectrum of substrates and 
reaction characteristics are remarkable versatile. This is mostly due to the βα-loops, 
in particular loop 7 and 8, which are most often involved in contacting the ligands in 
the active site and in determining the substrate specificity. These loops differ 
significantly between different AHS members in sequence, length and conformation 
(Seibert & Raushel, 2005; Roodveldt & Tawfik, 2005b). 
 
1.5 Bacterial phosphotriesterase (PTE) and phosphotriesterase-
like lactonases (PLL) 
1.5.1 Bacterial phosphotriesterase (PTE) 
 The opd (organophosphate-degradation) genes were isolated from the soil 
bacteria Pseudomonas diminuta (PTE) (Munnecke, 1976), Flavobacterium sp. (PTE) 
(Sethunathan et al., 1973), and Agrobacterium radiobacter (OpdA) (Horne et al., 
2003). The opd genes from P. diminuta and Flavobacterium sp. are identical in 
sequence and are both localized on extrachromosomal plasmids that comprise part 
of a transposable element (Raushel, 2002; Horne et al., 2003; Siddavattam et al., 
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2003). The opd gene of PTE codes for a 365 amino acid precursor containing a N-
terminal signal peptide. For expression in E. coli the gene was processed lacking the 
29 amino acid long leader peptide (Mulbry & Karns, 1989; Omburo et al., 1992). PTE 
and OpdA share greater than 90% sequence identity and similar activity profiles 
(Yang et al., 2003). The ability of soil bacteria to utilize OP compounds as energy 
and nutrient source is thought to provide significant evolutionary advantage for the 
affected organisms (Siddavattam et al., 2003; Bigely & Raushel, 2010). 
 PTE hydrolyzes a wide range of synthetic organophosphate compounds, 
catalyzing the cleavage of P-O, P-F, and P-S bonds in a variety of insecticides and 
organophosphate nerve agents (Dumas et al., 1989). The substrate specificity of 
PTE is relatively broad, and the rate of hydrolysis is very much dependent on the pKa 
of the leaving group (Hong & Raushel, 1996). A natural substrate for PTE remains 
unknown. However, the purified enzyme exhibits a remarkably catalytic activity 
towards the hydrolysis of the commercial insecticide paraoxon. The kinetic constants 
kcat and kcat/KM of the cobalt-substituted PTE for paraoxon are 4.9 × 103 s-1 and 
3.8 × 107 M-1s-1, respectively. The rate enhancement by this enzyme approaches 
1012 (Dumas et al., 1989; Omburo et al., 1992). The high kcat/KM value for PTE-
catalyzed paraoxon hydrolysis is close to the bimolecular rate constant for diffusion-
controlled encounter of enzyme and substrate (108-109 M-1s-1; Fersht, 1985). The 
synthesis of paraoxon was first reported in the 1950s (Schrader, 1950), suggesting 
that the phosphotriesterase activity has evolved in bacteria specifically to this high 
level of catalytic activity over the past several decades from an enzyme with a related 
catalytic function (Raushel & Holden, 2000). Besides the efficient hydrolysis of OPs, 
promiscuous esterase activity has been reported for wild-type PTE and esterase and 
lactonase activities for an engineered PTE variant with elevated expression level 
(Roodveldt & Tawfik, 2005a/b; Afriat et al., 2006). 
 The quaternary structure of PTE is dimeric, and the protomers adopt a distorted 
(βα)8-barrel fold with two antiparallel β-strands at the N-terminus (Benning et al., 
1994). PTE belongs to subtype I of the amidohydrolase superfamily 
(Seibert & Raushel, 2005). The binuclear metal center at the C-terminal end of the 
barrel (Benning et al., 1995) can be assembled in an active configuration with 
transition metal ions, such as Co2+, Ni2+, Cd2+, Zn2+ or Mn2+. The most active isozyme 
is the Co2+-substituted PTE (Omburo et al., 1992). High-resolution X-ray structures of 
different metal-substituted forms (Zn/Zn, Zn/Cd, Cd/Cd, and Mn/Mn) of PTE from 
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P. diminuta showed that the two metal ions are separated by 3.5–3.7 Å and are 
bridged by a post-translationally carboxylated lysine (Lys169) from β-strand 4 and a 
hydroxide. The α-metal is more buried and coordinated by His55 (β-strand 1), His57 
(β-strand 1), and Asp301 (β-strand 8) in a trigonal bipyramidal ligation sphere. The 
more solvent exposed β-metal is coordinated by His201 (β-strand 5), His230 (β-
strand 6) and water molecules. The observed coordination spheres are either 
octahedral (in the Cd2+/Cd2+, Mn2+/Mn2+, and the mixed Zn2+/Cd2+ species) or trigonal 
bipyramidal (in the Zn2+/Zn2+ species) (Benning et al., 2001). The structure of the 
binuclear metal center in PTE is identical to the ones found in urease (Jabri et al., 
1995) and dihydroorotase (Thoden et al., 2001). A representation of the binuclear 
metal center for Zn2+/Zn2+-substituted PTE with bound substrate analogue is depicted 
in Figure 4. 
 
Figure 4: Active site region and coordination geometry of Zn2+/Zn2+-substituted PTE (PDB ID 
1EZ2) with bound diisopropyl methylphosphonate inhibitor. 
The α and β zinc ions are depicted as dark grey spheres, while the bridging hydroxide is depicted as 
dark blue sphere. The amino acid side chains are colored by element (C: grey; N: blue; O: red). The 
side chain of Lys169 carries a post-translational carboxylation. The substrate analog, diisopropyl 
methylphosphonate (DIMP), is shown in purple and colored by element (C: purple; P: orange; O: red). 
 
 Kinetic studies with enantiomeric phosphotriesters showed that wild-type PTE 
stereoselectively hydrolyzes chiral organophosphate triesters with a general 
preference for SP-enantiomers over RP-enantiomers by up to 90-fold with the 
stereochemical selectivity increasing with the difference in size between side groups 
(Hong & Raushel, 1999; Chen-Goodspeed et al., 2001a). The same pattern has been 
observed for phosphonate compounds; however, due to a reversal of priority of the 
groups the corresponding preferred chirality is RP (Bigley & Raushel, 2012; Tsai et 
al., 2010a). The X-ray structure of P. diminuta PTE with bound substrate analogue, 
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diethyl 4-methylbenzylphosphonate (Vanhooke et al., 1996), revealed the locations of 
three hydrophobic binding pockets. These pockets have been labeled as large, small, 
and leaving group subsites, and it has been shown that the stereospecificity of the 
enzyme is dictated by the size of these pockets (Chen-Goodspeed et al., 2001a). 
Furthermore, the inherent stereoselectivity of the wild-type enzyme can be enhanced, 
relaxed or reversed by simultaneous alterations of the three subsites (Chen-
Goodspeed et al., 2001b; Tsai et al., 2010a). 
 The reaction mechanism for the hydrolysis of phosphotriesters by PTE has been 
discussed controversially (Aubert et al., 2004; Chen et al., 2007; Wong et al., 2007; 
Jackson et al., 2008; Zhang et al., 2009). Figure 5 presents a slightly modified 
reaction mechanism compared to the one originally proposed by Aubert et al. (2004), 
which is experimentally supported by various methods, including labeling studies 
(Lewis et al., 1988) and various kinetic methods (Omburo et al., 1992; 
Hong & Raushel, 1996), EPR (electron paramagnetic resonance) spectroscopy 
measurements (Samples et al., 2007) and several X-ray structures with bound 
substrate analogues, a hydrolysis product, and a product analogue (Aubert et al., 
2004; Kim et al., 2008). Furthermore, recent DFT (density functional theory) 
calculations by Chen et al. (2007) and quantum mechanical/molecular mechanical 
(QM/MM) simulations by Zhang et al. (2009) are in support of this mechanism. 
 
 
Figure 5: A plausible reaction mechanism of PTE for the hydrolysis of phosphotriesters, using 
paraoxon as an example. 
Paraoxon binds to the β-metal ion by replacing a water molecule. The metal bridging hydroxide 
attacks the phosphorus center in the substrate in an SN2-like reaction. The P-O bond breaks, p-
nitrophenol is released, and the proton is transferred to aspartate 301. The hydrolysis product, diethyl 
phosphate, dissociates from the metal center (metal ions depicted in red), and the binuclear metal 
center is regenerated for another round of catalysis. The figure was taken from Kim et al. (2008). 
 
 According to this mechanism, the organophosphate substrate binds to the active 
site with the displacement of a water molecule from the β-metal ion. The interaction 
of the substrate with the β-metal ion weakens the coordination of the bridging 
hydroxide to the β-metal ion and facilitates the nucleophilic attack of the hydroxide in 
an SN2-like reaction on the phosphorus center of the substrate. The bond to the 
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leaving group phenol is broken, and the single proton from the nucleophilic hydroxide 
is transferred to aspartate 301. The anionic diethyl phosphate is bound within the 
active site as a bridging ligand between the two divalent cations. The diethyl 
phosphate dissociates from the active site, and the binuclear metal center is 
subsequently recharged for another round of catalysis (Kim et al., 2008). 
 
1.5.2 Dr0930: a phosphotriesterase-like lactonase (PLL)  
 Genes similar to opd were also identified in bacteria and archaea. 
Representatives are from Sulfolobus solfataricus (SsoPox), Sulfolobus 
acidocaldarius (SacPox), Deinococcus radiodurans (Dr0930), Rhodococcus 
erythropolis (Ahla), Mycobacterium tuberculosis (PPH) and Geobacillus kaustophilus 
(GKL). These proteins are termed PLL enzymes, as they are the closest homologues 
to PTE, although they are only distantly related, sharing 26-35% sequence identity 
with P. diminuta PTE (Merone et al., 2005; Porzio et al., 2007; Afriat et al., 2006). 
PLL’s main activity is for the hydrolysis of various lactones. Most members hydrolyze 
quorum-sensing (QS) N-acylhomoserine (HSL) lactones, other members hydrolyze γ- 
and δ-lactones (Afriat et al., 2006; Elias et al., 2008; Elias & Tawfik, 2012). Quorum-
sensing is an integral part of microbial interaction and is responsible for virulence or 
pathogenicity of diseases-causing bacteria (Camilli & Bassler, 2006). Importantly, 
most PLL members exhibit promiscuous OPH activity (Afriat et al., 2006; Buchbinder 
et al., 1998). 
 A close homologue of P. diminuta PTE with reported OPH activity is the well-
characterized bacterial PLL enzyme Dr0930 from D. radiodurans (31% sequence 
identity). Dr0930 is a robust and thermostable enzyme, with reported promiscuous 
activity for phosphotriesters (Hawwa et al., 2009b; Xiang et al., 2009). Computational 
docking of high-energy intermediates of the KEGG database predicted potential 
lactones as native substrates for the enzyme. Kinetic characterization confirmed this 
functional assignment, showing that Dr0930 hydrolyzes γ- and δ-lactones with alkyl 
substitutions at the carbon adjacent to the ring oxygen. The kinetic constants kcat and 
kcat/KM of the cobalt-substituted Dr0930 for the best substrate (known to date), δ-
nonanoic lactone, are 180 s-1 and 1.8 × 106 M-1s-1, respectively. No activity for the 
hydrolysis of N-acyl derivatives of homoserine lactone was detected (Xiang et al., 
2009).  
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 The quaternary structure is dimeric, and Dr0930 is a metal-dependent (βα)8-barrel 
enzyme belonging to the AHS. Dr0930 and PTE share high similarities in their overall 
fold, key sequence and active site features. Major differences are in length and 
conformation of the βα-loops, in particular 1, 3, 7 and 8. Dr0930 contains the 
additional β-metal coordinating active site residue Y97 which is conserved within the 
PLL family. The active site of Dr0930 is shown in Figure 6. The metal ions are 
complexed by conserved residues and bridged by a carboxylated lysine (Lys143) 
from β-strand 4 and a hydroxide ion. The α-metal is coordinated by His21 (β-
strand 1), His23 (β-strand 1) and Asp264 (β-strand 8), whereas the β-metal ion is 
coordinated by the side chains of His176 (β-strand 5), His204 (β-strand 6), and Tyr97 
(βα-loop 3) (Xiang et al., 2009; Hawwa et al., 2009b). 
 
Figure 6: Active site region and coordination geometry of the Zn2+/Zn2+-substituted Dr0930 
(PDB ID 3FDK) with the docked high-energy intermediate of δ-nonanoic lactone hydrolysis.  
The α and β zinc ions are depicted as dark grey spheres. The amino acid side chains are colored by 
element (C: grey; N: blue; O: red). The side chain of Lys143 carries a post-translational carboxylation. 
The residue conserved among PLLs in the βα-loop at the C-terminal ends of the third β-strand, Y97, is 
shown. The PDB of the docked high-energy intermediate was kindly provided by Dr. P. Kolb, 
University of Marburg (from Xiang et al., 2009) and is shown in purple and colored by element (C: 
purple; O: red).  
 
 In the catalytic mechanism proposed for Dr0930 the carbonyl oxygen of the 
lactone ring is polarized by interaction with the β-metal ion. In simple lactones, such 
as δ-nonanoic lactone, the si face of the lactone ring would be orientated toward the 
bridging hydroxide. Nucleophilic attack by the bridging hydroxide on the sp2 carbonyl 
carbon of the lactone initiates the formation of a tetrahedral intermediate and the 
proton is transferred from the hydroxide to the active site aspartate. The intermediate 
would collapse with subsequent transfer of the proton to the leaving group alcohol 
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(Xiang et al., 2009). The reaction mechanism proposed by analogy to the reaction 
mechanism for the OP hydrolysis of PTE is illustrated in Figure 7. 
 
 
Figure 7: A proposed reaction mechanism of Dr0930 for the hydrolysis of lactones, using δ-
nonanoic lactone as an example. 
δ-nonanoic lactone binds to the β-metal ion by replacing a water molecule. The metal bridging 
hydroxide attacks the carbon center in the substrate in an SN2-like reaction forming a tetrahedral 
intermediate, which is presumably stabilized by electrostatic interaction with Y97 and R228. The C-O 
bond breaks and the proton is transferred to aspartate 264. The proton is transferred to the leaving 
group alcohol and the hydrolysis product, 5-hydroxy nonanoic acid, dissociates from the metal center 
(metal ions depicted in red). The binuclear metal center is regenerated for another round of catalysis. 
R: n-butyl substituent. 
 
 PLL members exhibit promiscuous OPH activity, which is thought to be due to 
physical similarities between the reactive intermediate for the native lactonase 
reaction and the ground/intermediate state for the promiscuous OPH reaction (Elias 
et al., 2008). The mutually identified OPH and esterase (and lactonase) activity in 
wild-type PTE (and an engineered PTE variant) and PLL enzymes, support that PTE, 
which degrades synthetic organophosphates, evolved rapidly within the last several 
decades from a PLL enzyme by gene duplication and diversification. The 
promiscuous OPH activity of the PLL enzymes potentially served as an essential 
starting point for its evolution (Dumas et al., 1989; Raushel & Holden, 2000; 
Roodveldt & Tawfik, 2005a/b; Afriat et al., 2006). 
 
1.6 Enzyme design: Rational design versus directed evolution  
 Rational design and directed evolution are the two approaches to generate 
enzymes with novel functions, enhanced activity, altered substrate specificity or 
stereoselectivity (Arnold, 2001; Bornscheuer & Pohl, 2001; Chen, 2001; Bloom et al., 
2005). 
 
22 INTRODUCTION 	  
1.6.1 Rational design 
 Using rational design, which requires a detailed knowledge of the structure and 
the catalytic mechanism, new enzymatic activities could be established or altered on 
a pre-existing protein scaffold (Woycechowsky et al., 2007; Toscano et al., 2007). 
Most challenging is the de novo design of enzymes with activities not found in natural 
biocatalysts. Besides structural information, the critical catalytic residues have to be 
identified, and an optimized active site has to be generated in the host protein to 
stabilize the geometry of the transition state. Computational design was used to 
establish ester hydrolysis on the thioredoxin-scaffold (Bolon & Mayo, 2001). Baker 
and co-workers are using the molecular modeling program Rosetta 
(Kuhlman & Baker, 2000; Zanghellini et al., 2006) in a comprehensive approach: a 
library of scaffolds are tested to fit the transition state model, and a series of top 
ranked designs are synthesized, expressed and characterized. In this way, several 
novel enzymes that catalyze a variety of reactions were designed, including the non-
natural retro-aldol and Kemp-elimination reactions (Jiang et al., 2008; Röthlisberger 
et al., 2008), a stereoselective intermolecular Diels-Alder cycloaddition (Siegel et al., 
2010), and most recently they computationally redesigned a mononuclear zinc 
metalloenzyme for organophosphate hydrolysis (Khare et al., 2012). Although the 
work reported demonstrates the feasibility of computational enzyme design, the 
catalytic efficiencies of the generated artificial enzymes are much lower than those 
evolved by nature (Sterner et al., 2008). 
 
1.6.2 Directed evolution 
 In contrast to rational design, directed evolution does not require structural and 
mechanistic information to achieve significant improvements. In this approach 
random mutagenesis is used to create large enzyme repertoires, from which 
optimized variants are isolated using either selection or high-throughput (HT) 
screening techniques (Bloom et al., 2005). Besides classical random mutagenesis by 
error-prone PCR (epPCR; Cadwell & Joyce, 1994), other methods such as DNA-
shuffling (Stemmer, 1994), StEP (Staggered Extension Process; Zhao et al., 1998) or 
ITCHY (Incremental Truncation for the Creation of Hybrid Proteins; Ostermeier et al., 
1999) have been developed and successfully applied. Using directed evolution, 
enzyme functions could be newly established and altered: By applying messenger 
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RNA display, Seelig & Szostak (2007) generated a RNA ligase enzyme with a rate 
enhancement of more than two-million-fold without mechanistic information. Through 
extensive sequence changes, including the deletion and insertion of several 
structural loops in the active site and subsequent directed evolution, Park et al. 
(2006) converted a member of the αβ/αβ metallohydrolase superfamily (glyoxalase II) 
into a new family member with a different catalytic function (degradation of a β-
lactam antibiotic). Sterner and co-workers established a sugar isomerization reaction 
on a natural and an artificial (βα)8-barrel scaffold, where the best variants showed 
substrate affinities and turnover numbers similar to those of wild-type enzymes 
catalyzing the same reaction (Claren et al., 2009). Savile et al. (2010) used structure-
based rational design and directed evolution to redesign the substrate specificity and 
stability of a native transaminase to replace a rhodium-based hydrogenation catalyst 
in the production of an antidiabetes compound sitagliptin. Recently, Tawfik and co-
workers used a combination of random and targeted mutagenesis in combination 
with a high-throughput fluorescence-activated cell sorting (FACS) based screen to 
enhance the catalytic efficiency of the mammalian paraoxonase PON1 for the 
fluorogenic analog of SP-cyclosarin, yielding catalytic efficiencies that approach 
105 M-1s-1 (Gupta et al., 2011). 
 Currently, the combination of rational design based on computational methods 
with the combinatorial diversity generated by directed evolution appears to be the 
most efficient strategy for the design of tailored enzymes (Ward, 2008; Sterner et al., 
2008; Toscano et al., 2007). Several examples of combined approaches are 
described in the literature (Wang et al., 2012; Khersonsky et al., 2010; Khersonsky et 
al., 2012; Khare et al., 2012). 
 
1.7 Objectives and approach in general 
 PTE, which degrades synthetic organophosphates, is thought to be an 
evolutionary young enzyme that has evolved by rapid molecular evolution from the 
PLL-family, whose promiscuous OPH activity might have acted as an essential 
starting point for its evolution. This work is based on this assumption and intends to 
reconstruct in the laboratory the bona fide natural evolutionary pathway using the 
robust scaffold of Dr0930 as a starting point.  
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 Initially, the promiscuous hydrolytic activity of wild-type Dr0930 for a broad 
spectrum of OPs is analyzed, and mutually the ability of wild-type PTE to hydrolyze 
of δ-nonanoic lactone. In the central second part, an efficient OPH enzyme is 
generated from Dr0930 using laboratory evolution and in vitro activity screening. A 
broad spectrum of OPs, with different phosphorus chemistry, is used to design a 
multi-efficient OPH. Evolved variants are characterized in terms of steady-state 
enzyme kinetics and crystal structure analysis. The stereoselectivity is monitored and 
the activity for the native reaction is analyzed to relate the trade-off between native 
and newly evolved activity. Ligand docking studies are performed to identify the 
structural basis for the altered substrate preference.  
 The study is directed to identify the structural determinants of the substrate 
specificity in the PLL family versus PTE, and in a more general sense addressed to 
gain a comprehensive understanding of the physical and chemical parameters that 
relate protein structure and substrate recognition in enzyme-catalyzed reactions. 
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2 MATERIALS 
 
2.1 Instrumentation 
Autoclaves: 
München 25     MMM, München 
 VE-40      SYSTEC GmbH, Wettenberg 
 TOMY SS-325    CS BIO CO, Menlo Park, USA  
Balances: 
 MC1      SARTORIUS, Göttingen 
SI-114     DENVER INSTRUMENT, Göttingen 
AB204-S     METTLER TOLEDO, Columbus, USA 
Cell Densitiy Meter Ultrospec 10   GE HEALTHCARE, München 
Centrifuges: 
 Centrifuge 5810R    EPPENDORF, Hamburg 
 Centrifuge 5415D    EPPENDORF, Hamburg 
 Centrifuge 5415R    EPPENDORF, Hamburg 
 Sorvall RC 2B, 5C plus   DU PONT Instruments, Bad Homburg 
 with SS34/GS3-Rotor 
Avanti J-26 XP BECKMAN COULTER, Krefeld 
Chromatographic devices: 
 ÄKTA basic better    GE HEALTHCARE, München 
 ÄKTA purifier 10    GE HEALTHCARE, München 
 FPLC LCC-501 plus   GE HEALTHCARE, München 
 Used columns: 
QSepharoseFF XK 26   GE HEALTHCARE, München 
 Superdex 75 pg HiLoad 16/60  GE HEALTHCARE, München 
Superdex 200 pg HiLoad 26/60 GE HEALTHCARE, München 
Computer 
Dell Optiplex Systems   DELL Inc., Round Rock, USA 
MacBook Pro    APPLE Inc., Cupertino, USA 
Electroporator     
 Electroporator 2510   EPPENDORF, HAMBURG 
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MicroPulserTM Electroporator BIO-RAD LABORATORIES, Hercules, 
USA 
Freezer -80 °C     MDF-U72V, SANYO, Tokyo, Japan 
THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
Freezer -20 °C LIEBHERR, Nussbaumen  
THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
Gas burner, Gasprofi 2SCS   WLD-TEC GmbH, Göttingen 
Gel electrophoresis system: 
 Agarose gel electrophoresis chamber  
Agarose electrophoresis unit HOEFER Pharmacia Biotech, USA 
GeneMate Compact Gel System BioExpress, Kaysville, USA  
SDS electrophoresis chamber 
  Mighty Small II   HOEFER Pharmacia Biotech, USA 
  Multi Gel Caster Assembling GE HEALTHCARE, München 
gel apparatus 
PhastSystem™ Separation GE HEALTHCARE, München 
Control 
Glass pipettes and glassware   SCHOTT, Mainz 
       FISCHER SCIENTIFIC, Schwerte 
       NOVOGLAS, Bern, Schweiz 
Heating block-Thermostat HBT-2 131  HLC, Bovenden 
Incubator      BINDER GmbH, Tuttlingen 
CURTIN MATHESON SCIENTIFIC 
Inc., Houston, USA 
Lyophphilizer  
Lyovac GT2     LEYBOLD-HERAEUS, Hürth 
Savant SpeedVac, M SVC100H THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
Magnetic stirrer: 
 MR0, MR2000    HEIDOLPH, Kehlheim 
 MR1, MR3001 (heatable)   HEIDOLPH, Kehlheim 
PC-351 CORNING Inc, Corning, USA 
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Microliter pipettes 
Research 2.5, 10, 100, 200, 1000 EPPENDORF, Hamburg 
Pipetman Classic™ P2, P20, P100 GILSON Inc., Middleton, USA 
P200, P1000  
Microplate absorbance reader    
Infinite M200 Pro    TECAN, Austria 
SpectraMax-340 plate reader MOLECULAR DEVICES, Sunnyvale, 
USA 
Microwave  
HMT 842C     BOSCH, Nürnberg 
KENMORE 565.87086 SEARS BRANDS LLC, Hoffman 
Estates, USA 
Multichannel pipettes, electronic    
 Research pro, 8-chanels, 5-100 µl,  EPPENDORF, Hamburg 
20-300 µl, 50-1200 µl  
 EP-M8-250, 8-chanel, 25-250 µl  RAININ, San Diego, USA 
Multi-Doc-It Digital Imaging System  UVP Inc., USA 
PCR-cycler: 
 Mastercycler personal   EPPENDORF, Hamburg 
 Mastercycler gradients   EPPENDORF, Hamburg 
PTC-200 Thermo Cycler MJ RESEARCH Inc., St. Buno, 
Canada 
Peristaltic pump, Miniplus 2 GILSON Medical Electronics, France 
pH-Meter  
inolab Level1 INOLAB, Weilheim 
Orion Star A214 THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
Plate shaker Rocking Platform   BIOMETRA, Göttingen 
Power supply unit: 
 Power Pack P25    BIOMETRA, Göttingen 
Power PAC300 BIO-RAD LABORATORIES, Hercules, 
USA 
Power Supply EPS 301   GE HEALTHCARE, München 
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Quartz cuvettes 
101-QS (layer thickness 10 mm) HELLMA GmbH & Co. KG, Müllheim 
105-QS (layer thickness 10 mm) HELLMA GmbH & Co. KG, Müllheim 
Retainer for deep-well plates   FISCHER SCIENTIFIC, Schwerte 
Shaking incubator: 
 GFL 3033     GFL, Burgwedel 
 Certomat H     BRAUN Biotech, Melsungen 
 Certomat BS-1    BRAUN Biotech, Melsungen 
Series 125, sticky pad NEW BRUNSWICK SCIENTIFIC, 
Enfield, USA 
Milli-Q Water Purification Systems   
Milli-Q Advantage A10 Water   MILLIPORE, Eschborn 
Purification System 
PCS Sybron Barnstead THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
Ultrasonic system, Sonifier  
Branson Sonifier 250 D   HEINEMANN, Schwäbisch Gmünd 
Branson Sonifier 102C(CE) EMERSON ELECTRIC Co, St. Louis, 
USA 
UV-light table  
Reprostar     CAMAG Chemie Erzeugnisse, Berlin 
UV Transilluminator , Spectroline  SPECTRONICS Co., Lincoln, USA 
UV-Vis spectral photometer  
Cary 100 Bio     VARIAN, Darmstadt 
V650      JASCO GmbH, Groß-Umstadt 
UV-Vis Biophotometer    EPPENDORF, Hamburg   
Vakuum pump ME 2C    VACUUMBRAND, Wertheim 
Vortex Genie 2     SCIENTIFIC IND., Bohemia, USA 
 
2.2 Consumables 
Centrifugal Filter Device     
Amicon Ultra-15 (mwco: 10 kDa)  Millipore, Bedford, USA 
Deep-well plates, 96 well/2000 µl  EPPENDORF, Hamburg 
CORNING Inc., Corning, USA 
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Desalting columns 
Micro Bio-Spin P-30 columns BIO-RAD LABORATORIES, Hercules, 
USA 
NAP-25™ columns    GE HEALTHCARE, München 
 PD-10 desalting columns   GE HEALTHCARE, München 
Dialysis tubing 
Visking, 27/32, 14 kDa   ROTH GmbH &Co, Karlsruhe 
Spectra/Por, 10 kDa SPECTRUM LABORATORIES Inc, 
Rancho Dominguez, USA 
Disposable syringes, Omnifix® 60 ml   BRAUN Biotech, Melsungen 
Electroporation cuvettes, 2 mm   PEQLAB, Erlangen 
Filter paper      WHATMAN, Maidstone, England 
Standard cellulose filter, grade 1 
DEAE cellulose filter, grade DE81 
Latex-gloves Sempermed    SEMPERIT Technical Products 
       GmbH, Vienna, Austria 
Membrane filter ME24 Ø47 mm; 0.2 µm SCHLEICHER&SCHUELL, Dassel 
Microtiter plates, 96 well/200 µl, flat bottom  
Vis, 96 well, flat bottom   GREINER, Nürtingen 
THERMO FISCHER SCIENTIFIC, 
Waltham, USA 
 Vis, 96 well, sterile, with lid  SARSTEDT, Nümbrecht 
UV-Vis, 96 well, flat bottom BD, Franklin Lakes, USA 
Nitrile gloves    VWR, Leuven, Belgium 
Nitrocellulose filter (Ø13 mm;   MILLIPORE, Eschborn 
Cat#: VSWP01300) 
Parafilm „M“ Laboratory Film   PECHINEY, Plastic Packaging,  
       Menasha, USA 
Pasteur pipettes     HIRSCHMANN, Ebermannstadt 
PCR-tubes 0.2 ml     PEQLAB, Erlangen 
Petri dish 150/25 and 94/16    GREINER bio-one, Nürtingen 
Petri dish, square 245×245×18, BioDish XL BD, Franklin Lakes, USA 
PhastGel™  consumables    GE HEALTHCARE, München 
PhastGel™  Homogeneous-12.5  
30 MATERIALS 	  
PhastGel™ Buffer Strips, SDS 
Pipette tips  
10 µl, 200 µl, 1000 µl   SARSTEDT, Nümbrecht 
 RAININ 10 µl, 20 µl, 250 µl, 1000 µl METTLER TOLEDO, Columbus, USA 
Plastic cuvettes 
½ microcuvettes, UV-transparent SARSTEDT, Nümbrecht 
1ml cuvettes     SARSTEDT, Nümbrecht 
Plastic tubes: 
15 ml, 50 ml     SARSTEDT, Nümbrecht 
Falcon, 15 ml and 50 ml BD, Franklin Lakes, USA 
Reaction vessels 1.5 ml and 2 ml  ROTH, Karlsruhe  
       EPPENDORF, Hamburg 
Reaction vessel with screw-cap, 2 ml  SARSTEDT, Nümbrecht 
Sealing tape, gas-permeable, 96 well  Brand, Wertheim 
QIAGEN, Hilden  
Sepharose Fast Flow bulk media   GE HEALTHCARE, München 
 DEAE and Q Sepharose 
Syringe filter, pore size 0.2 µm/0.45 µm  RENNER GmbH, Daunstadt  
       VWR, Leuven, Belgium 
 
2.3 Chemicals 
 All chemicals used were graded p.a. and purchased from the companies listed 
below or synthesized by Dr. Chengfu Xu (research group of Prof. Dr. F. M. Raushel, 
Texas A&M University, College Station, USA). 
ALFA AESAR    Karlsruhe 
APPLICHEM GmbH   Darmstadt 
BIO101 Inc.     Carlsbad, USA 
BIO-RAD LABORATORIES   Hercules, USA 
BIOZYM     Hess. Oldendorf 
BODE CHEMIE    Hamburg 
BOEHRINGER MANNHEIM  Mannheim 
CARL ROTH GMBH & Co. KG  Karlsruhe 
DIFCO      Dreieich 
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FLUKA     Neu-Ulm 
GE HEALTHCARE    München 
GERBU Biotechnik GmbH   Gailberg 
GIBCO/BRL      Eggestein 
MERCK      Darmstadt 
MP BIOCHEMICALS   Illkirch, France 
NATIONAL DIAGNOSTICS   Simerville, USA 
OXOID      Wesel 
RIEDEL-DE HAEN     Seelze 
ROCHE DIAGNOSTICS    Mannheim 
ROTH      Karlsruhe 
SERVA      Heidelberg  
SIGMA-ALDRICH     Deisenhofen 
VWR      Leuven, Belgium 
 
2.4 Kits 
ABI PRISM®  BigDye™ Terminator Cycle  LIFE TECHNOLOGIES, Carlsbad, 
Sequencing Ready Reaction Kit   USA  
Classic II Suite     QIAGEN, Hilden 
Crystal Screen I+II HAMPTON RESEACH, Aliso Viejo, 
USA 
GeneJET™ Plasmid Miniprep Kit   MBI FERMENTAS, St.-Leon-Rot 
GeneJET™ Gel Extraction Kit   MBI FERMENTAS, St.-Leon-Rot 
JBScreen Classic 1+4+5+8+9    JENA BIOSCIENCE, Jena 
Mutation Generation System™ Kit   FISHER SCIENTIFIC, Schwerte  
Nucleobond® PC100/500 DNA-Extraction Kit MACHEREY-NAGEL, Düren 
Nucleospin® Extract II    MACHEREY-NAGEL, Düren 
PEG/ION Screen 1+2 HAMPTON RESEACH, Aliso Viejo, 
USA  
PEG RX I+II HAMPTON RESEACH, Aliso Viejo, 
USA  
Phusion® Site-Directed Mutagenesis Kit  FISHER SCIENTIFIC, Schwerte 
QIAGEN Plasmid Maxi Kit/Midi Kit  QIAGEN, Hilden 
QIAprep® Spin Miniprep Kit   QIAGEN, Hilden 
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QIAquick PCR Purification    QIAGEN, Hilden 
Quick Ligation™ Kit NEW ENGLAND BIOLABS, Frankfurt 
a. M. 
Wizard I+II EMERALD BIOSYSTEMS, Bainbridge 
Island, USA 
 
2.5 Enzymes 
Alkaline phosphatase (CIP)   NEW ENGLAND BIOLABS, Frankfurt a. M. 
GoTaq DNA polymerase   PROMEGA, Mannheim 
HyperMu™ MuA Transposase EPICENTRE, Madison, USA 
Pfu DNA polymerase PEGLAB, Erlangen 
 STRATAGENE, La Jolla, USA 
Phusion® (Hot Start) High-Fidelity  NEW ENGLAND BIOLABS, Frankfurt a. M. 
DNA polymerase 
Restriction endonucleases  NEW ENGLAND BIOLABS, Frankfurt a. M. 
T4-DNA ligase    MBI FERMENTAS, St.-Leon-Rot 
NEW ENGLAND BIOLABS, Frankfurt a. M. 
 ROCHE DIAGNOSTICS, Mannheim 
 
2.6 Bacterial strains 
E. coli 5α (NEW ENGLAND BIOLABS, Frankfurt a. M.) 
fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 
hsdR17 
 The E. coli 5α strain is an E. coli DH5α derivative. Due to the deletion of the 
fhuA2 gene, the ferric hydroxamate uptake receptor is lacking on the cell surface, 
which prevents the binding of the bacteriophage T1 to this receptor and consecutive 
infection of the cells. Consequently E. coli 5α cells are T1-phage resistant. The 
E. coli 5α is a recombination-deficient strain as the recA function is deleted, which is 
associated with a slower cell growth. 
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E. coli Turbo (NEW ENGLAND BIOLABS, Frankfurt a. M.) 
F' proA+B+ lacIq Δ(lacZ)M15/fhuA2 Δ(lac-proAB) glnV gal R(zgb-210::Tn10) Tets endA1 
thi-1 Δ(hsdS-mcrB)5 
 E. coli Turbo cells are like E. coli 5α cells T1-phage resistant. As the recA function 
of the strain is intact, E. coli Turbo cells grow faster than the recA- strain E. coli 5α. 
E. coli Turbo cells form visible colonies after 8 h incubation at 37 °C. 
 
E. coli XL1 Blue MRFʼ (STRATAGENE, La Jolla, USA) 
Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac [F´ 
proAB lacIqZΔM15 Tn10 (Tetr)] 
 In XL1 Blue MRF’ cells all restriction endonucleases known in E. coli K12 are 
inactived at genome level.  
 
E. coli BL21(DE3) (Studier & Moffat, 1986) 
hsdS gal [λcl ts857 cnd1 hsdR17 racA1 endA1 gyrA96 thi1 relA1]    
 E. coli BL21(DE3) cells carry a gene for T7 RNA polymerase on their 
chromosome, which is used for gene expression in pET systems.  
 
E. coli BL21-CodonPlus(DE3) (STRATAGENE, La Jolla, USA) 
B F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte 
- RP-strain: [argU proL Camr] 
- RIL-strain: [argU ileY leuW Camr] 
- RIPL-strain: [argU proL Camr] [argU ileY leuW Strep/Specr] 
 BL21-CodonPlus (DE3) strains are engineered to contain extra copies of genes 
that encode the tRNAs that most frequently limit translation of heterologous proteins 
in E. coli. By supplying E. coli rare codons expression is enhanced where translation 
would otherwise be limited by the codon usage of E. coli. BL21-CodonPlus(DE3) RP 
cells contain a pACYC-based plasmid containing extra copies of the argU and proL 
tRNA genes. The RP expression strain therefore enables the efficient expression of 
genes that contain the E. coli rare arginine codons AGA and AGG and the proline 
codon CCC. BL21-CodonPlus(DE3) RIL cells contain a pACYC-based plasmid 
containing extra copies of the argU, ileY and leuW tRNA genes. The RIL expression 
strain therefore enables the efficient expression of genes that contain the E. coli rare 
arginine codons AGA and AGG, the isoleucine codon AUA, and leucine codon CUA. 
BL21-CodonPlus(DE3) RIPL cells contain a pACYC-based plasmid containing extra 
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copies of the argU and proL tRNA genes, and a pACYC-compatible plasmid pSC101 
containing extra copies of the argU, ileY und leuW tRNA genes. The RIPL expression 
strain therefore enables the efficient expression of genes that contain the E. coli rare 
codons mentioned for both the RP and RIL strains. The pACYC-plasmid additionally 
contains a gene for the chloramphenicol acetyltransferase that confers 
chloramphenicol resistance. The pSC101-plasmid additively confers streptomycin 
and spectinomycin resistence. 
 
E. coli BL21(DE3) Rosetta 2 (MERCK, Darmstadt) 
B F– ompT hsdSB(rB– mB–) gal dcm (DE3) pRARE2 (Camr) 
 E. coli BL21(DE3) Rosetta 2 cells contain on a pACYC-based plasmid termed 
pRARE2, genes for the tRNAS argU, argW, argX, glyT, ileX, leuW, metT, proL, thrT, 
thrU and tyrU. The expression strain therfore enables the efficient expression of 
genes that contain the E. coli rare codons AGA, AGG and CGG for arginine, GGA for 
glycin, AUA for isoleucine, CUA for leucine, ACC and ACA for threonine, TAC for 
tyrosin and CCC for proline. The plasmid additively confers chloramphenicol 
resistance.  
 
E. coli T7 Express Rosetta (research group of Prof. Dr. R. Sterner) 
fhuA2 lacZ::T7gene1 lon ompT gal sulA11 dcm R(zgb-210::Tn10--TetS) endA1 Δ(mcrC-
mrr)114::IS10 R(mcr-73::miniTn10--TetS)2) [argU argW glyT ileX, leuW metT proL thrT 
thrU tyrU Camr] 
 This expression strain was constructed in the research group of Prof. R. Sterner. 
Originating from E. coli T7 expression cells (NEW ENGLAND BIOLABS, Frankfurt 
am Main), the strain contains an additional pRARE plasmid from E. coli 
Rosetta(DE3)pLysS (Merck, Darmstadt), which enables the expression of genes with 
rare codons in a T1-phage resistant E. coli strain. Besides the tetracycline resistance, 
the cells exhibit, due to the pRARE plasmid, accessory chloramphenicol resistance. 
 
E. coli BW25113 (Datsenko & Wanner, 2000) 
Δ(araD-araB)567 ΔlacZ4787(::rrnB-3) lacIp-4000(lacIQ) λ- rph-1 Δ(rhaD-rhaB)568 
hsdR514 
 A ΔhisA-ΔhisF strain was generated based on the E. coli BW25113 strain and 
kindly provided by Dr. J. Claren (Claren, 2008). 
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2.7 Vectors 
2.7.1 pET vectors 
 Genes inserted into the multiple clonig site (MCS) of pET vectors (MERCK, 
plasmid for expression by T7 RNA Polymerase) are transcribed by the RNA-
polymerase of the phage T7 (Studier et al., 1990). The expression of genes takes 
place in special E. coli strains, which carry a chromosomal copy of the T7 RNA 
polymerase. The expression of the T7 RNA polymerase gene proceeds under the 
control of the lacUV5 promotor operator and is induced by the addition of isopropyl-β-
D-thiogalactopyranoside (IPTG). The gene for the lac-repressor (lacI), which is 
required for suppression of gene expression in the absence of induction, is located 
on the plasmid and is constitutively expressed. 
 
pET20b(+) 
 The pET20b(+) vector encodes an N-terminal pelB signal sequence for 
periplasmic localization, plus an optional C-terminal (His)6-tag sequence. The vector 
confers ampicillin resistance. 
pET24a(+) 
 The pET24a(+) vector encodes an optional C-terminal (His)6-tag sequence and 
confers kanamycin resistance. 
pET30a(+) 
 The pET30a(+) vector encodes an N-terminal (His)6-tag followed by a thrombin 
restriction site. Consequently, the hexahistidin-tag can be proteolytically cleaved off 
from the target protein by incubation with thrombin. Furthermore, the vector encodes 
an optional C-terminal (His)6-tag and confers kanamycin resistance. 
 
2.7.2 pTNA vector 
 The pTNA-vector is a variant form of the pDS56/RBSII-vector (Bujard et al., 1987; 
Stüber et al., 1990). The T5 promotor and the lac operator sequence have been 
replaced by the (-30)–(-10)-region of the tryptophanase operon promoter (pTNA) of 
E. coli, which leads to weak constitutive expression (Merz et al., 2000). In general, 
the gene is inserted between the SphI- und HindIII-restriction sites. The pTNA vector 
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contains a gene mediating ampicillin resistance. The vector was kindly provided by 
Prof. Dr. Charles Yanofsky (Stanford University, USA). 
 
2.8 Oligodeoxynucleotides 
 Oligonucleotides were obtained from METABION (Martinsried) or Integrated DNA 
Technologies, Inc. (Coralville, USA). The restriction sites in terminal amplification 
primers are underlined. Bases in mutagenic primers that differ from wild-type bases 
are printed in bold. (Partially) degenerated condons are printed in bold and italic. 
 
2.8.1 Vector-specific amplification and sequencing primers 
5'T7Promotor 
5’- TAA TAC GAC TCA CTA TAG GG -3’ 
3'T7Terminator 
5’- GCT AGT TAT TGC TCA GCG G -3’ 
5'CyRI 
5’- TCA CGA GGC CCT TTC GTC TT -3’ 
3'CyPstI 
5’- TCG CCA AGC TAG CTT GGA TTC T -3’ 
5'pTNA-SphI 
5’- ATT CAT TAA AGA GGA GAA ATT AAG CAT GC -3’ 
3'pTNA-HindIII 
5’- AGG AGT CCA AGC TCA GCT AAT TAA GCT TTT A -3’ 
5’pTNA-F-MCS 
5’- GAA AGC AAT TTT CGT ACT GTA AGG TTG -3’ 
3’pTNA-B-MCS 
5’- CCA GAT GGA GTT CTG AGG TCA TTA CTG -3’ 
 
2.8.2 Amplification and mutagenic primers for dr0930 
 Partially degenerated codons (coding mutations) used are listed in the following: 
DKY (C, F, G, I, S, V), GYG (A, V), AYY (I, T), MWS (H, I, K, L, M, N, Q), GBS (A, G, 
V), MTG (L, M), WGC (C, S), RAH (D, E, K, N), KCG (A, S), GAW (D, E), HRY (C, H, 
N, R, S, Y), MTK and MKK (L, I, M), GYG (A, V). 
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 The NNS codon is coding for all 20 amino acids and one stop codon (TAG). The 
stop codons TGA and TAA are excluded. 
 
5'dr0930-SphI-T2Q 
5’- TAT GCA TGC AGG CAC AGA CGG TGA CGG GCG C -3’ 
3'dr0930-HindIII 
5’- ATA AAG CTT TTA CCC GAA CAG CCG GGC CGG GTT -3’ 
5'dr0930-NdeI 
5’- AGC CAT ATG ACG GCA CAG ACG GTG ACG GGC GC -3’ 
5’dr0930-NdeI-T2Q 
5’- AAT CAT ATG CAG GCA CAG ACG GTG ACG GGC GC -3’ 
5’dr0930-NdeI-T2Q+A3T 
5’- AAT CAT ATG CAG ACA CAG ACG GTG ACG GGC GC -3’ 
3'dr0930-EcoRI 
5’- TGT GAA TTC TTA CCC GAA CAG CCG GGC CGG GTT -3’ 
3'dr0930-XhoI 
5’- TGT CTC GAG TTA CCC GAA CAG CCG GGC CGG GTT -3’ 
3’dr0930-NotI 
5’- ATT GCG GCC GCT TAC CCG AAC AGC CGG GCC GGG TT -3’ 
5‘dr0930-D71N 
5’- ACC CCC AAC AAC TGC GGA CGC AAC CCG GC -3’ 
3’dr0930-D71N 
5’- GCC GGG TTG CGT CCG CAG TTG TTG GGG GT -3’ 
5'dr0930-F26G 
5’- CCC CAC GAA CAC GTG ATT GGC GGC TAC CCC GG -3’ 
3'dr0930-F26G 
5’- CCG GGG TAG CCG CCA ATC ACG TGT TCG TGG GG -3’ 
5’dr0930-F26DKY+Y28GYG 
5’- CCC CAC GAA CAC GTG ATT DKY GGC GYG CCC GGC TAC GCG GGC GAC -3’ 
3’dr0930-F26DKY+Y28GYG 
5’- GTC GCC CGC GTA GCC GGG CRC GCC RMH AAT CAC GTG TTC GTG GGG -3’  
5’dr0930-F26DKY+Y28AYY 
5’- CCC CAC GAA CAC GTG ATT DKY GGC AYY CCC GGC TAC GCG GGC GAC -3’ 
3’dr0930-F26DKY+Y28AYY 
5’- GTC GCC CGC GTA GCC GGG RRT GCC RMH AAT CAC GTG TTC GTG GGG -3’ 
5’dr0930-D71MWS+C72 
5’- GTG GTG GAC GCC ACC CCC AAC MWS TGC GGA CGC AAC CCG GCC TTC -3’  
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3’dr0930-D71MWS+C72 
5’- GAA GGC CGG GTT GCG TCC GCA SWK GTT GGG GGT GGC GTC CAC CAC -3’ 
5’dr0930-D71MWS+C72I 
5’- GTG GTG GAC GCC ACC CCC AAC MWS ATT GGA CGC AAC CCG GCC TTC -3’ 
3’dr0930-D71MWS+C72I 
5’- GAA GGC CGG GTT GCG TCC AAT SWK GTT GGG GGT GGC GTC CAC CAC -3’  
5’dr0930-D71GBS+C72 
5’- GTG GTG GAC GCC ACC CCC AAC GBS TGC GGA CGC AAC CCG GCC TTC -3’ 
3’dr0930-D71GBS+C72 
5’- GAA GGC CGG GTT GCG TCC GCA SVC GTT GGG GGT GGC GTC CAC CAC -3’ 
5’dr0930-D71GBS+C72I 
5’- GTG GTG GAC GCC ACC CCC AAC GBS ATT GGA CGC AAC CCG GCC TTC -3’ 
3’dr0930-D71GBS+C72I 
5’- GAA GGC CGG GTT GCG TCC AAT SVC GTT GGG GGT GGC GTC CAC CAC -3’ 
5’dr0930-E101GBS 
5’- GGC TTT TAT TAC GAG GGC GBS GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101GBS 
5’- CTT GAA GTA GGT CGT GGC GCC SVC GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-E101MTG 
5’- GGC TTT TAT TAC GAG GGC MTG GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101MTG 
5’- CTT GAA GTA GGT CGT GGC GCC CAK GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-E101WGC 
5’- GGC TTT TAT TAC GAG GGC WGC GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101WGC 
5’- CTT GAA GTA GGT CGT GGC GCC GCW GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-E101RAH 
5’- GGC TTT TAT TAC GAG GGC RAH GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101RAH 
5’- CTT GAA GTA GGT CGT GGC GCC DTY GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-Q178MWS+E179GAW 
5’- GTG CCG ATC ATC ACC CAC ACT MWS GAW GGC CAG CAG GGA CCG CAG -3’  
3’dr0930-Q178MWS+E179GAW 
5’- CTG CGG TCC CTG CTG GCC WTC SWK AGT GTG GGT GAT GAT CGG CAC -3’ 
5’dr0930-Q178KCG+E179GAW 
5’- GTG CCG ATC ATC ACC CAC ACT KCG GAW GGC CAG CAG GGA CCG CAG -3’  
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3’dr0930-Q178KCG+E179GAW 
5’- CTG CGG TCC CTG CTG GCC WTC CGM AGT GTG GGT GAT GAT CGG CAC -3’ 
5’dr0930-R228HRY+V235MTK 
5’- ATC GCC TTT GAC HRY ATC GGC TTG CAG GGC ATG MTK GGC ACC CCC -3’ 
3’dr0930-R228HRY+V235MTK 
5’- GGG GGT GCC MAK CAT GCC CTG CAA GCC GAT RYD GTC AAA GGC GAT -3’ 
5’dr0930-L270GYG 
5’- GAC AGC ATC TGG CAC TGG GYG GGA CGC CCG CCG GCC ATC -3’ 
3’dr0930-L270GYG 
5’- GAT GGC CGG CGG GCG TCC CRC CCA GTG CCA GAT GCT GTC -3’ 
5’dr0930-L270MKK 
5’- GAC AGC ATC TGG CAC TGG MKK GGA CGC CCG CCG GCC ATC -3’ 
3’dr0930-L270MKK 
5’- GAT GGC CGG CGG GCG TCC MMK CCA GTG CCA GAT GCT GTC -3’ 
5’dr0930-F26C-Y28I 
5’- CCC CAC GAA CAC GTG ATT TGC GGC ATT CCC GGC TAC GCG GGC GAC -3’ 
3’dr0930-F26C-Y28I 
5’- GTC GCC CGC GTA GCC GGG AAT GCC GCA AAT CAC GTG TTC GTG GGG -3’ 
5’dr0930-F26V-Y28I 
5’- CCC CAC GAA CAC GTG ATT GTG GGC ATT CCC GGC TAC GCG GGC GAC -3’ 
3’dr0930-F26V-Y28I 
5’- GTC GCC CGC GTA GCC GGG AAT GCC CAC AAT CAC GTG TTC GTG GGG -3’ 
5’dr0930-D71N-C72 
5’- GTG GTG GAC GCC ACC CCC AAC AAC TGC GGA CGC AAC CCG GCC TTC -3’ 
3’dr0930-D71N-C72 
5’- GAA GGC CGG GTT GCG TCC GCA GTT GTT GGG GGT GGC GTC CAC CAC -3’ 
5’dr0930-D71G-C72 
5’- GTG GTG GAC GCC ACC CCC AAC GGC TGC GGA CGC AAC CCG GCC TTC -3’ 
3’dr0930-D71G-C72 
5’- GAA GGC CGG GTT GCG TCC GCA GCC GTT GGG GGT GGC GTC CAC CAC -3’ 
5’dr0930-E101G 
5’- GGC TTT TAT TAC GAG GGC GGC GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101G 
5’- CTT GAA GTA GGT CGT GGC GCC GCC GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-E101S 
5’- GGC TTT TAT TAC GAG GGC AGC GGC GCC ACG ACC TAC TTC AAG -3’ 
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3’dr0930-E101S 
5’- CTT GAA GTA GGT CGT GGC GCC GCT GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-E101N 
5’- GGC TTT TAT TAC GAG GGC AAC GGC GCC ACG ACC TAC TTC AAG -3’ 
3’dr0930-E101N 
5’- CTT GAA GTA GGT CGT GGC GCC GTT GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-Q178S-E179 
5’- GTG CCG ATC ATC ACC CAC ACT AGC GAA GGC CAG CAG GGA CCG CAG -3’ 
3’dr0930-Q178S-E179 
5’- CTG CGG TCC CTG CTG GCC TTC GCT AGT GTG GGT GAT GAT CGG CAC -3’ 
5’dr0930-Q178S-E179D 
5’- GTG CCG ATC ATC ACC CAC ACT AGC GAT GGC CAG CAG GGA CCG CAG -3’ 
3’dr0930-Q178S-E179D 
5’- CTG CGG TCC CTG CTG GCC ATC GCT AGT GTG GGT GAT GAT CGG CAC -3’ 
5’dr0930-V235I 
5’- ATC GCC TTT GAC CGC ATC GGC TTG CAG GGC ATG ATT GGC ACC CCC -3’ 
3’dr0930-V235I 
5’- GGG GGT GCC AAT CAT GCC CTG CAA GCC GAT GCG GTC AAA GGC GAT -3’ 
5’dr0930-L270 
5’- GAC AGC ATC TGG CAC TGG CTG GGA CGC CCG CCG GCC ATC -3’ 
3’dr0930-L270 
5’- GAT GGC CGG CGG GCG TCC CAG CCA GTG CCA GAT GCT GTC -3’ 
5‘dr0930-D71G 
5’- GTG GAC GCC ACC CCC AAC GGC TGC GGA CGC AAC CCG GCC -3’ 
3‘dr0930-D71G 
5’- GGC CGG GTT GCG TCC GCA GCC GTT GGG GGT GGC GTC CAC -3’ 
5’dr0930-E101G 
5’- GGC TTT TAT TAC GAG GGC GGG GGC GCC ACG ACC TAC TTC -3’ 
3’dr0930-E101G 
5’- GAA GTA GGT CGT GGC GCC CCC GCC CTC GTA ATA AAA GCC -3’ 
5’dr0930-V235L 
5’- GGC TTG CAG GGC ATG CTG GGC ACC CCC ACC GAC GCC -3’ 
3’dr0930-V235L 
5’- GGC GTC GGT GGG GGT GCC CAG CAT GCC CTG CAA GCC -3’ 
5’dr0930-M234I 
5’- ATC GGC TTG CAG GGC ATT GTG GGC ACC CCC ACC GAC -3’ 
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3’dr0930-M234I 
5’- GTC GGT GGG GGT GCC CAC AAT GCC CTG CAA GCC GAT -3’ 
5‘dr0930-Y28NNS 
5’- CCC CAC GAA CAC GTG ATT TTC GGC NNS CCC GGC TAC GCG GGC GAC -3’ 
3‘dr0930-Y28NNS 
5’- GTC GCC CGC GTA GCC GGG SNN GCC GAA AAT CAC GTG TTC GTG GGG -3’ 
5’dr0930_Δ101 
5’- GGC GCC ACG ACC TAC TTC AAG TTC CGC -3’ 
3’dr0930_Δ99+100+101 
5’- GTA ATA AAA GCC GGT CGC GCA CAG AAT -3’ 
3’dr0930_Δ100+101 
5’- CTC GTA ATA AAA GCC GGT CGC GCA CAG -3’ 
3’dr0930_Δ101 
5’- GCC CTC GTA ATA AAA GCC GGT CGC GCA -3’ 
5’dr0930-V235L+ΔSphI 
5’- GGC TTG CAG GGG ATG CTG GGC ACC CCC AC -3’ 
3’dr0930-V235L+ΔSphI 
5’- GTG GGG GTG CCC AGC ATC CCC TGC AAG CC -3’ 
5’dr0930-Y97NNS+E101G 
5’- TGC GCG ACC GGC TTT NNS TAC GAG GGC GGC GGC GC -3’ 
3‘dr0930-Y97NNS+E101G 
5’- GCG CCG CCG CCC TCG TAS NNA AAG CCG GTC GCG CA -3’ 
5’dr0930-Y97Q+E101G 
5’- CAG ATT CTG TGC GCG ACC GGC TTT CAG TAC GAG GGC GGC GGC GCC ACG 
AC -3’ 
3’dr0930-Y97Q+E101G 
5’- GTC GTG GCG CCG CCG CCC TCG TAC TGA AAG CCG GTC GCG CAC AGA ATC 
TG -3’ 
5’dr0930-Y97W+E101G 
5’- CAG ATT CTG TGC GCG ACC GGC TTT TGG TAC GAG GGC GGC GGC GCC ACG 
AC -3’ 
3’dr0930-Y97W+E101G 
5’- GTC GTG GCG CCG CCG CCC TCG TAC CAA AAG CCG GTC GCG CAC AGA ATC 
TG -3’ 
5’dr0930-Y97C+E101G 
5’- CAG ATT CTG TGC GCG ACC GGC TTT TGC TAC GAG GGC GGC GGC GCC ACG 
AC -3’ 
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3’dr0930-Y97C+E101G 
5’- GTC GTG GCG CCG CCG CCC TCG TAG CAA AAG CCG GTC GCG CAC AGA ATC 
TG -3’ 
5’dr0930-F26Y+Y28L 
5’- CAC GAA CAC GTG ATT TAT GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26Y+Y28L 
5’- GTA GCC GGG CAG GCC ATA AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26C+Y28L 
5’- CAC GAA CAC GTG ATT TGC GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26C+Y28L 
5’- GTA GCC GGG CAG GCC GCA AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26W+Y28L 
5’- CAC GAA CAC GTG ATT TGG GGC CTG CCC GGC TAC -3’ 
3’ dr0930-F26W+Y28L 
5’- GTA GCC GGG CAG GCC CCA AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26L+Y28L 
5’- CAC GAA CAC GTG ATT CTG GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26L+Y28L 
5’- GTA GCC GGG CAG GCC CAG AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26H+Y28L 
5’- CAC GAA CAC GTG ATT CAT GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26H+Y28L 
5’- GTA GCC GGG CAG GCC ATG AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26Q+Y28L 
5’- CAC GAA CAC GTG ATT CAG GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26Q+Y28L 
5’- GTA GCC GGG CAG GCC CTG AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26R+Y28L 
5’- CAC GAA CAC GTG ATT CGT GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26R+Y28L 
5’- GTA GCC GGG CAG GCC ACG AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26I+Y28L 
5’- CAC GAA CAC GTG ATT ATT GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26I+Y28L 
5’- GTA GCC GGG CAG GCC AAT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26M+Y28L 
5’- CAC GAA CAC GTG ATT ATG GGC CTG CCC GGC TAC -3’ 
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3’dr0930-F26M+Y28L 
5’- GTA GCC GGG CAG GCC CAT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26T+Y28L 
5’- CAC GAA CAC GTG ATT ACC GGC CTG CCC GGC TAC -3’ 
3’ dr0930-F26T+Y28L 
5’- GTA GCC GGG CAG GCC GGT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26N+Y28L 
5’- CAC GAA CAC GTG ATT AAC GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26N+Y28L 
5’- GTA GCC GGG CAG GCC GTT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26K+Y28L 
5’- CAC GAA CAC GTG ATT AAA GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26K+Y28L 
5’- GTA GCC GGG CAG GCC TTT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26S+Y28L 
5’- CAC GAA CAC GTG ATT AGC GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26S+Y28L 
5’- GTA GCC GGG CAG GCC GCT AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26V+Y28L 
5’- CAC GAA CAC GTG ATT GTG GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26V+Y28L 
5’- GTA GCC GGG CAG GCC CAC AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26A+Y28L 
5’- CAC GAA CAC GTG ATT GCG GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26A+Y28L 
5’- GTA GCC GGG CAG GCC CGC AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26D+Y28L 
5’- CAC GAA CAC GTG ATT GAT GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26D+Y28L 
5’- GTA GCC GGG CAG GCC ATC AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26E+Y28L 
5’- CAC GAA CAC GTG ATT GAA GGC CTG CCC GGC TAC -3’ 
3’dr0930-F26E+Y28L 
5’- GTA GCC GGG CAG GCC TTC AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26G+Y28L 
5’- CAC GAA CAC GTG ATT GGC GGC CTG CCC GGC TAC -3’ 
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3’dr0930-F26G+Y28L 
5’- GTA GCC GGG CAG GCC GCC AAT CAC GTG TTC GTG -3’ 
5’dr0930-F26P+Y28L 
5’- CCC CAC GAA CAC GTG ATT CCG GGC CTG CCC GGC TAC GCG -3’ 
3’dr0930-F26P+Y28L 
5’- CGC GTA GCC GGG CAG GCC CGG AAT CAC GTG TTC GTG GGG -3’ 
5'dr0930-G38R 
5’- GGC GAC GTG ACG CTC CGT CCA TTC GAC CAC GCG -3’ 
3 dr0930-G38R 
5’- CGC GTG GTC GAA TGG ACG GAG CGT CAC GTC GCC -3’ 
5'dr0930-L270M+P274L 
5’- TGG ATG GGA CGC CCG CTG GCC ATC CCC GAA GCC -3’ 
3'dr0930-L270M+P274L 
5’- GGC TTC GGG GAT GGC CAG CGG GCG TCC CAT CCA -3’ 
5'dr0930-L270+P274L 
5’- TGG CTG GGA CGC CCG CTG GCC ATC CCC GAA GCC -3’ 
3'dr0930-L270+P274L 
5’- GGC TTC GGG GAT GGC CAG CGG GCG TCC CAG CCA -3’ 
5'dr0930-E101G+T105S 
5’- GGC GGC GGC GCC ACG AGC TAC TTC AAG TTC CGC -3’ 
3'dr0930-E101G+T105S 
5’- GCG GAA CTT GAA GTA GCT CGT GGC GCC GCC GCC -3’ 
5'dr0930-L270M+R272C 
5’- TGG CAC TGG ATG GGA TGC CCG CCG GCC ATC CCC -3’ 
3 dr0930-L270M+R272C 
5’- GGG GAT GGC CGG CGG GCA TCC CAT CCA GTG CCA -3’ 
5'dr0930-L270+R272C 
5’- TGG CAC TGG CTG GGA TGC CCG CCG GCC ATC CCC -3’ 
3'dr0930-L270+R272C 
5’- GGG GAT GGC CGG CGG GCA TCC CAG CCA GTG CCA -3’ 
5'dr0930-L270+P274L (OE-PCR) 
5’- ATC TGG CAC TGG CTG GGA CGC CCG CTG GCC ATC CCC GAA -3’ 
3'dr0930-L270+P274L (OE-PCR) 
5’- TTC GGG GAT GGC CAG CGG GCG TCC CAG CCA GTG CCA GAT -3’ 
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2.8.3 Amplification primers for pte 
5'pte-SphI-S2Q 
5’- ATT GCA TGC AAA TCG GGA CCG GTG ACC GTA TCA ACA C -3’ 
3'pte-HindIII 
5’- TAT AAG CTT TCA GGA AGC ACG CAG GGT CGG GGA CAG GAA -3’ 
 
2.9 Ladders and markers 
 In order to determine the size of DNA fragments in agarose gels the GeneRuler™ 
1 kb Plus DNA Ladder (MBI FERMENTAS, St. Leon-Rot) was commonly used 
(Figure 8A). Alternatively, the EZ Load™ 100 bp/500 bp Molecular Ruler (Bio-Rad, 
Hercules, USA) was applied. 
 In order to determine the size of proteins for SDS-PAGE the Unstained Protein 
Molecular Weight Marker (MBI FERMENTAS, St. Leon-Rot) was commonly used 
(Figure 8B). Alternatively, the Prestained SDS-PAGE Standards, low range (Bio-Rad, 
Hercules, USA) or the Prestained Protein Marker, broad range (7-175 kDa) (NEW 
ENGLAND BIOLABS, Frankfurt a. M.) were applied. 
 
 
Figure 8: DNA and protein ladders and markers. 
A: GeneRuler™ 1 kb Plus DNA Ladder (MBI FERMENTAS). B: Unstained Protein Molecular Weight 
Marker (MBI FERMENTAS) for SDS-PAGE (12.5 %). 
 
2.10 Buffers and solutions 
 Unless otherwise specified, the buffers used were filter-sterilized and stored at 
room temperature. For all preparations Milli-Q grade water (MILLIPORE) or double 
distilled water (ddH20) was used. 
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2.10.1 Buffers and solutions for working with E. coli 
Antibiotics 
Dissolved and filter-sterilized antibiotics for long-term storage were stored at -20 °C.  
Ampicillin (1000×) 150 mg/ml ampicillin (Na-salt) dissolved in water and 
filter-sterilized 
Chloramphenicol (1000×) 30 mg/ml chloramphenicol dissolved in 100 % EtOH 
and filter-sterilized 
Kanamycin (1000×) 75 mg/ml kanamycin dissolved in water and filter-
sterilized 
Tetracycline (1000×) 12.5 mg/ml tetracycline dissolved in 100 % EtOH and 
filter-sterilized 
CoCl2 1 M CoCl2 dissolved in water, filter-sterilized, and 
stored at RT 
Glucose 20% (w/v) glucose dissolved in water, filter-sterilized, 
and stored at RT 
Glycerol (87 %) 
IPTG stock solution  0.5 M IPTG dissolved in water, filter-sterilized, and 
stored at -20 °C 
KCl 1 M KCl dissolved in water, filter-sterilized, and stored 
at RT 
MgCl2 1 M MgCl2 dissolved in water, filter-sterilized, and 
stored at RT 
MgSO4 1 M MgSO4 dissolved in water, filter-sterilized, and 
stored at RT 
MnCl2 1 M MnCl2 dissolved in water, filter-sterilized, and 
stored at RT 
10 × TB-Phosphate 2.31 g KH2PO4 (acid, 0.17 M) and 12.54 g K2HPO4 
(base, 0.72 M) dissolved in water (total volume of 
100 ml); autoclaved and stored at RT 
TFB I-buffer 100 mM KCl, 50 mM MnCl2, 30 mM KAc, 10 mM 
CaCl2, 15% glycerol; stock solutions for the single 
components were stored at 4 °C. A volume of 100 ml 
TFBI-buffer was prepared prior to use. 
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TFB II-buffer 100 mM Tris/HCl, pH 7.0, 10 mM KCl, 75 mM CaCl2, 
15% glycerol; stock solutions for the single 
components were stored at 4 °C. A volume of 100 ml 
TFBII-buffer was prepared prior to use. 
ZnCl2 1 M ZnCl2 dissolved in water, filter-sterilized, and 
stored at RT 
 
2.10.2 Buffers and solutions for screening and enzyme kinetics 
Acetic acid 1 mM acetic acid prepared by diluting glacial acetic 
acid with water and stored at RT 
BICINE 25 mM BICINE pH 8.3; pH adjusted using NaOH; 
filter-sterilized and stored at RT 
BugBuster Lysis buffer (1×) 1 × BugBuster (Novagen) in 50 mM HEPES, 
pH 8.5, 100 µM CoCl2; prepared prior to use and 
stored at 4 °C 
CHES (pH 9.0) stock solution 0.5 M CHES pH 9.0; pH adjusted using KOH; filter-
sterilized and stored at RT 
m-cresol purple m-cresol purple dissolved in 100% DMSO and 
stored at RT 
δ-nonanoic lactone δ-nonanoic lactone dissolved in 100% DMSO and 
stored at -20 °C 
Freeze-down solution 65% glycerol, 20 mM Tris-HCl pH 5.6, 100 mM 
MgSO4; autoclaved and stored at RT 
HEPES (pH 8.5) stock solution 1 M HEPES pH 8.5; pH adjusted using NaOH; filter-
sterilized, and stored at 4 °C 
OP substrate stock solution p-nitrophenyl substituted OP compounds were 
dissolved in water to maximum solubility (<10 mM), 
or dissolved in 20% MeOH in case of GD p-NP and 
GF p-NP (OPs 4 and 5). Due to spontaneous 
substrate hydrolysis the precise concentration of 
non-hydrolyzed substrate was determined by 
titration with 10 M KOH using Lambert-Beer’s law 
(ε400 = 17000 M-1cm-1). Aliquots were stored at        
-80 °C. 
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DEVX substrate stock DEVX was dissolved in 20% MeOH to maximum 
solubility (<10 mM). The concentration was 
determined enzymatically using wild-type PTE at 
50 mM HEPES pH 8.0, 0.3 mM DTNB, 100 µM 
CoCl2 (ε412 = 14150 M-1cm-1). 
 
2.10.3 Buffers and solutions for working with DNA and agarose gel 
electrophoresis 
PCR dNTP solution (2 mM) A solution of dNTP’s (2 mM of each A, C, G, and T) 
was prepared and stored at -20 °C. 
Agarose (1%) 5 g agarose dissolved in 500 ml 0.5 × TBE, boiled 
and stored at 60 °C 
Ethidium bromide stock solution 10 mg/ml ethidium bromide (EtBr) 
Sucrose color marker 60% (w/v) sucrose, 0.1% (w/v) bromphenol blue, 
0.1% (w/v) xylencyanole FF dissolved in 0.5 × TBE; 
TBE (5×) 445 mM boric acid, 12.5 mM EDTA, 445 mM Tris 
(resulting pH-value: 8.15) 
 
2.10.4 Buffers and solutions for working with proteins 
Wild-type Dr0930 and Dr0930 variants 
Buffer for AEX chromatography 
 Binding buffer   20 mM HEPES, pH 7.5, 100 µM CoCl2 
Elution buffer 20 mM HEPES, pH 7.5, 100 µM CoCl2, 2 M 
NaCl 
Buffer for preparative gel filtration 20 mM HEPES, pH 7.5, 100 µM CoCl2, 
300 mM NaCl; filter-sterilized and degassed 
Dialysis- and storage buffer   20 mM HEPES, pH 7.5, 100 µM CoCl2 
HEPES (pH 7.5) stock solution 1 M HEPES (pH 7.5); pH adjusted using 
NaOH; filter-sterilized and stored at 4 °C 
Resuspension buffer for expression 20 mM HEPES, pH 7.5, 100 µM CoCl2 
in analytical and preparative scale 
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Wild-type PTE  
Buffer for AEX chromatography   
Binding buffer   50 mM HEPES, pH 8.5, 100 µM CoCl2 
Elution buffer 50 mM HEPES, pH 8.5, 100 µM CoCl2, 2 M 
NaCl 
Buffer for preparative gel filtration 50 mM HEPES, pH 8.5, 100 µM CoCl2, 
300 mM NaCl; filter-sterilized, and degassed 
Dialysis- and storage buffer   50 mM HEPES, pH 8.5, 100 µM CoCl2 
HEPES (pH 8.5) stock solution 1 M HEPES (pH 8.5); pH adjusted using 
NaOH; filter-sterilized and stored at 4 °C 
Resuspension buffer for expression 50 mM HEPES, pH 8.5, 100 µM CoCl2 
in analytical and preparative scale 
 
2.10.5 Buffers and solutions for SDS-PAGE 
Ammonium persulfate (APS)  10% (w/v) APS solution; filter-sterilized, and 
stock solution (10%)   stored at -20 °C 
Coomassie staining solution 0.2% (w/v) Coomassie Brilliant Blue G-250 
and R-250, 50% (v/v) ethanol, 10% (v/v) 
glacial acetic acid; filtered and stored at RT; 
protected from light 
Protogel™ 30% (v/v) acrylamide, 0.8% (v/v) bis-
acrylamide; stored at 4 °C 
Buffer for SDS-PAGE resolving gel 0.4% (w/v) SDS, 1.5 M Tris-HCl, pH 8.8 
Buffer for SDS-PAGE stacking gel 0.4% (w/v) SDS, 0.5 M Tris/HCl, pH 6.8 
SDS-PAGE electrophoresis buffer  0.1% (w/v) SDS, 0.025 M Tris, 0.2 M glycine 
(resulting pH-value: 8.5) 
SDS-PAGE sample buffer (5×) 5% (w/v) SDS, 25% (w/v) glycerol, 12.5% (v/v) 
β-mercaptoethanol, 0.025% (w/v) bromphenol 
blue, 1.25 M Tris/HCl, pH 6.8 
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2.11 Bacterial growth media 
 For sterilization the medium was autoclaved for 20 min at 121 °C and 2 bar. For 
selective media, the corresponding antibiotics were added after cooling down of the 
medium to 60 °C in terms of a filter-sterilized, 1000-fold concentrated stock solution. 
 
Luria-Bertani (LB) medium 0.5% (w/v) yeast extract, 1.0% (w/v) NaCl, 
1.0% (w/v) tryptone 
LB agar     LB medium plus 1.5% (w/v) Bacto-Agar 
SOB medium (Sambrook et al., 1989) 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 
2.0% (w/v) tryptone. Following autoclaving, 
10 mM MgSO4, 10 mM MgCl2 and 2.5 mM 
KCl (each filter-sterilized) were added prior to 
use. 
SOC medium SOB medium was supplemented with 20 mM 
glucose (filter-sterilized) following 
autoclavation. 
SOC agar     SOC medium plus 1.5% (w/v) Bacto-Agar 
Super Broth 3.2% (w/v) tryptone, 2% (w/v) yeast extract, 
0.5% (w/v) NaCl, 0.5% (v/v) 1 N NaOH 
TB medium  12 g tryptone, 24 g yeast extract, 4 ml 
glycerol (87%); dissolved in a total volume of 
900 ml water, and autoclaved; 100 ml sterile 
10 × TB-Phosphate was added prior to use. 
 
2.12 Software 
Local applications 
ÄKTA Unicorn Version 5.01 (318) © GE HEALTHCARE 
Bioedit Sequence Alignment Editor © IBIS BIOSCIENCES, Tom Hall 
V.7.0.5.3     
Cary Eclipse Version 1.1 (175)  © VARIAN Australia Pty. Ltd. 2002 
Cary Win UV Version 3.0 (182)  © VARIAN Australia Pty. Ltd. 2002 
CCP4 suite Collaborative Computational Project, Number 
4, 1994; Potterton et al., 2004 
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CNS      Brunger et al., 1998 
Corel Draw X5    © 2003 COREL Corp. 
CS ChemBioDraw Ultra,    © 1986-2010 CambridgeSoft 
version 12.02.1092    
Endnote Version X4   © 2000 WINTERTREE Software Inc. 
HKL2000 package    Otwinowski & Minor, 1997 
Jalview 2.6.1     Waterhouse et al., 2009 
Magellan V4.0 and V7.1   © 2003 TECAN Austria 
MS Office 2007(Win)/2011(Mac)  © 2010 Microsoft Corporation 
Phaser version 2.1    McCoy et al., 2007 
PHENIX     Adams et al., 2002 
PyMOL™ 0.99rc6    © 2006 DELANO SCIENTIFIC LCC. 
Refmac5     Murshudov et al., 1997 
Sequoia     Bruns et al., 1999 
Sequencher 4.10.1, Demo version © Gene codes Corporation (Ann Arbor, USA) 
SigmaPlot 11.0 and 12.0   © 2004/2006 SPSS Inc. 
Coot and WinCoot (version 0.6.2) Emsley & Cowtan, 2004 
Emsley et al., 2010 
XDS      Kabsch, 1993, 2010 
XtalView package    McRee, 1999 
 
Server-assisted applications 
DaliLite     http://www.ebi.ac.uk./DaliLite 
T-COFFEE/Expresso Notredame et al. (2000), Armougom et al. 
(2006); http://www.tcoffee.org 
MolProbity Davis et al., 2007; 
 http://www.molprobity.biochem.duke.edu 
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3 METHODS 
 
3.1 Preparation of instrumentation and solutions 
 All thermostable solutions and media were autoclaved for 20 min at 121 °C and 
2 bar prior to use. Glassware and heat-stable expendable items, such as pipette tips, 
were also autoclaved and subsequently dried at 50 °C in a compartment drier. 
Additionally, glassware was incubated at 200 °C for 4 h for sterilization. Heat-labile 
solutions were prepared in stock solutions and filtered, either via a membrane filter 
with a pore size of 0.2 µm by use of a vacuum pump, or by using a syringe filter with 
a pore size of 0.2 µm or 0.45 µm. Solutions intended for use in chromatographic 
systems were degassed if required for at least 30 min in a desiccator. 
 
3.2 Microbiological methods 
3.2.1 Cultivation and storage of E. coli strains 
 All E. coli strains used were cultivated at 37 °C while shaking at 140 rpm (1 liter 
cultures) or 220 rpm (5, 50 and 250 ml cultures), respectively. For cultivation LB-
medium was used, unless otherwise stated. For plasmid-harboring strains the 
medium was supplemented with the corresponding antibiotics (150 µg/ml ampicillin, 
30 µg/ml chloramphenicol, 75 µg/ml kanamycin, 12.5 µg/ml tetracycline) using a 
filter-sterilized, thousand fold concentrated stock solution. To obtain single colonies, 
the cell suspension was plated on agar plates containing the adequate antibiotics, 
and incubated overnight at 37 °C. For temporary storage the plates or suspensions 
were sealed and stored at 4 °C. For long-term storage, glycerol cultures were made 
and stored at -80 °C. For this purpose an aliquot of an overnight culture was mixed in 
a 1:1 ratio with 87% glycerol, and stored in a sterile screw cap reaction vessel. 
 
3.2.2 Preparation of chemically competent E. coli cells (Inoue et al., 
1990) 
 For preparation of chemically competent E. coli cells, 500 ml SOB medium was 
inoculated with the respective overnight culture to an OD600 of 0.1, and cultured at 
37 °C and 220 rpm until an OD600 of 0.6 was reached. The culture was incubated on 
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ice for 15 min, transferred into 50 ml tubes, and cells were harvested by 
centrifugation (EPPENDORF Centrifuge 5810R, 4000 rpm, 10 min, 4 °C). The cell 
pellet was resuspended in 100 ml ice-cold TFB I buffer, centrifuged a second time 
under the same conditions as stated above. The resulting pellet was resuspended in 
10 ml ice-cold TFB II-buffer. Immediately after resuspension, 100 µl aliquots of the 
cell suspension were transferred to Eppendorf reaction vessels on ice and stored at         
-80 °C. 
 
3.2.3 Transformation of chemically competent E. coli cells 
 For transformation of chemically competent cells a 100 µl aliquot was thawed on 
ice, and about 100 ng plasmid DNA (maximum volume: 20 µl) was added. Following 
incubation on ice for 5 min, cells were heat-shocked for 45 s at 42 °C, and incubated 
again on ice for 5 min. A volume of 900 µl LB-medium was added, and cells were 
incubated for 1 h at 37 °C in a shaker at 220 rpm to develop antibiotic resistance. 
Finally, adequate dilutions of the cell suspension were plated on LB agar plates 
containing the appropriate antibiotics for selection. 
 
3.2.4 Preparation of electro-competent E. coli cells (Dower et al., 1988) 
 For preparation of electro-competent E. coli cells, 50 ml or 200 ml SOB-medium 
were inoculated with the respective overnight culture to an OD600 of 0.1, and 
incubated at 37 °C and 220 rpm until an OD600 of 0.6 was reached. The culture was 
incubated on ice for 30 min, transferred to 50 ml tubes, and cells were harvested by 
centrifugation (EPPENDORF Centrifuge 5810R, 4000 rpm, 10 min, 4 °C). The pellet 
was resuspended in 50 ml ice-cold, sterile water and incubated on ice for another 
15 min. Following centrifugation the pellet was resuspended in 20 ml ice-cold, sterile 
water and incubated again on ice for 15 min. The cells were pelleted by 
centrifugation and resuspended in 10 ml ice-cold, sterile water. After the last 
incubation and centrifugation step the supernatant was discarded, and the cells were 
incubated on ice. The cell pellet was resuspended in a minimum of 1 ml sterile water, 
and 100 µl aliquots were transferred to Eppendorf reaction vessels. Aliquots of 
electro-competent cells were directly used for transformation or stored at -80 °C in 
10% glycerol. 
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3.2.5 Preparation of DNA for electroporation 
 For electroporation the salt content of the DNA solution should be as low as 
possible, to avoid a short-circuit during the electric pulse. Therefore, the DNA which 
is generally dissolved in a saline buffer (e.g. ligation mixture) has to be dialyzed prior 
to transformation. For this purpose 10-20 µl of the DNA solution was placed for at 
least 1 h onto a nitrocellulose filter (MILLIPORE), which was then put onto the 
surface of MILLIPORE-water in a small petri dish. 
 
3.2.6 Transformation of electro-competent E. coli cells 
 For electroporation a maximum of 20 µl salt-free DNA-solution was added to 
100 µl electro-competent cells. After 5 min incubation on ice the transformation 
mixture was transferred into a pre-cooled electroporation cuvette (gap length 2 mm). 
Following the electrical pulse (2500 V, 25 µF, 200 Ω) in the electroporator (time 
constant between 4.0 and 6.0 ms in case of successful electroporation) the cell 
suspension was immediately supplemented with 1.5 ml SOC medium, and incubated 
for 1 h at 37 °C in a shaker. Aliquots were plated on selective agar plates, and 
incubated overnight at 37 °C. 
 
3.2.7 Determination of transformation efficiency 
 For determination of the transformation efficiency (TE) one aliquot of competent 
cells was transformed with 100 ng plasmid DNA, as described above (3.2.3 & 3.2.6). 
The cells were plated on selective agar using various dilutions (undiluted, 1:10, 
1:100, 1:1000 etc.). The transformation efficiency was calculated as follows: 
!! = !!"#"$%&' ∙ !!!!"  
Equation 1: Determination of the transformation efficiency. 
TE  transformation efficiency (colonies per µg DNA) 
ncolonies number of colonies 
f  dilution factor 
mDNA  applied DNA amount [µg] 
 
3.2.8 In vitro activity screening 
 In vitro activity screening is a fast and reliable method used to assay enzyme 
activities of lysed colony replicates on filter paper (filter paper activity pre-screen) or 
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in crude extracts (96-well block activity screen). Upon incubation with substrate, OP 
hydrolysis is detected as a colorimetric signal, which is based on the release of the 
product p-nitrophenol under basic conditions at 400 nm. An overview of the in vitro 
activity screening process is illustrated in Figure 9. 
 
 
Figure 9: Overview of the in vitro activity screening procedure. 
Filter paper based and 96-well block activity screening.  
 
 In vitro activity screening was used to compare activities of Dr0930 variants and 
to screen the pTNA-dr0930 and pET24a-dr0930 gene libraries for variants with 
increased OPH activity. The 96-well block activity screen enabled to analyze several 
hundred colonies per day. 
 If not state otherwise, chemically competent E. coli BL21-CodonPlus(DE3) cells 
were transformed with the pTNA-dr0930 gene library, incubated for 1 h at 37 °C, 
plated on LB agar plates containing the appropriate antibiotics, and incubated 
overnight.  
 In case the DEAE-filter paper activity pre-screen was performed to discriminate 
active and inactive colonies, cells were plated on large square LB agar plates 
(245 × 245 × 18, BioDish XL, BD). Colony replicates were generated on Whatman 
DEAE cellulose filter paper (grade DE81) and the master plate was incubated for 
additional 6 h at 37 °C. DEAE-filter paper limited the diffusion of p-nitrophenol due to 
electrostatic interaction of the product with the diethylaminoethyl (DEAE) tertiary 
amine functional group of the anion exchange cellulose. Colony replicates on the 
DEAE-filter paper were lysed by incubation with a second Whatman filter paper 
(standard Whatman cellulose filter, Grade 1) soaked with 1 x BugBuster® protein 
extraction reagent (MERCK) in 50 mM HEPES pH 8.5, 100 µM CoCl2 and incubated 
for 15 min. The activity was assayed by subsequent incubating of the replicate filter 
paper with Whatman filter paper soaked with 0.5 mM ethyl-paraoxon in 50 mM CHES 
pH 9.0. Active colonies turned yellow upon substrate hydrolysis and were identified 
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visually or by digital imaging (using a band pass filter of 406.5-8.1 nm). Positive 
colonies were picked from the master plate after overnight incubation and restreaked 
to obtain single colonies for subsequent 96-well block activity screening.  
 Single colonies were used to inoculate 96-deep-well blocks (EPPENDORF, deep-
well blocks 96/2000) containing 0.75 ml Super Broth medium supplemented with the 
appropriate antibiotics and 0.5-1.0 mM CoCl2, unless otherwise stated. The deep-
well blocks were covered with a gas-permeable, self-adhesive sealing tape 
(QIAGEN, air-pore sheets) and incubated overnight at 37 °C, upon shaking at 
240 rpm. Each 96-deep-well block contained a set of controls in triplicates, unless 
otherwise stated. If applicable, an aliquot of the master plate overnight culture was 
mixed with 65% (v/v) glycerol, 20 mM Tris-HCl pH 5.6, 100 mM MgSO4 in a 1:1 ratio 
and stored at -80 °C. The cells were lysed by incubation with 1 x BugBuster in 50 mM 
HEPES pH 8.5, 100 µM CoCl2 and incubated for 30 minutes at RT. To this end, the 
1 x BugBuster solution was either directly added to the 96-deep-well block cultures or 
to an aliquot that was transferred to a new microtiter plate. Subsequently, an aliquot 
of the crude lysate was used to assay activities for OP substrates 1-7 (p-NP 
analogues of VX, GB, VR, GD, and GF; MPXN and EPXN; 4.2.2) in 50 mM CHES 
pH 9.0 using a new microtiter plate. Depending on the OP compound and the 
stringency of the screen, substrate concentrations of 0.15-0.5 mM were used. If 
applicable, the crude lysate was diluted in a 1:5 or 1:10 ratio in 50 mM HEPES 
pH 8.5, 100 µM CoCl2 prior to use. For substrates 4 (GD p-NP) and 5 (GF p-NP) a 
final concentration of 10% methanol was added to the assay set-up. The release of 
p-nitrophenol was spectrophotometrically monitored in constant time intervals at 
400 nm and 30 °C, using an absorbance plate reader (TECAN, Infinite M200 Pro or 
MOLECULAR DEVICES, SpectraMax-340 plate reader). Plasmids of the most active 
colonies were extracted and analyzed by sequencing. In combination with the DEAE 
filter paper activity pre-screen, the method enables for high-throughput analysis of 
several thousand colonies per day. 
 
3.3 Molecular biology methods 
3.3.1 Isolation and purification of plasmid DNA from E. coli 
 Purification of plasmid DNA was performed according to the principle of alkaline 
cell lysis (Le Gouill et al., 1994). Bacterial cell cultures were lysed by adding SDS 
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and sodium hydroxide. The suspension was subsequently neutralized by addition of 
ammonium acetate; proteins and genomic DNA precipitated, whereas circular 
plasmid DNA remained in solution. 
 
3.3.1.1 Isolation of plasmid DNA in analytical amounts (mini-preparation) 
 For analytical isolation and purification of plasmid DNA from E. coli mini 
preparation kits from either FERMENTAS (GeneJET™ Plasmid Miniprep Kit) or 
QIAGEN (QIAprep® Spin Miniprep Kit) were used. For this purpose 5 ml from 
overnight cell cultures were harvested by centrifugation (EPPENDORF 5415D, 
13200 rpm, 1 min, RT). The isolation of plasmid DNA was performed according to the 
protocol supplied by the manufacturer. For elution of plasmid DNA from the silica 
column a volume of 50 µl of sterile water was used. The recovered plasmid DNA was 
stored at -20 °C. 
 
3.3.1.2 Isolation of plasmid DNA in preparative amounts (midi/maxi-
preparation) 
 For isolation of plasmid DNA for preparative applications midi/maxi preparation 
kits from either MACHERY-NAGEL (Nucleobond® PC 100/500 DNA-Extraction Kits) 
or QIAGEN (QIAGEN Plasmid Midi/Maxi Kits) were used.  
 For midi-preparation 50 ml of an E. coli overnight culture was harvested by 
centrifugation (EPPENDORF 5810R, 4000 rpm, 10 min, 4 °C). The subsequent 
isolation was performed according to the protocol supplied by the manufacturer. The 
plasmid DNA was eluted using 50 µl of sterile water and stored at -20 °C.  
 Maxi-preparation was applied to extract plasmids from gene libraries. To this end, 
transformants grown on large plates (Ø 14.5 cm) were scraped off using a sterile 
spatula and liquid LB medium. The resulting cell suspension was centrifuged 
(EPPENDORF 5810R, 4000 rpm, 10 min, 4 °C) and the plasmid mixture was isolated 
according to the protocol supplied by the manufacturer. For each maxi-preparation a 
maximum of 5 g cell pellet was used. 
 
3.3.2 Determination of DNA concentration 
 The DNA concentration was spectroscopically determined at a wavelength of 
260 nm. According to Lambert-Beer’s law an OD260 value of 1 (with 
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0.1%A260 = 20 cm2 mg-1 and a pathlength of 1 cm) corresponds to a DNA concentration 
of 50 µg/ml dsDNA (35 µg/ml RNA and 33 µg/ml ssDNA, respectively). Thus, the 
DNA concentration can be calculated as follows: 
!!"#$% = !!"# ∙ !" ∙ !!"""  
Equation 2: Determination of DNA concentration. 
cdsDNA concentration of double stranded DNA [µg/µl] 
A260 absorbance at 260 nm 
f dilution factor 
 
A pure DNA solution should not show measurable absorption above 300 nm, and its 
OD260/OD280 quotient should be at least 1.8. 
 
3.3.3 Agarose gel electrophoresis 
 DNA fragments were separated by agarose gel electrophoresis according to their 
length. By adding ethidium bromide, a DNA intercalating fluorescent dye, the bands 
in the gel become visible under UV-light (Sharp et al., 1973). For preparation of 
agarose gels 1% (w/v) agarose was dissolved in 0.5% TBE buffer by boiling it up in 
the microwave. Following cooling down to 50-60 °C, 0.2 µl of an ethidium bromide 
stock solution (10 mg/ml) was added per ml agarose. The solution was then cast into 
the gel chamber, and a comb was inserted. Following solidification, the gel was 
covered with 0.5% TBE buffer, and the comb was removed. The DNA samples were 
supplemented with DNA loading dye if required and pipetted into the gel pockets. 
The electrophoresis was performed using a voltage of 190 V for about 20 min. The 
negatively charged DNA migrates to the anode, whereby DNA fragments are 
retarded to a different extent by the agarose matrix due to differences in size. The 
fragments were detected under UV-light (λ = 302 nm) and documented using the 
Imager Multi-Doc-It Digital Imaging system if applicable. To estimate the size of the 
fragments, a volume of 5 µl of the GeneRuler™ 1 kb Plus DNA Ladder (Fermentas) 
or EZ Load™ 500bp/100bp Molecular Ruler (Bio-Rad) was applied to a separate 
pocket of the gel. 
 
3.3.3.1 Isolation of DNA fragments from agarose gels 
 The corresponding fragments were excised from the agarose gel under UV-light 
(λ = 302 nm) with a scalpel and transferred to a reaction vessel. DNA was extracted 
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using gel extraction kits from MACHERY-NAGEL (Nucleospin®II-Kit), FERMENTAS 
(GeneJET™ Gel Extraction Kit) or QIAGEN (QIAquick Gel Extraction Kit) according 
to the protocol supplied by the manufacturer. The isolated DNA was eluted in 30 µl 
sterile water and stored at -20 °C. 
 
3.3.4 Enzymatic manipulation of dsDNA 
3.3.4.1 Cleavage of dsDNA by restriction endonucleases 
 For specific cleavage of dsDNA type II restriction endonucleases were applied 
(Sambrook et al., 1989, Wilson & Murray, 1991), which bind to a palindromic 
recognition sequence (restriction site). These restriction enzymes generate single 
stranded overhangs (sticky ends), which contain 3’-hydroxyl and 5’-phosphate ends. 
For analytical cleavage a maximum of 1 µg DNA was incubated at 37 °C in the 
appropriate buffer with 20 U of each restriction enzyme for about 2 h in a volume of 
50 µl. For preparative cleavage, with the objective of subsequent ligation, 2 µg or the 
entire amount of PCR product and 2 µg of vector DNA were digested with 20 U of 
each restriction enzyme in a volume of 50 µl at 37 °C for 2 h. The volume of added 
restriction endonuclease in the reaction mixture should not exceed 10% of the total 
volume, as the activity of enzymes is influenced by glycerol, a component of the 
enzyme storage solution. The fragments were analyzed by agarose gel 
electrophoresis (3.3.3) and purified for subsequent ligation (3.3.3.1). 
 
3.3.4.2 Ligation of DNA fragments 
 For ligation, digested vector and insert were mixed at an estimated molar ratio of 
1:3 and ligated in a total volume of 20 µl with 1 U T4 DNA ligase (FERMENTAS or 
NEB) in the buffer supplied by the manufacturer, either overnight in a thermal cycler 
at 16 °C or for 1 h at RT. In order to increase the transformation efficiency, the 
T4 DNA ligase was heat inactivated by incubation at 65 °C for 10 min. Alternatively, 
the Quick Ligation™ Kit (NEW ENGLAND BIOLABS) was used, which allows for 
ligation within 5 minutes at RT. The procedure was performed according to the 
protocol supplied by the manufacturer. Subsequently, competent E. coli cells were 
chemically (3.2.3) transformed with the ligation mixture. 
 For ligation of gene libraries the digested vector and the randomized insert were 
also mixed in an estimated molar ratio of 1:3 and ligated in the buffer supplied by the 
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manufacturer with 1 U T4 DNA ligase (Roche). Incubation was performed overnight 
at 16 °C in a thermal cycler in a total volume of 20 µl. Subsequently, the T4 DNA 
ligase was heat inactivated by incubation at 65 °C for 10 min and dialyzed. 
Subsequently, competent E. coli cells were transformed by electroporation 
(3.2.5 & 3.2.6). 
 
3.3.5 Amplification of DNA fragments by standard PCR (polymerase 
chain reaction) 
 The polymerase chain reaction (PCR; Mullis & Faloona, 1987; Saiki et al., 1988) 
is used to amplify a specific DNA fragment in vitro. This is achieved by cyclic 
repetition of the denaturation of the double-stranded DNA, followed by the 
hybridization (annealing) of primers (synthetic oligonucleotides that flank the DNA 
sequence of interest) and enzymatic DNA synthesis (extension). The DNA fragment 
is exponentially amplified. The reaction was performed in a total volume of 50 µl in a 
thermal cycler (lid temperature 110 °C). The standard reaction mixture contained 5-
100 ng of template DNA, 2.5 U GoTaq® DNA polymerase, 5× Green GoTaq® reaction 
buffer [contains 7.5 mM MgCl2 (final concentration: 1.5 mM MgCl2) and loading 
buffer], 0.2 mM dNTP mix, and 1 µM of each primer. The standard PCR program was 
as follows: 
step temperature [°C] duration 
1. Initialization step 95 3 min 
2. Denaturation 95 45 s 
3. Annealing TA 45 s 
4. Extension 72 1 min/kb 
5. Finale elongation 72 10 min 
6. Final hold 16 ∞ 
Steps 2 to 4 were repeated 30 times. 
 The optimum annealing temperature TA of the primers was calculated according 
to the following equation (Chester & Marshak, 1993), which takes the GC-content 
and the length of the primers into account: 
!! = !",!+ !,!" ∙ %!" − !"#!  
Equation 3: Calculation of the melting temperature of oligonucleotides. 
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TM melting temperature of primers [°C] 
%GC GC-content of primers [%]  
n number of nucleotides in the primer 
 !! = !!" + !!"! − !°! 
Equation 4: Calculation of the optimum annealing temperature of a primer in the PCR 
reaction. 
TA  annealing temperature [°C] 
TM1 & TM2  melting temperatures of the primers [°C] 
 
 The optimum annealing temperature was also experimentally determined using a 
thermal cycler with gradient function (EPPENDORF Mastercycler ep). To this end, 
different PCRs with annealing temperatures between 50 °C and 70 °C were set up in 
parallel, and the yields of the amplification products were determined. 
 If applicable, the specificity and yield of the amplification product was increased 
by applying nested PCR. To this end, two successive PCRs were carried out using 
two sets of primers. The PCR product from the first amplification step served as 
template for the second amplification using nested primers that bind within the PCR 
product and result in a shorter DNA fragment. 
 For high fidelity amplification of DNA fragments Phusion® High-Fidelity DNA 
polymerase was used, which – in contrast to Taq polymerase – possesses 3’→5’ 
proofreading activity. The reaction was performed in a total volume of 50 µl 
containing 10 ng of template DNA, 1 U Phusion® High-Fidelity DNA polymerase, 5 × 
Phusion® HF reaction buffer [contains 7.5 mM MgCl2 (final concentration: 1.5 mM 
MgCl2)], 3 % (v/v) DMSO (optional; added for GC-rich templates), 0.2 mM dNTP mix, 
and 1 µM of each primer. The standard PCR program for Phusion® High-Fidelity DNA 
polymerase was as follows: 
step temperature [°C] duration 
1. Initialization step 98 30 s 
2. Denaturation 98 10 s 
3. Annealing TA 20 s 
4. Extension 72 15 s/kb 
5. Finale elongation 72 10 min 
6. Final hold 16 ∞ 
Steps 2 to 4 were repeated 30 times. 
Best amplification results were achieved with an annealing temperature of 65 °C. 
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3.3.6 Colony PCR 
 To verify the success of cloning, an insert screening was performed by colony 
PCR. Transformants grown on selective LB agar were added to the PCR mixture by 
picking a single colony with a pipette tip and transferring small quantities of cells to 
the reaction mixture. The cells were subsequently disrupted in the initial denaturation 
step at 95 °C, and the released DNA was used as template in the following 
amplification cycles. If not stated otherwise, vector-specific amplification primers 
were used. The standard reaction mixture included 1 U GoTaq® DNA polymerase, 
5 × Green GoTaq® reaction buffer, 0.2 mM dNTP-mix, 1 µM of each primer, and 
water to a final volume of 20 µl. The amplification was performed according to the 
standard protocol described in 3.3.5. 
 
3.3.7 PCR methods for site-directed mutagenesis 
3.3.7.1 QuikChange site-directed mutagenesis (QCM) 
 The QuikChange site-directed mutagenesis method allows for the efficient 
introduction of point mutations, insertions and deletions in any type of dsDNA 
plasmids. It is performed using Pfu DNA polymerase, which replicates both plasmid 
strains with high fidelity due to its 3’→5’ proofreading activity.  
 The technique originally developed by STRATAGENE (La Jolla, USA) was 
modified according to a protocol published by Wang & Malcolm (1999) using a two-
stage mutagenesis protocol. For introduction of point mutations complementary 
mutagenic primers with up to 35 bases in length and 12-15 bases of template 
complementary sequence on both sides of the mismatch were used. Pfu DNA 
polymerase extends and incorporates mutagenic primers during temperature cycling 
and generates a mutated plasmid containing staggered nicks. To avoid unproductive 
primer dimer formation, two separate primer extension reactions were performed 
initially. In the second step both primer extension reactions are combined and linearly 
amplified. Methylated DNA template is digested by treatment of the product with 
DpnI. E. coli cells are transformed with the nicked vector DNA carrying the desired 
mutations, and the nicks are sealed by the DNA repair apparatus of the cells. See 
Figure 10 for illustration. 
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Figure 10: Overview of the QuikChange site-directed mutagenesis method. 
In the first step the mutated plasmids containing staggered nicks are generated in two parallel primer 
extension reactions (E1 and E2). The reactions E1 and E2 are combined and amplified. In the second 
step, the DNA template is digested by treatment with DpnI, and E. coli cells are transformed with the 
nicked vector DNA containing the desired mutations. The figure was adapted from the QuikChangeTM 
Site-Directed Mutagenesis Kit manual (STRATAGENE). 
 
 The two separate primer extension reactions (E1 and E2) were performed each in 
a total volume of 50 µl containing 50 ng of template plasmid comprising the gene of 
interest, 2.5 U Pfu DNA polymerase, 10× Pfu DNA polymerase reaction buffer 
[contains 20 mM MgCl2 (final concentration: 2 mM MgCl2)], 0.2 mM dNTP mix, and 
1.6 µM of either the 5’ or 3’ primer. The standard primer extension program using Pfu 
DNA polymerase was as follows: 
step temperature [°C] duration 
1. Initialization step 95 3 min 
2. Denaturation 95 45 s 
3. Annealing TA 1 min 
4. Extension 72 2 min/kb 
5. Finale elongation 72 10 min 
6. Final hold 16 ∞ 
Steps 2 to 4 were repeated 4 times. 
Best results were achieved with an annealing temperature of 55 °C. 
 Subsequently, 25 µl of each primer extension reaction (E1 and E2) were mixed, 
supplemented with additional 2.5 U Pfu DNA polymerase and subjected to 18 cycles 
of QCM as described above. The methylated template DNA was digested by directly 
adding 20 U DpnI to 25 µl of the QCM reaction mix and incubated at 37 °C for 1.5 h. 
Then, chemically competent E. coli Turbo cells were transformed using 10 µl of DpnI-
digested QCM mix. 
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3.3.7.2 Phusion® Site-Directed Mutagenesis Kit 
 For multiple amino acid insertions and deletions in plasmid DNA site-directed 
mutagenesis was performed using the Phusion® Site-Directed Mutagenesis Kit 
(FISHER SCIENTIFIC), according to the protocol supplied by the manufacturer. The 
complementary mutagenic primers required 5’ phosphorylation. Details for the primer 
design are shown in Figure 11. 
 
 
Figure 11: Schematic overview of the primer design for introducing point mutations (A), 
deletions (B), and insertions (C1+C2) applying the Phusion Site-Directed Mutagenesis Kit. 
5’ P: 5’ phosphorylation. The figure was adapted from the Phusion® Site-Directed Mutagenesis Kit 
manual. 
 
 Amplification of the target plasmid with two 5’ phosphorylated primers and 
Phusion® Hot Start II DNA polymerase was performed essentially as described in 
3.3.5. The PCR product was circularized with Quick T4 DNA Ligase in a 5 min 
reaction (3.3.4.2) and chemically competent E. coli Turbo cells were transformed 
using 10 µl of the reaction mix. 
 
3.3.7.3 Megaprimer PCR (Sarkar & Sommer, 1990) 
 The megaprimer PCR method is a site-directed mutagenesis method that is 
conducted in two sequential PCR reactions. In a first PCR the megaprimer was 
generated, by amplifying a DNA fragment using a gene flanking primer and the 
mutagenic primer. The gel-purified megaprimer (3.3.3 & 3.3.3.1) was used, together 
with a gene flanking primer of the opposite site of the gene, to obtain the full-length 
gene in a second PCR. 
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Figure 12:  Scheme for standard megaprimer PCR.  
Site-directed mutations were introduced in the first step by mutagenic primer, complementary to the 
target DNA. 
 
 Both PCRs were performed according to the previously described method (3.3.5). 
The optimum annealing temperature was experimentally determined, if required. In 
general, this method was applied, when the mutated nucleotide was located within 
the first or last 100 bases of a gene. 
 
3.3.7.4 Overlap extension PCR (Ho et al., 1989) 
 Site-directed mutagenesis by overlap extension PCR (OE-PCR) uses two 
complementary mutagenic primers with a length of 25-35 bp that are complementary 
to the target DNA and comprise the nucleotide changes in the central region of their 
sequences. The first two separate PCRs generated two overlapping fragments 
carrying the desired mutation, using a set of mutagenic primer and flanking primer 
each. These mutagenic fragments were subsequently purified by preparative gel 
electrophoresis (3.3.3 & 3.3.3.1). The gel-purified fragments were used as templates 
in combination with the flanking primers to amplify the entire gene. The amplification 
was carried out according to the standard protocol described in 3.3.5. For an 
illustrating scheme see Figure 13. 
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Figure 13: Scheme for standard OE-PCR. 
In the first step the 5’ and 3’ fragments are amplified in two separate PCRs with a gene flanking primer 
and a mutagenic primer using the target DNA as template. In the second step the fragments served as 
template and the mutagenized full length construct is amplified using the flanking primers. 
 
3.3.8 In vitro recombination by StEP (staggered extension process) 
 In vitro recombination by staggered extension process (Zhao et al., 1998) is an 
efficient method for the recombination of homologous template sequences. Template 
sequences are primed followed by repeated cycles of denaturation and extremely 
abbreviated annealing/polymerase-catalyzed extension. Partially extended fragments 
hybridize randomly on templates harboring different mutations and extend further. 
This is repeated until full-length sequences are formed. At each round of annealing, 
template switching results in crossovers in regions of sequence homology, yielding 
polynucleotides contain sequence information from different parental sequences. The 
recombination diversity can be controlled by altering time and temperature of the 
annealing/extension steps. See Figure 14 for illustration. 
 
 
Figure 14: Scheme for StEP recombination. 
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A: Denatured templates genes are primed with one defined primer. B: Short fragments are produced 
by brief polymerase-catalyzed extension. C: In a subsequent cycle of StEP, fragments randomly prime 
the templates (template switching) and extend further. D+E: The process is repeated until full-length 
gens are produced. The figure was adapted from Zhao et al. (1998). 
 
 The technique was applied to rapidly recombine beneficial mutations from positive 
first-generation variants while deleterious mutations are removed due to 
backcrossing with the wild-type sequence. 
The reaction was performed in a total volume of 50 µl containing 10 ng of each 
template DNA, 2.5 U GoTag® DNA polymerase, 5× Green GoTaq® reaction reaction 
buffer [contains 7.5 mM MgCl2 (final concentration: 1.5 mM MgCl2) and loading 
buffer], 0.2 mM dNTP mix, and 0.15 µM of each primer. The PCR program was as 
follows: 
step temperature [°C] duration 
1. Initialization step 95 5 min 
2. Denaturation 94 30 s 
3. Annealing/Extension TA 3 s 
4. Final hold 4 ∞ 
Steps 2 to 3 were repeated 130 times. 
 The optimum annealing temperature was experimentally determined applying a 
gradient of 40-55°C (EPPENDORF Mastercycler ep). Subsequently, nested PCR 
was performed as described in 3.3.5 in order to increase the yield of the amplification 
product.  
 
3.3.9 Transposon-mediated insertion mutagenesis (MGS™ Kit) 
 The Mutation Generation System™ Kit (MGS™ Kit, FISHER SCIENTIFIC) has 
been designed for rapid and efficient construction of linker scanning libraries for 
functional analysis of proteins and regulatory DNA regions. The system employs the 
highly efficient transposition machinery of the bacteriophage Mu to insert an artificial 
transposon, designated as Entranceposon, randomly into any target plasmid. MuA 
Transposase catalyzes the in vitro transposition reaction. The inserted clones 
generated in the transposition reaction are digested with the NotI restriction 
endonuclease to remove the body of the Entranceposon, and subsequent self-
ligation results in a 15 bp insertion in the target DNA. See Figure 15 for illustration. 
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Figure 15: Flowchart of insertion mutagenesis. 
A: In vitro transposition reaction/transposon insertion reaction, transformation and selection of 
transposon insertion clones, and plasmid preparation. The insert containing the Entranceposon is 
subcloned into a fresh vector. B: Plasmid preparation. NotI digestion, ligation, and transformation. The 
Figure was adapted from the MGS™ Kit manual. 
 
 In case the transposition occurs in the coding region of the target gene, the 15 bp 
insertion is translated into five extra in-frame amino acids (Figure 16).  
 
 
Figure 16: Structure of the 15 bp insertion (A) and translation of 15 bp insertion (B). 
A: 15bp insertion into target DNA results in duplicated target sites. B: In-frame translation. The Figure 
was adapted from the MGS™ Kit manual. 
 
 The transposon insertion reaction using HyperMu MuA transposase 
(EPICENTRE; 50× more active than regular MuA transposase) and M1-CamR 
Entranceposon (supplied with MGS™ Kit; 1254 bp) was performed in a total volume 
of 20 µl containing a minimum of 150 ng of template plasmid, 100 ng M1-CamR 
Entranceposon, 1 U HypeMu MuA transposase (EPICENTRE), 10× HyperMu 
reaction buffer. The reaction mix was incubated at 30 °C for 4 h using a thermal 
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cycler. The HyperMu MuA transposase was inactivated by adding HyperMu 10x 
STOP solution (containing 1% SDS) and heat inactivation at 75 °C for 10 min. 
Chemically competent E. coli Turbo cells were transformed with the reaction mix and 
plated on LB agar plates containing the plasmid and Entranceposon selection marker 
(10 µg/ml CHLOR for M1-CamR). Transformants from plates were scraped, pooled, 
and plasmid DNA was prepared using QIAGEN Midi prep kit (3.3.1.2). As the 
transposon insertion occurs also in the vector backbone, the insert containing the 
entranceposon was subcloned into a fresh vector (3.3.4.1 and 3.3.4.2), and plasmid 
DNA was prepared. Subsequently, the body of the entranceposon was removed by 
NotI digestion and the fragment was gel-purified (3.3.3 & 3.3.3.1). Subsequently, 
NotI-digested fragments were re-ligated using the Quick Ligation™ Kit. To favour 
self-ligation of the NotI-digested fragments the DNA concentration in the ligation set 
up was diluted to 1-5 ng/µl. Chemically competent E. coli Turbo cells were 
transformed with the reaction mix and plated on LB agar plates containing the 
plasmid selection marker. Transformants from plates were scraped, pooled and 
plasmid DNA was prepared using QIAGEN Midi prep kit (3.3.1.2). To map the 
insertion site of randomly chosen transposon insertion clones colony-PCR (3.3.6) 
was performed using NotI mini-primers provided with the kit (forward and reverse 
transposon specific primers) and vector-specific flanking primers. Alternatively, 
insertion sites can be mapped by NotI restriction endonuclease digestion of the 
plasmid preparation. 10 randomly chosen transposon insertion clones were 
subjected to sequencing to determine the exact position of the insert and the inserted 
amino acid sequence. 
 
3.3.10 Construction of a gene library 
 The gene, from which a library was generated, was subjected to simultaneous 
mutagenesis of selected positions (SHM) (3.3.7.3 and 3.3.7.4), StEP recombination 
(3.3.8) or transposon-mediated insertion mutagenesis (3.3.9). The reaction product 
and 2 µg target vector were cleaved with the corresponding restriction 
endonucleases and purified by agarose gel electrophoresis (3.3.3 & 3.3.3.1). The 
DNA was eluted in 50 °C warm, sterile water to obtain optimum yield. The ligation 
(3.3.4.2) was performed in 6-9 parallel reactions à 20 µl overnight at 16 °C. Freshly 
prepared electro-competent ΔhisA-ΔhisF or NEB Turbo cells (100 µl) were 
transformed with 5 µl dialyzed ligation mixture each (3.2.5 & 3.2.6), i.e. 15-30 
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transformations were carried out per gene library. The cell suspension was 
supplemented with 1.5 ml SOC medium per transformation assay, pooled in 50 ml 
falcon vessels, and incubated for 1 h at 37 °C and 220 rpm. Subsequently, the cells 
were harvested by centrifugation (EPPENDORF Centrifuge 5810R, 4000 rpm, 
10 min, 25 °C) and resuspended in 8 ml SOC medium. The cell suspension was then 
plated in aliquots à 200 µl on 40 large SOC selective agar plates (Ø 14.5 cm). For 
determination of the gene library size, 100 µl of different dilutions were streaked out 
on small selective SOC agar plates (Ø 8.5 cm) (see 3.3.10.1). 
 The transformants grown on large SOC plates were scraped off using a sterile 
spatula and liquid LB media. The resulting cell suspension was pooled and 
centrifuged (EPPENDORF Centrifuge 5810R, 4000 rpm, 15 min, 4 °C). The cell 
pellet was weighted, and the plasmid gene library was isolated by maxi-preparation 
(3.3.1.2). 
 
3.3.10.1 Determination of the size of a gene library 
 To determine the size of a gene library (number of independent clones with 
correct insert length), 100 µl of transformed cells were diluted 10-1 to 10-8-fold, and 
plated on small SOC agar plates containing the adequate antibiotics. Following 
overnight incubation at 37 °C colonies were counted, and the number of transformed 
cells was determined according to Equation 5: !! = !! ∙ ! ∙ !! 
Equation 5: Determination of the number of transformed cells. 
nT number of transformed cells 
nC number of colonies on the agar plate 
f plating dilution factor 
Vs volume dilution factor (total volume of plated cell suspension, divided by 100 µl) 
 
 Subsequently the ligation efficiency (0≤L≤1) was determined by performing colony 
PCR with at least 20 selected colonies (3.3.6) using Equation 6. ! = !!!! 
Equation 6: Determination of the ligation efficiency. 
L ligation efficiency 
nV number of colonies with correct insert 
nG number of analyzed colonies (usually 20) 
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 The size of the gene library (G) was determined with Equation 7 by multiplying the 
number of transformed cells (nT) by the ligation efficiency (L): ! = !! ∙ !   
Equation 7: Determination of the gene library size. 
 
 In order to determine the quality of a gene library usually 10 randomly selected 
clones were analyzed by sequencing. 
 
3.3.11 DNA sequencing  
 All Dr0930 and PTE gene constructs generated and used in this work were 
entirely sequenced to exclude inadvertent mutations. The determination of nucleotide 
sequences was performed either by the company Geneart (part of Life Technologies, 
Regensburg) or at the Gene Technologies Laboratory at the Texas A&M University 
(College Station, USA). DNA was sequenced according to the dideoxy-chain 
termination method (Sanger et al., 1977). In this technique 2’, 3’-dideoxynucleotides 
stained with different fluorescence labels are used in addition to the 2’-
deoxynucleotides in a thermal cycle sequencing reaction (Sears et al., 1992; Slatko, 
1994). The reaction products are 3’-labelled single-stranded termination fragments, 
which were separated by gel electrophoresis. Subsequently, the nucleotide sequence 
was analyzed.  
 Samples for sequencing orders at Genart contained 100-300 ng DNA and 
1.25 µM of sequencing primer in a total volume of 8 µl. Genart performed the 
sequencing reaction, and analyzed the data using an ABI PRISM® 3700 DNA 
Analyzer (APPLIED BIOSYSTEMS). 
 Alternatively, templates were sequenced with an ABI PRISM® BigDye™ 
Terminator Cycle Sequencing Ready Reaction Kit (PERKIN ELMER APPLIED 
BIOSYSTEMS) and analyzed by the Gene Technologies Laboratory using an ABI 
PRISM® 3100 Genetic Analyzer (APPLIED BIOSYSTEMS). To this end, the 
sequencing reaction was performed in a total volume of 6 µl in a thermal cycler. The 
standard reaction mixture contained 2 µl BigDye™ Terminator Ready Reaction Mix 
(contains 5× reaction buffer, dNTPs, ddNTPs, AmpliTaq DNA Polymerase FS), 400-
600 ng plasmid DNA, and 3 µM of sequencing primer, according to the protocol 
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supplied by the manufacturer. The PCR program for cycle sequencing was as 
follows: 
step temperature [°C] duration 
1. Initialization step 96 2 min 
2. Denaturation 96 30 s 
3. Annealing TA 15 s 
4. Extension 60 4 min 
5. Final hold 4 ∞ 
Steps 2 to 4 were repeated 30 times. 
Best results were achieved with an annealing temperature of 55 °C. 
 Extension products were purified and excess dye-terminators were removed 
using Micro Bio-Spin P-30 spin columns (BIO-RAD) according to the protocol 
supplied by the manufacturer. Samples were dryed using a SpeedVac device, and 
submitted to the Gene Technologies Laboratory for evaluation. 
 The sequences were received in ABI-formate and analyzed using the software 
Sequencher. 
 
3.4 Protein biochemistry methods 
3.4.1 Gene expression and purification of recombinant protein 
3.4.1.1 Gene expression in analytical scale 
 To test, whether cloned genes are overexpressed and in order to analyze whether 
the recombinant proteins were produced in soluble form, expression was performed 
in analytical scale in triplicates (“test expression”). 
 To this end, 5 ml LB medium were supplemented with the appropriate antibiotics, 
inoculated with an overnight culture of a single colony to an OD600 of 0.1, and 
incubated at 37 °C and 220 rpm. At an OD600 value of 0.4–0.6, the cultures were 
supplemented with 1.0 mM CoCl2, if not stated otherwise, and induced by adding 
IPTG to a final concentration of 0.5 mM. Following incubation at 37 °C (wild-type 
Dr0930 and Dr0930 variants) or 30 °C (wild-type PTE) for 4 h, the cell suspension 
was centrifuged (EPPENDORF Centrifuge 5415R, 8000 rpm, 5 min, 4 °C). The pellet 
was resuspended in 100 µl of 20 mM HEPES, pH 7.5, 100 µM CoCl2 (wild-type 
Dr0930 and Dr0930 variants) or 50 mM HEPES, pH 8.5, 100 µM CoCl2 (wild-type 
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PTE). The cells were disrupted by sonication (amplitude 20%, 20 s) or by addition of 
100 µl PopCulture® reagent (1×; ready to use reagent; MERCK) followed by 
incubation at RT for 40 minutes. Following centrifugation (EPPENDORF Centrifuge 
5415R, 13200 rpm, 10 min, 4 °C) the supernatant (containing soluble protein) was 
taken off, and the pellet (containing insoluble protein) was resuspended in an equal 
volume of the appropriate resuspension buffer. Aliquots of the supernatant (S) and 
the resuspended pellet (P) were supplemented with SDS sample buffer (5×), and 
incubated for 5 min at 95 °C. Subsequently, a volume of 5-10 µl of both S and P was 
analyzed by SDS-PAGE. 
 
3.4.1.2 Gene expression and purification of recombinant proteins in 
preparative scale 
 For purification of proteins in preparative scale, 1 l LB (wild-type Dr0930 and 
Dr0930 variants) or TB (wild-type PTE) medium was supplemented with the 
corresponding antibiotics and 0.5 mM CoCl2 or 1.0 mM CoCl2, respectively. The 
medium was inoculated with a freshly prepared overnight E. coli culture from a single 
colony to an OD600 value of 0.1. The suspension was incubated at 37 °C and 
140 rpm. At an OD600 value of 0.4-0.6, for wild-type Dr0930 and variants the 
suspension was supplemented with additional 0.5 mM CoCl2. The suspension was 
induced with 0.5 mM IPTG and incubated overnight at 37 °C (wild-type Dr0930 and 
Dr0930 variants) or 30 °C (wild-type PTE), respectively. The cells were harvested by 
centrifugation (Sorvall RC5B plus, GS3 Rotor, 4000 rpm, 10 min, 4 °C), and the pellet 
was resuspended in 30 ml of 20 mM HEPES, pH 7.5, 100 µM CoCl2 (wild-type 
Dr0930 and Dr0930 variants) or 50 mM HEPES, pH 8.5, 100 µM CoCl2 (wild-type 
PTE), respectively. Cells were disrupted by sonication on ice (amplitude 70%, 4 min, 
interval: 15 s pulse and 15 s pause). The suspension was centrifuged (Sorvall RC5B 
plus, SS34 Rotor, 13000 rpm, 30 min, 4 °C) and the supernatant (S) was further 
processed. 
 
3.4.2 Protein purification from the soluble cell fraction 
3.4.2.1 Protamine sulfate and ammonium sulfate precipitation 
 Protamine sulfate and ammonium sulfate precipitation are efficient methods used 
for initial sample concentration and cleanup (GE HEALTHCARE, Strategies for 
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Protein Purification, Handbook). Protamine sulfate, a small cationic protein that binds 
and precipitates nucleic acids, is used to remove DNA impurities from protein 
samples. During ammonium sulfate precipitation, proteins will begin to salt out as 
increased salt concentrations enhance hydrophobic interactions between proteins. 
Different proteins are precipitated at different salt concentrations, consequently 
differences in hydrophobicity result in a fractionated precipitation. Proper selection of 
ammonium sulfate concentration allows for the removal of protein impurities from the 
crude extract.  
 A 1% (w/v) protamine sulfate solution was prepared by dissolving 0.2 g protamine 
sulfate in 20 ml resuspension buffer (20 mM HEPES, pH 7.5, 100 µM CoCl2 or 
50 mM HEPES, pH 8.5, 100 µM CoCl2) by incubation at 40-50 °C. Prior to use the 
solution was cooled down. The following steps were carried out in the cold room at 
4 °C: 1% (w/v) protamine sulfate solution was added dropwise to the supernatant on 
ice, while stirring vigorously, and the suspension was incubated for another 20 min 
on ice. The suspension was centrifuged (Sorvall RC5B plus, SS34 Rotor, 13000 rpm, 
30 min, 4 °C), and the supernatant (S) was subjected to ammonium sulfate 
precipitation. For this purpose, (NH4)2SO4 was added to a final concentration of 45% 
saturated solution, portion-wise as crystalline (NH4)2SO4 salt using a spatula, while 
stirring vigorously on ice. The amount of (NH4)2SO4 was calculated using the weblink 
provided by EnCor Biotechnology Inc (Gainesville, USA; 
www.encorbio.com/protocols/AM-SO4.htm). The suspension was centrifuged (Sorvall 
RC5B plus, SS34 Rotor, 13000 rpm, 30 min, 4 °C), and the pellet, containing the 
protein of interest, was resuspended in 15 ml of 20 mM HEPES, pH 7.5, 100 µM 
CoCl2 or 50 mM HEPES, pH 8.5, 100 µM CoCl2. Both fractions were further analyzed 
by SDS-PAGE (3.5.2) and absorption spectroscopy. Subsequently, (NH4)2SO4 was 
removed by dialysis (3.4.2.4.1). 
 
3.4.2.2 Ion exchange chromatography (IEX) 
 Ion exchange chromatography is based on the competition of charged molecules 
(proteins and salt ions) for interaction with immobilized ion exchange groups of 
opposite charge. In the first stage, charged molecules adsorb reversibly to the 
immobilized support material. Subsequently, bound molecules are eluted by a 
gradient of steadily increasing ionic strength, or alternatively a pH-gradient. The 
charge of the protein is mainly dependent on the amino acids with charged side 
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chains. In the acidic or neutral pH-range the amino groups, mainly those of Lys, Arg 
and His, are protonated and the protein exposes cationic behavior, whereas in a 
neutral or basic pH-range, the carboxyl groups of Asp and Glu residues are 
negatively charged and consequently the protein is anionic. The total charge of 
proteins is mainly dependent on the amino acid composition and the pH-value of the 
surrounding buffer. Ion exchange chromatography can be subdivided into cation 
exchange chromatography, in which positively charged ions bind to a negatively 
charged resin, and anion exchange chromatography, where negatively charged ions 
bind to a positively charged resin. 
 Wild-type Dr0930 and Dr0930 variants were purified using a XK26 column packed 
with Q Sepharose Fast Flow ion exchange media (GE HEALTHCARE, CV: 40 ml) or 
another anion exchange column (Resource Q 6 ml; MonoQ 5/50 GL). Wild-type PTE 
was purified using a simple gravity flow column (SIGMA ALDRICH) packed with 
DEAE Fast Flow ion exchange material (GE HEALTHCARE, CV: 20 ml). 
 The purification with the Q Sepharose Fast Flow column was performed using the 
chromatography system ÄKTA™ Purifier 10 (GE HEALTHCARE) as follows: 
Flow rate:   5 ml/min 
Equilibration:  1 CV binding buffera  
Sample volume:  15-30 ml protein solution in binding buffera 
Wash:   2 CV binding buffera 
Elution:   8 CV 1st gradient (0–0.5 M NaCl in binding buffera), 
    1 CV 2nd gradient (0.5–2 M NaCl in binding buffera); 
4 ml fractions were collected. 
Column purification: 5 CV elution bufferb 
Reequilibration:  3 CV binding buffera 
Purging and storage: 5 CV H2O; 3 CV 20% ethanol 
a: binding buffer: 20 mM HEPES, pH 7.5, 100 µM CoCl2  
b: elution buffer: 20 mM HEPES, pH 7.5, 100 µM CoCl2, 2 M NaCl 
 
 The purification with the Resource Q 6 ml column was performed using the 
chromatography system ÄKTA™ Purifier 10 (GE HEALTHCARE) as follows: 
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Flow rate:   5 ml/min 
Equilibration:  2 CV binding buffera  
Sample volume:  35 ml protein solution in binding buffera 
Wash:   6 CV binding buffera 
Elution:   20 CV gradient (0–1.5 M NaCl in binding buffera); 
3 ml fractions were collected. 
Column purification: 5 CV elution bufferb 
Reequilibration:  5 CV binding buffera 
Purging and storage: 5 CV H2O; 3 CV 20% ethanol 
a: binding buffer: 20 mM HEPES, pH 7.5 
b: elution buffer: 20 mM HEPES, pH 7.5, 2 M NaCl 
 
 The purification with the MonoQ 5/50 GL column was performed using the 
chromatography system ÄKTA™ Purifier 10 (GE HEALTHCARE) as follows: 
Flow rate:   2 ml/min 
Equilibration:  2 CV binding buffera  
Sample volume:  20 ml protein solution in binding buffera 
Wash:   10 CV binding buffera 
Elution:   30 CV gradient (0–0.5 M NaCl in binding buffera); 
0.5 ml fractions were collected. 
Column purification: 5 CV elution bufferb 
Reequilibration:  5 CV binding buffera 
Purging and storage: 5 CV H2O; 3 CV 20% ethanol 
a: binding buffer: 20 mM HEPES, pH 7.5 
b: elution buffer: 20 mM HEPES, pH 7.5, 2 M NaCl 
 
 The elution of protein was monitored by detecting the absorbance at 260, 280 and 
550 nm (inherent absorption of wild-type Dr0930 and Dr0930 variants). Further 
analysis of the eluted fractions was done using SDS-PAGE (3.5.2). Pure fractions 
were pooled and dialyzed against 5 l of 20 mM HEPES, pH 7.5, 100 µM CoCl2 
(3.4.2.4.1). 
 The purification of wild-type PTE by the DEAE Sepharose Fast Flow column was 
performed manually using a gravity flow column and an isocratic gradient in a simple 
and fast bind-wash-elute procedure: impurity proteins bind to the column whereas 
wild-type PTE elutes (reverse-purification). The procedure is described as follows: 
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Equilibration:  2 CV binding buffera  
Sample volume:  25 ml protein solution in binding buffera 
Elution:   2 CV binding buffera; 1 ml fractions were collected. 
Column purification: 5 CV elution bufferb 
Reequilibration:  5 CV binding buffera 
Purging and storage: 5 CV H2O; 3 CV 20% ethanol 
a: binding buffer: 50 mM HEPES, pH 8.5, 100 µM CoCl2 
b: elution buffer: 50 mM HEPES, pH 8.5, 100 µM CoCl2, 2 M NaCl 
 
 The eluted fractions were analyzed using SDS-PAGE (3.5.2). Pure fractions were 
pooled and dialyzed against 5 l of 50 mM HEPES, pH 8.5, 100 µM CoCl2 (3.4.2.4.1). 
 
3.4.2.3 Preparative gel filtration 
 Gel filtration is a chromatographic technique, which is based upon the principle of 
a reverse molecular sieve (size exclusion chromatography). When the mobile phase 
passes through the porous support material at a constant flow rate, small molecules 
are able to diffuse into the pores, while larger molecules are excluded. As a 
consequence, small molecules are retarded with respect to larger molecules, which 
cause proteins to be fractionated according to their size. 
 In this work preparative gel filtration was performed with the ÄKTA purifier 10 (GE 
HEALTHCARE) at RT or the FPLC LCC-501 device (GE HEALTHCARE) in the cold 
room at 4 °C, using a Hi Load 26/60 Superdex 200 Prep Grade (GE HEALTHCARE, 
CV: 320 ml) or Hi Load 16/60 Superdex 75 Prep Grade column (GE HEALTHCARE, 
CV: 120 ml). These columns consist of highly cross-linked porous agarose beads 
(mean particle size: 34 µm; different pore size) to which dextran has been covalently 
bound. The maximum volume of loaded protein was about 5-10 ml. For this reason 
the sample had to be concentrated (3.4.2.5) before it was loaded onto the column 
using a superloop. The column was equilibrated with 20 mM HEPES, pH 7.5, 100 µM 
CoCl2, 300 mM NaCl  (wild-type Dr0930 and Dr0930 variants) or 50 mM HEPES, 
pH 8.5, 100 µM CoCl2, 300 mM NaCl (wild-type PTE). Proteins were eluted with 
1.2 CV of the same buffer at a flow rate of 1 ml/min (back pressure: max. 0.3 MPa). 
The run was recorded using a manual plotter, which measured the absorbance at 
280 nm. The fraction collector was started at the beginning of the elution, and 
fractions of 4 ml volume were collected. The fractions were further analyzed by SDS-
PAGE (3.5.2). 
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3.4.2.4 Desalting of protein solutions 
3.4.2.4.1 Dialysis of protein solutions 
 To exchange the buffer of a protein solution or to remove salt, a dialysis was 
performed overnight against an at least 100-fold volume excess of buffer at 4 °C in 
the cold room. A dialysis tubing (Visking or Spectra/Por) with a molecular cut-off of 
14 kDa (or 10 kDa) was used, which retains the protein while low molecular 
substances can pass through the membrane. For enzyme kinetic measurements the 
purified Dr0930 variants were dialyzed once against 5 l of 20 mM HEPES, pH 7.5, 
100 µM CoCl2 (wild-type Dr0930 and Dr0930 variants) or 50 mM HEPES, pH 8.5, 
100 µM CoCl2 (wild-type PTE). 
 
3.4.2.4.2 Desalting and buffer exchange by GE illustra NAP™ or PD-10 
columns  
 If applicable, protein solutions were desalted or buffers were exchanged in-
between chromatography runs, prior to ICP-MS measurements or prior to the pH-
dependent colorimetric assay using the GE illustra NAP™ (prepacked with 
Sephadex™ G-25 DNA Grade) or PD-10 columns according to the protocols 
supplied by the manufacturer. 
 
3.4.2.4.3 Desalting via GE Sephadex G25 Desalting 
 If the Dr0930 variants were purified by two successive anionic exchange 
chromatography steps (3.4.2.2), the protein solution was desalted after the first 
purification step using the GE Sephadex G25 Desalting column. Desalting was 
performed with the chromatography system ÄKTA™ Purifier 10 (GE HEALTHCARE) 
as follows: 
Flowrate:   10 ml/min 
Equilibration:  0.1 CV  
Sample volume:  max. 20 ml protein solution in buffera, containing up to  
1.5 mM NaCl 
Isocratic elution:  2 CV binding buffera; 5 ml fractions were collected. 
Storage:  binding buffera 
a: binding buffer: 20 mM HEPES, pH 7.5 
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3.4.2.5 Concentrating protein solutions 
 Protein solutions were concentrated using Amicon® centrifugal filter devices 
(Amicon Ultra-15; molecular cut-off: 10 kDa) by a semi-permeable membrane 
according to the instructions of the manufacturer (Eppendorf Centrifuge 5810R, 
4000 rpm, 4 °C). 
 
3.4.2.6 Storage of purified proteins 
 Purified and concentrated proteins were frozen in liquid nitrogen either dropwise 
or as aliquots in reaction vessels and stored at -80 °C. 
 
3.5 Analytical methods 
3.5.1 Protein concentration determination via UV-absorption 
spectroscopy 
 The aromatic amino acids tryptophan, tyrosin and phenylalanine as well as 
disulfide bonds (cystine) absorb UV-light in a wavelength interval between 250 and 
300 nm. The molar extinction coefficient at 280 nm (ɛ280) can be determined from the 
amino acid composition (Pace et al., 1995) (Equation 8).  !!"# = !"# ∙ !!""+ !"# ∙ !"#$+ !"#$%&' ∙ !"# 
Equation 8: Determination of the molar extinction coefficient ɛ280. 
ɛ280 molar extinction coefficient at 280 nm [M-1cm-1] 
 
 The specific extinction coefficient (0.1%A280) can be calculated according to 
Equation 9 taking the molecular weight into account. 
 
 
0.1%!!"# = !!"#!" 
Equation 9: Determination of the specific extinction coefficient 0.1%A280. 
0.1%A280 specific extinction coefficient at 280 nm [cm2/mg] 
MW molecular weight of the protein [g/mol] 
 
 Using Lambert-Beer’s law, the protein concentration can be determined by 
measuring the absorbance at 280 nm (Equation 10): !!"#= 0.1%!!"# ∙   !   ∙   ! 
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Equation 10: Determination of the protein concentration by using the specific extinction 
coefficient 0.1%A280. 
A280 absorbance at 280 nm 
c concentration [mg/ml] 
d pathlength [cm] 
0.1%A280 specific extinction coefficient at 280 nm [cm2/mg]  
 
 Absorbance spectra between 220 and 350 nm were recorded. The absorbance 
maximum should be at 278 nm and the A280/A250 ratio should be at least 1.8 for a 
pure protein solution. No absorbance above 300 nm should be detectable to exclude 
any distortion of the results caused by light scattering resulting from aggregation. 
Table 2 shows the molar extinction coefficients, molecular weights, and specific 
extinction coefficients of the wild-type proteins used in this work. For protein variants 
the respective coefficients were recalculated. 
 
Table 2: Properties of wild-type Dr0930 and wild-type PTE relevant for concentration 
determination. 
Number of tryptophan and tyrosine residues, molar extinction coefficients, molecular weight (MW) and 
specific extinction coefficients of investigated wild-type proteins. 
protein Σ Trp + Tyr ɛ280 [M-1cm-1] MW [g/mol] 0.1%A280 [cm/mg] 
wild-type PTE  4 × Trp + 5 × Tyr 29450 36420 0.81 
wild-type Dr0930  3 × Trp + 9 × Tyr 29910 34728 0.86 
 
3.5.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 Proteins are denatured by the detergent sodium dodecyl sulfate (SDS) and 
negatively charged in proportion to their molecular weights. SDS binds to the protein 
in a ratio of approximately one molecule SDS per 1.4 amino acid residues. The net 
charge of proteins can be neglected compared to the negative charge of the protein 
complexed with SDS, which yields an approximately uniform mass to charge ratio. As 
a consequence, electrophoretic mobility depends only on the sieve effect of the gel: 
the migration speed is inversely proportional to the logarithm of mass (Laemmli 
1970). Table 3 shows the composition of the 12.5% SDS gels used in this work. 	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Table 3: Composition of a 12.5% SDS-PAGE gel. 
Amount specification applies to 13 gels. 
 resolving gel (12.5%) stacking gel (6%) 
resolving/stacking gel buffer   19.5 ml   7.38 ml 
acrylamide-SL (30%)   26.2 ml     5.9 ml 
H2O 31.58 ml 15.95 ml 
TEMED 0.089 ml 0.029 ml 
APS (10%) 0.195 ml 0.089 ml 
 
 Samples were supplemented 1:4 with 5× SDS-PAGE sample buffer and 
incubated for 5 min at 95 °C. Gel pockets were loaded with 5-20 µl of sample, and 
gels were run at 50 mA and 300 V for about 30 min. Subsequently gels were stained 
with SDS-PAGE staining solution, whereby the detection limit of the Coomassie 
Brilliant Blue dye G-250 is between 200-500 ng protein/mm2. Gels were swayed for 
10 min in the staining solution and excess dye was removed by repeatedly boiling in 
water (microwave 900 W). 
 Alternatively, ready-to use PhastGel™ Homogeneous-12.5 gels with PhastGel™ 
Buffer Strips, SDS (GE HEALTHCARE) were used in a PhastSystem™ Separation 
Control (GE HEALTHCARE) according to the protocols supplied by the 
manufacturer. 
 
3.5.3 ICP-MS measurements 
 ICP-MS measurements were performed by Dr. Siddhesh Kamat and Swapnil 
Ghodge (group of Prof. Dr. F. M. Raushel), using the PerkinElmer DRC II ICP-MS 
device (software: Eland, PerkinElmer). For this purpose protein buffer was 
exchanged to metal-free buffer using GE illustra NAP™-25 or PD-10 columns. If 
applicable, protein and buffer samples were lyophilized for the shipment. 
 
3.5.4 Steady-state enzyme kinetics 
3.5.4.1 Colorimetric assay for OPH activity with p-nitrophenol substituted OPs 
 The OPH activity for p-nitrophenyl substituted OPs (compounds 1-7, 4.2.2) was 
measured in a colorimetric assay (Dumas et al., 1989). The activity was followed by 
observing the release of the product p-nitrophenol under basic conditions at 400 nm 
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(ɛ400 = 17000 M-1 cm-1) and 30 °C. Reactions were performed in 50 mM CHES, 
pH 9.0, 100 µM CoCl2 and various concentrations of substrate (Omburo et al., 1992). 
For OP compounds 4 and 5 the assay was supplemented with 12% MeOH, due to 
limited solubility of the substrates. Measurements were performed with a Cary 100 
Bio (VARIAN) or V650 (JASCO) spectrophotometer (total volume = 1 ml) or a 
SpectraMax-340 plate reader (MOLECULAR DEVICES, total volume = 250 µl), using 
plastic cuvettes and VIS 96-well plates, respectively. The reaction was started by 
adding the enzyme. Background of free p-nitrophenol, associated with absorbance at 
400 nm, as well as limited solubility of substrates restricted the maximum substrate 
concentration applicable. The concentration of OP compounds 1-7 was determined 
by titration with KOH prior to steady-state enzyme kinetics (2.10.2). 
 
3.5.4.2 Coupled DTNB (Ellman’s Reagent) assay 
 The OPH activity for the hydrolysis of phosphorothiolates (OP compound 8, 4.2.2) 
was measured in a coupled colorimetric assay (adapted from Yang et al., 2003). 
Cleavage of the phosphorothiolate bond was followed by inclusion of DTNB (Ellman’s 
reagent, 5,5’-dithiobis-(2-nitrobenzoic acid)), which reacts with the free thiol released 
as product. The disulfide bond of DTNB is cleaved yielding 2-nitro-5-thiobenzoate 
(NTB-), which ionizes to NTB2- dianion (yellow color) under basic conditions. The 
reaction is followed at 412 nm (ɛ412 = 14150 M-1 cm-1) and 30 °C. Reactions were 
performed in 50 mM HEPES pH 8.0, 0.3 mM DTNB, 100 µM CoCl2, 12% MeOH, and 
various concentrations of substrate. The concentration of OP compound 8 was 
determined enzymatically using wild-type PTE (2.10.2).  
 
3.5.4.3 pH-dependent colorimetric assay 
 The hydrolysis of δ-nonanoic lactone (δ-NL; 4.2.2) was monitored using a pH-
sensitive colorimetric assay (Chapman & Wong, 2002; Khersonsky & Tawfik, 2005). 
Proton release from carboxylic acid formation was followed using the pH-indicator m-
cresol purple. The reactions were performed in 2.5 mM BICINE (initial pH: 8.3), 
0.1 mM CoCl2, 1.4% DMSO, 0.1 mM m-cresol purple, 0.2 M NaCl and various 
concentrations of substrate (0-2 mM). The change in absorbance at 577 nm was 
monitored at 30 °C.  
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 The proteins Dr0930 and PTE were stored in 20 mM HEPES pH 7.5, 100 µM 
CoCl2 or 50 mM HEPES pH 8.5, 100 µM CoCl2, respectively. Prior to use, the buffer 
was exchanged to 10 mM bicine pH 8.3, 100 µM CoCl2 using a NAP-25 desalting 
column. The assay mixture was pre-incubated for 10 min at 30 °C to obtain a 
constant baseline, and the reaction was started by adding the enzyme. The 
conversion factor was determined by in-situ calibration with acetic acid (change of 
absorbance A577 per change in proton concentration, ɛ577 = 1.17 × 103 M-1cm-1). A 
slight background rate was observed in the absence of any enzyme, presumably due 
to acidification of the reaction assay by atmospheric CO2 (Khersonsky & Tawfik, 
2005). The background rate was independent of the substrate concentration, and 
subtracted from the initial rates.  
 
3.5.4.4 Data analysis 
 Steady-state kinetic parameters were determined by fitting the experimental data 
of the saturation curves to the Michaelis-Menten equation (Equation 11), using the 
computer program SigmaPlot.  !   =   !!"# ∙ [!]!! + [!] 
Equation 11: Michaelis-Menten Equation. 
v: initial velocity 
vmax: maximum velocity 
S: substrate concentration 
KM:  Michaelis constant 
 
 The catalytic rates (v) were corrected for background rate of spontaneous 
hydrolysis in the absence of enzyme. If the substrate concentration required to 
saturate an enzyme variant was higher than the maximal solubility of the substrate, 
Vmax/KM was determined by a linear regression of the initial part of the saturation 
curve. 
 
3.5.5 Dixon plot for competitive inhibition 
 The Dixon plot is used to determine the type of enzyme inhibition and the 
dissociation constant (Ki) for an enzyme-inhibitor complex (Segel, 1993). The velocity 
equation for competitive inhibition can be converted to a linear form in which the 
varied ligand is [I] (Equation 12). 
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Equation 12: Velocity equation for competitive inhibition in linear form. 
v: initial velocity 
vmax: maximum velocity 
S: substrate concentration 
KM:  Michaelis constant 
Ki:  dissociation constant 
 
 The effect on velocity (v) is determined over a range of inhibitor concentrations [I]. 
A plot of 1/v versus [I] at a constant unsaturating concentration of [S] (here: [S] = KM) 
yields a straight line with a positive slope. If the inhibition is known to be competitive, 
Ki can be determined from the slope of a linear fit of the data points according to 
Equation 12. The type of enzyme inhibition is confirmed to be competitive, when the 
linear graph intersects with the y-achses (1/v) at 1/vmax and the x-achses ([I]) at -Ki. 
 
3.5.6 Determination of stereopreference 
 The enzymatic hydrolysis of racemic OP compounds was monitored as a function 
of time. The change of A400 over time is an exponential time courses. Depending on 
the compound and enzyme variant used, one or two phases can be observed and fit 
by a single- or double exponential fit according to Equation 13. 
 ! ! = !! + !   !− !!!!!  ! ! = !! + !   !− !!!!! +   !   !− !!!!!  
Equation 13: Single- and double-exponential fit of an exponential time course.  
A(t): absorption at time t 
y0: off-set (in absorbance) 
a, b: magnitudes of exponential phases 
k1, k2: observed rate constants 
t  time 
 
 If a double-exponential fit did not converge due to limited data points, either the 
observed rate constant of the second phase, k2, or the magnitude of the second 
exponential phase, b, were constrained. The substrate concentration was kept below 
the KM value; hence, the time course follows pseudo-first order kinetics and the 
associated rate constants are directly proportional to the amount of enzyme added 
(Cleland, 1970; Nowlan et al., 2006). The catalytic efficiency, kcat/KM, was estimated 
from the exponential components according to Equation 14. 
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Equation 14: Determination of the catalytic efficiency of individual enantiomers.  
kx: observed rate constant 
[E]: enzyme concentration 
 
 To identify the configuration of the non-hydrolyzed isomer in solution after the 
reaction has approached an end point at approximately half amplitude, wild-type PTE 
or engineered PTE variants, with previous reported stereopreference for 4-
acetylphenol leaving group analogues of OPs 1-5 (Tsai et al., 2010a), were added to 
the reaction mixture, inducing the (exclusive) hydrolysis of the residual isomer. 
 
3.6 Protein crystallization and X-ray structure determination 
 Data collection and X-ray structure determination was performed in collaboration 
with Nicholas Fox (group of Prof. Dr. David Barondeau, Texas A&M University, 
College Station, USA) and Dr. Chitra Rajendran (group of Prof. Dr. Christine Ziegler, 
University of Regensburg).  
 
3.6.1 Protein crystallization 
 Protein crystallization was performed by sitting- and hanging drop vapor diffusion 
methods (McPherson, 1982). To explore various conditions, initial crystal screening 
was performed using commercially available crystallization kits containing 96 unique 
conditions. The crystallization kits used in this work are listed as follows: Crystal 
Screen I+II (Hampton Research), PEG/ION Screen 1+2 (Hampton Research), PEG 
RX I+II (Hampton Research), and Wizard I+II (Emerald BioSystems) were used for 
Dr0930_81. Crystall screens Classic II Suite (Qiagen) and JBScreen Classic 1, 4, 5, 
8, 9 (Jena Bioscience) were used for Dr0930_106 and Dr0930_134. Initial crystal 
screening was either performed manually or using an automatic robotic system: 
Phoenix Liquid Handling System (96-syringe, ARI-Art Robins Instrumentation, sitting-
drop method; 1 µl protein mix + 1 µl reservoir solution, 55 µl reservoir volume; 
T = 22 °C). In any case, crystallization conditions were manually refined applying a 
one or two variable (precipitant concentration, additive, pH, protein concentration) 
grid screen. For all set-ups, the protein solution was supplemented with 1.0 mM 
CoCl2. In order to obtain a structure with bound ligand, co-crystallization set-ups with 
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substrate and product analogues, soaking experiments with higher amounts of 
ligand, and streak- and macro-seeding experiments were performed. For co-
crystallization experiments inhibitors were added in the following amount to the 
protein solution: 3% (v/v) diisopropyl methylphosphonate (DIMP; 165 mM), 1% (v/v) 
diethyl 4-methylbenzylphosphonate (DE4MBP; 41 mM; limited solubility), 100 mM 
diethyl phosphate (DEP), 100 mM sodium cacodylate (CAC). To increase the 
solubility of the inhibitors, organic solvents such as DMSO and methanol were added 
to some of the set-ups. Set-up volumes in a typical manual performed hanging drop 
co-crystallization experiment, were as follows: 2 µl of protein (approximately 12.8 -
 13.5 mg/ml, supplemented with 1.0 mM CoCl2 and inhibitor) and 2 µl of precipitating 
agent were mixed and placed on a siliconized coverslip, and equilibrated over 500 µl 
of the precipitating agent (T = 20 °C). The Crystals of the Dr0930 variants were 
diamond shaped, purple in color and obtained under various conditions within a few 
days to weeks. 
 
3.6.2 Data collection 
 Single crystals were transferred to a cryo protectant solution and flash frozen in 
liquid nitrogen. Diffraction data was collected at Stanford Synchrotron Radiation 
Lightsource (SSRL; at Stanford University, Menlo Park, USA) by remote data 
collection on beamline 7-1 or measurements were performed on-site at the Swiss 
Light Source (SLS; at Paul Scherrer Institute, Villigen, Switzerland) at beamline PXII 
at 295 K and 100 K, recording single 0.1 or 0.5 degree images on a CCD (ADSC 
QUANTUM 315r) or PILATUS detector, respectively. 
 
3.6.3 Data processing and structure determination 
 The data sets for Dr0930_81 were indexed, integrated and scaled with the 
HKL2000 package (Otwinowski & Minor, 1997), and phases were determined by 
molecular replacement with Phaser version 2.1 (McCoy et al., 2007). For 
Dr0930_106 and Dr0930_134, data processing was done using XDS (Kabsch, 1993), 
and the data quality assessment was performed using phenix.xtriage (Adams et al., 
2002). Molecular replacement was performed with MOLREP within the CCP4i suite 
(Potterton et al., 2004). In all cases the structure of wild-type Dr0930 (PDB ID 3FDK) 
was used as search model and initial refinement of the structures was performed 
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using Refmac5 (Murshudov et al., 1997) of the CCP4 suite (Collaborative 
Computational Project, Number 4, 1994). 
 For Dr0930_81 difference electron density and omit maps were manually fit with 
the XtalView package (McRee, 1999), and further refinement was done with CNS 
(Brunger et al., 1998). All structures were superimposed with Sequoia (Bruns et al., 
1999). For Dr0930_106 and Dr0930_134, the model was further improved in several 
refinement rounds using the automated restrained refinement within the program 
PHENIX (Adams et al., 2002) and interactive modeling with Coot (Emsley & Cowtan, 
2004). The final models were analyzed using the program MolProbity (Davis et al., 
2007). 
 
3.7 RosettaLigand Docking 
 Ligand docking was performed by Christoph Malisi (group of Dr. Birte Höcker, 
MPI Tübingen) using the RosettaLigand program as implemented in the Rosetta 
software suite version 3.3 (Davis & Baker, 2009; http://www.rosettacommons. 
org/manuals/archive/rosetta3.3_user_guide/d4/d47/ligand_dock.html). The program 
parameters applied were based on the parameters used in Khare et al. (2012). The 
RosettaLigand application tries to identify conformations and relative orientations of a 
receptor-ligand complex that minimizes the Rosetta energy score function, employing 
a stochastic search algorithm. Many conformations are created, of which only the 
best scoring ones are used for further analysis. The program was used in this work to 
dock DIMP and EPXN ligands into the active site of wild-type PTE and Dr0930_134.  
 
3.7.1 Protein receptor and cofactor preparation for docking 
 The protein receptor structures (PTE: PDB ID 1EZ2; Dr0930_134) and cofactors 
were reformatted for ligand docking experiments. Hydrogen atoms were added in the 
protein receptor structures using Chimera (Pettersen et al., 2004). A residue 
parameter file was created for the carboxylated Lysine (KCX 143) as described in the 
Rosetta documentation. The identity of the active site cobalt atoms for the Dr0930 
variant were changed to zinc and distance constraints were calculated for the side 
chain atoms coordinating these metals in order to maintain the native coordination 
geometry. A penalty energy term was applied, if these atoms deviate more than 0.2 Å 
from the measured distances. Rosetta's receptor minimization protocol was used to 
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create ten minimized structures for each receptor protein. The resulting repacked 
structure with the lowest energy was used for docking calculations. 
 
3.7.2 Ligand preparation and ligand positioning 
 Ligand conformers were created with the software omega2, and charges were 
added by molcharge (Hawkins et al., 2010). Ligand parameter files were created as 
described in the Rosetta documentation.  
 The selection of starting positions for the ligands is decribed in the following: For 
the PTE protein receptor, a random conformation of DIMP, excluding the native one 
the ligand assumes in the crystal structure, was chosen as starting position to avoid 
biasing of the docking algorithm toward the known binding mode. The starting 
positions of EPXN were determined by roughly positioning an arbitrary ligand 
conformer in the binding pocket of PTE. For Dr0930_134, the ligand conformer was 
superimposed with the phosphorus atom of DIMP in the PTE structure 1EZ2, and 
then the complex was superimposed onto the Dr0930 structure.  
 For some Dr0930_134 docking runs, geometric constraints, derived from the 
1EZ2 structure, were put on the phosphoryl oxygen and the phosphorus atoms of the 
ligand to enrich results containing the desired catalytic geometry. The distance 
between the phosphoryl oxygen and the interacting β-zinc ion was constrained to 2.5 
± 0.4 Å and the angle formed by zinc, phosphoryl oxygen and phosphorus atom was 
set to 140° ± 30°.  
 
3.7.3 Docking calculations and analysis of docking results 
 For each receptor-ligand pair, 5000 receptor-ligand conformations were created 
with the RosettaLigand application. For analysis, the top 5% docking results by 
Rosetta's total energy score were ranked according to their predicted binding 
energies. The top 10 or 20 ranked binders were then used for analysis. The 
described ranking scheme is suggested by the RosettaLigand documentation to 
identify good binders among low energy and therefore plausible complex structures. 
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4 RESULTS AND DISCUSSION 
 
4.1 D. radiodurans Dr0930: a close homologue of P. diminuta PTE 
 Dr0930 from D. radiodurans R1 belongs to the family of phosphotriesterase-like 
lactonases (PLL). PLL enzymes are the closest homologues to PTE, although they 
share only 26-35% sequence identity with the bacterial phosphotriesterase 
P. diminuta PTE (Merone et al., 2005; Porzio et al., 2007; Afriat et al., 2006). The 
native enzymatic activity of PLL enzymes is for the hydrolysis of 5- and 6-membered 
lactones that vary in type and position of the substitution on the lactone ring (C-O 
bond cleaved). Furthermore, PLL enzymes share a low promiscuous OPH activity for 
ethyl-paraoxon (P-O bond cleaved).  
 Mutually, promiscuous esterase activity (2-naphthyl acetate) has been reported 
for wild-type PTE and esterase and lactonase activities (e.g. 2-naphthyl acetate, 
dihydrocoumarine, 5-thiobutyl-γ-butyrolactone) for an engineered PTE variant with 
elevated expression level. However, no activity has yet been reported for δ-nonanoic 
lactone, the most proficient substrate of Dr0930 (Roodveldt & Tawfik, 2005a/b; Afriat 
et al., 2006). 
 Table 4 summarizes annotated and characterized PLL enzymes and lists the 
corresponding native and promiscuous substrates. 
 
Table 4: PTE and selected homologues PLL enzymes.  
 seq. identity annotated substrates promiscuous substrates 
P. diminuta PTE - various OPs  2-naphthyl acetate 
D. radiodurans Dr0930 31% γ-/δ-lactone  EPXN, MPXN 
G. kaustophilus GKL 28% γ-/δ-lactone  EPXN, HSL  
S. solfataricus SsoPox 31% TBBL  
MPXN, EPXN, diazinon, 
chlorpyrifos, coumaphos, 
parathion 
R. erythropolis AhlA 28% TBBL, HSL, γ-/δ-lactone EPXN 
M. tuberculosis PPH 34% γ-/δ-lactone, TBBL, HSL EPXN 
Seq. identity: sequence identity relative to P. diminuta PTE. OP: organophosphate. HSL: N-acyl 
homoserine lactone (5-membered lactone ring with N-acyl substitution at position C3). TBBL: 5-
thiobutyl-γ-butyrolactone (5-membered lactone ring with thiobutyl substitution at position C5). Ethyl-
paraoxon: O,O-diethyl O-(4-nitrophenyl) phosphate. γ-/δ-lactone: 5- and 6-membered lactone ring with 
alkyl substitution at position C5 and C6, respectively. EPXN: ethyl-paraoxon. MPXN: methyl-paraoxon. 
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P.  diminuta PTE: Pseudomonas diminuta PTE (Omburo et al., 1992; Dumas et al., 1989; Roodveldt & 
Tawfik, 2005a/b). D. radiodurans Dr0930: Deinococcus radiodurans R1 Dr0930 (Xiang et al., 2009; 
Hawwa et al., 2009b). G. kaustophilus GKL: Geobacillus kaustophilus GKL (Chow et al., 2010). 
S. solfataricus SsoPox: Sulfolobus solfataricus SsoPox (Elias et al., 2008; Merone et al., 2008). 
R. erythropolis AhlA: Rhodococcus erythropolis AhlA (Afriat et al., 2006). M. tuberculosis PPH: 
Mycobacterium tuberculosis PPH (Afriat et al., 2006). The listed PLL enyzmes share 29-59% 
sequence identity among each other. 
 
 The structures of substrates listed in Table 4 are shown in Figure 65 in the 
appendix. 
 A structure based sequence alignment of PTE and PLL enzymes from Table 4, 
generated by 3D-Coffee (Expresso; www.tcoffee.org), is shown in Figure 17. 
 
Figure 17: Structure based sequence alignment of PTE and selected PLL enzymes generated 
by 3D-coffee.  
Sequence alignment of P. diminuta PTE, D. radiodurans Dr0930, G. kaustophilus GKL, S. solfataricus 
SsoPox, R. erythropolis AhlA, and M. tuberculosis PPH. Conserved residues are colored in shades of 
blue. Catalytic important residues for PTE and PLL enzymes are highlighted in orange. Catalytic 
important residues only conserved for PLL enzymes are highlighted in light green. The boxes highlight 
the residues corresponding to loops at the C-terminal ends of β-strands 7 and 8.  
 
 The H-E-H motif in β-strand 1, the carboxylated lysine from β-strand 4, the 
histidine residues at the ends of β-strands 5 and 6, and an aspartate residue at the 
end of β-strand 8 are conserved. Conserved active site residues of PLL enzymes are 
tyrosine and arginine in the βα-loops 3 and 7. These residues differ from the PTE 
residues (Trp131 and His254). Major structural differences are in the length and 
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conformation of the βα-loops (in particular loops 7 and 8). X-ray structures of ligated 
PLL enzymes and docking experiments, revealed that particularly residues from 
these loops form a hydrophobic channel accomodating the aliphatic side chain of the 
substituted lactones (see also Figure 19A); the lactone ring is positioned by polar 
(e.g. conserved Tyr and Arg, and others residues depending on enzyme and 
substrate) and non-polar interactions (Elias et al., 2008; Chow et al., 2010, Xiang et 
al., 2009). 
 D. radiodurans Dr0930 is the best structurally and functionally characterized 
bacterial PLL enzyme. Dr0930 is a robust, thermostable (TM = 88°C) and highly 
soluble protein, exhibiting promiscuous activity for the hydrolysis of the insecticides 
methyl- and ethyl-paraoxon (Hawwa et al., 2009b; Xiang et al., 2009). A partial 
structural superposition of D. radiodurans R1 Dr0930 and P. diminuta PTE is shown 
in Figure 18A. The polar residues important for substrate positioning in Dr0930 and 
PTE are shown in Figure 18B and C. 
 
 
Figure 18: Structural superposition of D. radiodurans R1 Dr0930 and P. diminuta PTE (A) and 
excerpts of the active sites of Dr0930 (B) and PTE (C).  
Dr0930 (PDB ID 3FDK) and PTE (PDB ID 1EZ2) are depicted in grey and green, respectively. 
A: Parts of the backbone are shown, which illustrate major structural differences in the length and 
conformation of the βα-loops (predominately βα-loop 1, 3, 7 and 8). The over-all backbone 
conformation of Dr0930 is quite similar to that of PTE (backbone r.m.s.d = 1.3 Å), in particular the 
central barrel (not shown) and metal coordinating residues superimpose well. Residue Y97, which is 
conserved within the PLL family and located in βα-loop 3 (Figure 17), aligns with W131 in PTE. The 
quartenary structure of PTE and Dr0930 is dimeric; the dimer is formed by interaction of βα-loop 1 and 
3 (not shown). 
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B:	  Excerpt of the active site of Dr0930 with the docked tetrahedral intermediate that is formed upon 
the hydrolysis of δ-nonanoic lactone (depicted in dark grey). The lactone intermediate in Dr0930 is 
positioned by polar interactions with Y97 (2.8 Å; Y97 aligns with W131 in PTE), R228 (5.3 Å; R228 
aligns with H254 in PTE) and D264 (2.3 Å; D264 aligns with D301 in PTE). The side chain of the R228 
residue is shifted by approximately 3 Å in the docked structure relative to the conformation observed in 
the crystal structure to accommodate the ligand (native conformation is not shown).  
C:	  Excerpt of the active site of PTE, complexed with the substrate analogue DIMP (diisopropyl 
methylphosphonate; depicted in dark green). PTE exhibits only one hydrogen bond (3.2 Å) between 
NE1 of Trp131 and the phosphoryl oxygen of DIMP. Together with D301 and D233, H254 is involved in 
proton shuttling in PTE. The equivalent residues in Dr0930 to D301 and H254 are D264 and R228. At 
the equivalent position of D233 in Dr0930 is a glycine (G207; not shown). 
 
 The substrate binding pockets for Dr0930 and PTE are shown in Figure 19A and 
B, respectively. 
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Figure 19: The substrate binding pockets of Dr0930 (A) and PTE (B) (same view as in Figure 
18A).  
Dr0930 (PDB ID 3FDK) and PTE (PDB ID 1EZ2) are depicted in grey and green, respectively. For 
Dr0930 the docked tetrahedral intermediate that is formed upon the hydrolysis of δ-nonanoic lactone 
is shown and depicted in dark grey. For PTE the co-crystallized substrate analogue DIMP (diisopropyl 
methylphosphonate) is shown and depicted in dark green. 
A: The substrate binding pocket of Dr0930 is formed by βα-loops 1, 3, 7 and 8. The lactone 
intermediate is positioned by polar interactions with Y97, R228 and D264 and non-polar interactions 
with mainly F26, L231, V235, and W287. The βα-loops 7 and 8 form a hydrophobic channel that 
accommodates the aliphatic side chain of the substitued lactone. 
B: The substrate binding pocket of PTE is formed by βα-loops 1, 2, 3, 7 and 8. Except for the 
electrostatic interaction between Trp131 and the phosphoryl oxygen of the DIMP ligand, PTE exhibits 
a hydrophobic substrate binding pocket. The substrate binding pocket is subdivided in three subsites. 
The small subsite is occupied by the O-isopropyl substituent of DIMP and formed by βα-loops 1, 2, 
and 8 (G60, I106, L303, and S308; overlined). The large subsite is occupied by the methyl substituent 
of DIMP and formed by βα-loops 7 and 8 (H254, H257, L271, and M317; underlined). The leaving 
group subsite is occupied by the O-isopropyl substituent of DIMP and formed by βα-loops 3 and 8 
(W131, F132, F306, Y309; boxed).  
 
 The hydrolytic activity of PLL enzymes towards various lactone derivatives has 
been characterized extensively. However, except for SsoPox, the promiscuous OPH 
activity of PLL enzymes has only been investigated for methyl- and ethyl-paraoxon 
so far (Afriat et al., 2006; Chow et al., 2009; Chow et al., 2010; Elias et al., 2008; 
Hawwa et al., 2009b; Merone et al., 2008; Xiang et al., 2009). However, the hitherto 
determined kinetic parameters for the hydrolysis of ethyl-paraoxon by PLL enzymes 
are not comparable as assay conditions vary significantly (Merone et al., 2008; Afriat 
et al., 2006; Chow et al., 2010; Hawwa et al., 2009a/b; Xiang et al., 2009).  
 To explore the substrate scope, wild-type Dr0930 was characterized here for its 
promiscuous activity using a broad spectrum of OPs. Mutually, wild-type PTE was 
analyzed for its ability to hydrolyze δ-nonanoic lactone.  
 
4.2 Dr0930 and PTE: promiscuous and native activities  
4.2.1 Heterologous expression in E. coli and purification of the 
recombinant wild-type Dr0930 and wild-type PTE proteins 
 Chemically competent E. coli BL21(DE3) Rosetta 2 and E. coli BL21(DE3) cells 
were transformed with the pET30a-dr0930 and pET20b-pte constructs, and single 
colonies were used to inoculate 2 l LB and 8 l TB medium, respectively. The medium 
was supplemented with 0.5 mM CoCl2 and 1.0 mM CoCl2 each. Following induction 
of gene expression with 0.5 mM IPTG and addition of extra 0.5 mM CoCl2 for the 
Dr0930 expression cultures, the cell suspension was incubated overnight at 37 °C 
and 30 °C, respectively (3.4.1.2). The cells were resuspended in 20 mM HEPES, 
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pH 7.5, 100 µM CoCl2 and 50 mM HEPES, pH 8.5, 100 µM CoCl2, respectively. Cells 
were disrupted by sonication. The recombinant proteins were purified from the 
soluble fraction of the cell extract by protamine sulfate and ammonium sulfate 
precipitation (3.4.2.1) and, either anion exchange chromatography (3.4.2.2) or a 
combination of anion exchange chromatography and gel filtration chromatography 
(3.4.2.3). Combined pure protein fractions were dialyzed overnight against 5 l of 
20 mM HEPES, pH 7.5, 100 µM CoCl2 and 50 mM HEPES, pH 8.5, 100 µM CoCl2, 
respectively. 
 Typical elution profiles and SDS-gels of the purification steps of wild-type Dr0930 
and wild-type PTE are shown in Figure 20 and Figure 21.  
 
 
Figure 20: Exemplary purification overview of the recombinant wild-type Dr0930 protein. 
A: Elution profile of the purification step via anion exchange chromatography (Q Sepharose Fast flow), 
monitored by measuring the absorbance at 260 nm (red) and 280 nm (blue). The elution was 
performed with a gradient of 0-2 M NaCl (green). The absorbance at 550 nm, which corresponds to 
the absorbance maximum of wild-type Dr0930 in the VIS-spectrum, is shown in black. The combined 
fractions are shaded in grey. 
B: SDS-PAGE (12.5% polyacrylamide) of the elution fractions of protamine sulfate precipitation (PS), 
ammonium sufate precipitation (AS; 45%), and anion exchange chromatography (AEX: combined and 
dialyzed fractions after QSepharoseFF purification step). P: pellet (insoluble fraction); S: supernatant 
(soluble fraction); M: protein ladder and marker (LMW); C: crude extract (soluble fraction of the cell 
extract) providing the starting point for purification.  
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Figure 21: Purification overview of the recombinant wild-type PTE protein. 
SDS-PAGE (12.5% polyacrylamide) of the elution fractions of protamine sulfate (PS) and ammonium 
sulfate precipitation (AS; 45%), gel filtration (GF), and anion exchange chromatography (AEX). P: 
pellet (insoluble fraction); S: supernatant (soluble fraction); M: protein ladder and marker (LMW); C: 
crude extract (soluble fraction of the cell extract) providing the starting point for purification. The 
resuspended pellet of the ammonium sulfate precipitation was further purified by preparative gel 
filtration (Hi Load 16/60 Superdex 75 Prep Grade). Combined, dialyzed and concentrated fractions 
were purified by anion exchange chromatography using a DEAE column. 
 
 For wild-type Dr0930 and Dr0930 variants, as well as wild-type PTE, a purification 
grade of more than 95% was achieved as judged by SDS-PAGE. Wild-type Dr0930 
yielded approximately 50 mg protein/liter culture. The protein yield for wild-type PTE 
of 4.7 mg protein/liter culture was significantly lower. 
 The metal content was analyzed by ICP-MS measurements (3.5.3), and yielded 
0.6-1.2 equivalent Co and 0-0.12 equivalent Zn, and up to 0.23 equivalent Fe for 
wild-type Co/Co-Dr0930. Wild-type Co/Co-PTE contained 1.22 equivalent Co and 
0.12 equivalent Zn. Purified wild-type Co/Co-Dr0930 was found to contain a mixture 
of Co, Zn and Fe when expressed in medium supplemented with CoCl2. Fe2+ is easily 
oxidized to Fe3+, which might lead to diminished enzymatic activity. Therefore, 
0.1 mM iron chelator 2,2’ bipyridal was added to the expression culture of wild-type 
Dr0930 to reduce the iron content, however without success. At high concentrations 
wild-type Co/Co-Dr0930 and Dr0930 variants were intensively purple colored 
(absorption maximum at 550 nm), presumably due to a charge transfer complex 
between active site residue Y97 and incorporated iron within the binuclear metal 
center (Xiang et al., 2009).  
 
4.2.2 Chemical structures of δ-nonanoic lactone and OP compounds 
 Figure 22 shows the chemical structures of OP compounds (Figure 22A-D) and δ-
nonanoic lactone (Figure 22E). Compounds in Figure 22B-E were used in this study. 
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Figure 22: Chemical structures of OP compounds (A-D) and δ-nonanoic lactone (E).  
A: Organophosphate nerve agents: VX, GB (sarin), VR, GD (soman), GF (cyclosarin). B: p-
nitrophenol analogues of nerve agents, abbreviated by numbers: OPs 1-5. C: Commercially available 
insecticides, methyl-paraoxon (MPXN, OP 6) and ethyl-paraoxon (EPXN, OP 7). D: Diethyl-VX 
(DEVX; O, O-diethyl-S-(2-diisopropylaminoethyl) phosphorothiolate, OP 8), a close analogue of VX. E: 
δ-nonanoic lactone (δ-NL). Bonds cleaved upon hydrolysis: P-S/P-F (A), P-O (B, C), P-S (D), C-O (E). 
 
 The OP compounds used in this study can be devided in three groups regarding 
their phosphorus chemistry: methylphosphonates (Figure 22A and B), phosphor-
triesters (Figure 22C), and phosphorothiolates (Figure 22D). Methylphosphonates, 
exhibit a direct P-C bond. Due to the extremely high toxicity of the original nerve 
agents p-nitrophenol analogues of G- and V-type OP nerve agents were used here. 
Likewise, the p-nitrophenol leaving group allows for colorimetric signal detection 
upon OP hydrolysis. The methylphosphonates are distinguished by various 
substituents at the phosphorus center with the size of the substituent increasing for 
OP compounds 1 to 5: O-ethyl (VX, OP 1), O-isopropyl (GB, OP 2), O-isobutyl (VR, 
OP 3), O-pinacolyl (GD, OP 4), O-cyclohexyl (GF, OP 5). The phosphonate 
compounds 1-5 are chiral (exhibit two enantiomers, termed RP and SP), due to a 
chiral P-center. Soman exhibits four stereoisomers due to an additional chiral C-
center within the pinacolyl substituent: the isomers are termed RPRC, RPSC, SPSC, 
and SPRC. The methylphosphonates used in this study were used as racemates. 
Phosphotriesters exhibit three O-linked groups at the P-center. The commerically 
available insecticides, methyl-paraoxon (MPXN, OP 6) and ethyl-paraoxon (EPXN, 
OP 7), used in this study are achiral. In phosphorothiolates the ester oxygen is 
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replaced by sulfur. DEVX (OP 8) differs from VX by substitution of the methyl 
substituent at the P-center by O-ethyl.  
 The δ-nonanoic lactone (δ-NL; Figure 22E), used in this study to determine the 
lactonase activity, is a cyclic ester with an alkyl substitution (n-butyl) at the carbon 
adjacent to the ring oxygen.  
 
4.2.3 Steady-state kinetic characterization of wild-type Dr0930 and wild-
type PTE for native and promiscuous activities 
 Dr0930 efficiently hydrolyzes γ- and δ-lactones with alkyl substitutions at the 
carbon adjacent to the ring oxygen. Moreover, promiscuous OPH activity of wild-type 
Dr0930 for the hydrolysis of the phosphotriesters methyl- and ethyl-paraoxon has 
been described (Xiang et al., 2009; Hawwa et al., 2009b). Wild-type PTE exhibits 
broad substrate specificity for the hydrolysis of OPs. Moreover, Tawfik and co-
workers reported promiscuous esterase activity for wild-type PTE towards 2-naphthyl 
acetate (kcat/KM of 2.5 × 102 M-1s-1) and esterase and lactonase activities an 
engineered PTE variant with elevated expression level (Roodveldt & Tawfik, 2005a/b; 
Afriat et al., 2006). 
 Here, the native and promiscuous activities of wild-type Dr0930 and wild-type 
PTE were analyzed and both enzymes were kinetically characterized for the 
hydrolysis of OP compounds 1-7 and δ-nonanoic lactone (Figure 22). 
 The reaction schemes and transition states for the hydrolysis of δ-nonanoic 
lactone and ethyl-paraoxon are exemplarily shown in Figure 23. A C-O bond versus a 
P-O bond is cleaved and reactions proceed via a tetrahedral versus a pentavalent 
oxyanionic intermediate. The promiscuous OPH activity of PLL enzymes is thought to 
be due to physical similarities between the reactive intermediate for the native 
lactonase reaction and the ground/intermediate state for the promiscuous OPH 
reaction (Elias et al., 2008; Ben-David et al., 2012). 
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Figure 23: Reaction schemes including their transition states for the hydrolysis of δ-nonanoic 
lactone (A) and ethyl-paraoxon (B). 
A: δ-nonanoic lactone is hydrolyzed to 5-hydroxy nonanoic acid and proton release resulting from 
carboxylic acid formation was followed using the pH-indicator m-cresol purple. The cleaved C-O bond 
is highlighted in red. The hydrolysis of proceeds via a sp3 transition state (tetrahedral intermediate). B: 
Ethyl-paraoxon is hydrolyzed to diethyl phosphate, and the released p-nitrophenol causes a yellow 
color change. The cleaved P-O bond is highlighted in red. The hydrolysis of ethyl-paraoxon proceeds 
via a pentavalent transition state. 
 
 Wild-type Dr0930 and wild-type PTE were characterized for the hydrolysis of δ-
nonanoic lactone (δ-NL) using a pH-sensitive colorimetric assay (3.5.4.3). The 
saturation curves deduced from the initial velocity measurements in presence of 
different substrate concentrations are shown in Figure 24.  
 
 
Figure 24: Saturation curves of wild-type Dr0930 (A) and wild-type PTE (B) for the hydrolysis 
of δ-nonanoic lactone. 
The reactions were performed in 2.5 mM BICINE (initial pH: 8.3), 0.1 mM CoCl2, 1.4% DMSO, 0.1 mM 
m-cresol purple, 0.2 M NaCl and variable concentration of δ-nonanoic lactone (0-2mM). The reaction 
was monitored at 577 nm (ɛ577 = 1.17 × 103 M-1cm-1) and 30 °C. Prior to use, the protein buffer was 
exchanged to 10 mM bicine, pH 8.3, 100 µM CoCl2 using a NAP-25 desalting column. Reactions with 
wild-type PTE (B) were performed with 25 µM enzyme concentration. Wild-type Dr0930 was diluted in 
10 mM bicine pH 8.3, 100 µM CoCl2, 1 mg/ml BSA prior to use. BSA has no influence on the activity 
(data not shown). Reactions with wild-type Dr0930 (A) were performed with 10 nM enzyme 
concentration. The initial velocity vi is plotted versus the concentration of substrate. The solid line 
shows the result of the hyperbolic fit of the data points (SigmaPlot). 
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 The steady-state kinetic parameters, turnover number (kcat), Michaelis constant 
(KM), and the catalytic efficiency (kcat/KM), determined from the fit of the saturation 
curves to the Michealis-Menten equation (Equation 11) are summarized in Table 5. 
 
Table 5: Steady-state kinetic constants of wild-type Co/Co-Dr0930 and wild-type Co/Co-PTE 
for the hydrolysis of δ-nonanoic lactone.  
 wild-type Co/Co-Dr0930   wild-type Co/Co-PTE  
 kcat [s-1] KM [mM] kcat/KM [M-1s-1]  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
δ-NL 2.2 × 102 0.028 7.9 × 106  5.7 × 10-2 0.84 6.8 × 101 
Kinetic parameters of wild-type Dr0930 for the hydrolysis of δ-nonanoic lactone are in accordance with 
literature values. Xiang et al. (2009) reported kcat = 1.8 × 102 s-1, KM = 0.09 mM, kcat/KM = 1.8 × 106    
M-1s-1 measured at essentially identical conditons in the absence of 0.1 mM CoCl2 in the reaction 
assay.  
 
 The cobalt-substituted Dr0930 hydrolyzes δ-nonanoic lactone with a catalytic 
efficiency of 7.9 × 106 M-1s-1. The lactonase activity of wild-type Co/Co-PTE for δ-
nonanoic lactone yielded a 105-fold lower catalytic efficiency of 6.8 × 101 M-1s-1.  
 Wild-type Dr0930 and wild-type PTE were characterized for the hydrolysis of 
various OPs: methylphosphonates (OPs 1-5) and phosphotriesters (OPs 6+7) using 
a colorimetric assay for p-nitrophenol substituted OPs performed at 400 nm (3.5.4.1). 
Saturation curves of wild-type Dr0930 and wild-type PTE for OPs 1-7 are shown in 
Figure 25 and Figure 26, respectively. 
 
 
Figure 25: Saturation curves of wild-type Dr0930 for the hydrolysis of OPs 1-7. 
A: Saturation curves for OPs 2-5. OP 2 (), OP 3 (), OP 4 (), OP 5 (). B: Saturation curves for 
OPs 1, 6 and 7. OP 1 (), OP 6 (), OP 7 (). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed 
using 5 µM wild-type Dr0930. The initial velocity vi is plotted versus the concentration of substrate. The 
solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). 
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Figure 26: Saturation curves of wild-type PTE for the hydrolysis of OPs 1-7. 
Saturation curves of wild-type PTE for the hydrolysis of OP 1 (), OP 2 (), OP 3 () (A), OP 4 () 
(B), OP 5 () (C), OP 6 () and OP 7 () (D).  
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed 
with varied concentrations of wild-type PTE: 50 pM (A), 10 nM (B), 0.25 nM (C), and 10 pM (D) 
enzyme concentration. The enzyme was diluted in 50 mM HEPES, pH 8.5, 100 µM CoCl2 buffer 
supplemented with 1 mg/ml BSA in order to stabilize the protein at low concentrations. BSA has no 
influence on the activity (data not shown). The initial velocity vi is plotted versus the concentration of 
substrate. The solid line shows the result of the hyperbolic fit of the data points (SigmaPlot). 
 
 Steady-state kinetic parameters deduced from the saturation curves are 
summarized in Table 6.  
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Table 6: Steady-state kinetic constants for wild-type Co/Co-Dr0930 and wild-type Co/Co-PTE 
for the hydrolysis of OPs 1-7. 
 wild-type Co/Co-Dr0930   wild-type Co/Co-PTE  
 kcat [s-1] KM [mM] kcat/KM [M-1s-1]  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP 3.0 × 10-1 0.49 6.1 × 102  9.6 × 103 0.75 1.28 × 107 
2: GB p-NP - - 9.8 × 100a  4.3 × 103 0.42 1.0 × 107 
3: VR p-NP 2.6 × 10-2 5.1 5.1 × 100  3.4 × 103 0.40 8.5 × 106 
4: GD p-NP 1.2 × 10-2 2.6 6.8 × 100a  8.8 × 101 7.7 1.15 × 104a 
5: GF p-NP - - 2.1 × 100  1.5 × 103 2.26 6.6 × 105 
6: MPXN 5.0 × 10-2 0.25 2.0 × 102  2.6 × 104 1.10 2.4 × 107 
7: EPXN 5.7 × 10-2 2.0 2.9 × 101  1.7 × 104 0.14 1.2 × 108 
a: average of two independent measurements. -: kcat/KM was determined from non-saturating 
concentrations by a linear fit of the initial part of the saturation curve, as the substrate concentration 
required to saturate an enzyme variant was higher than the maximal solubility of the substrate. 
Compounds 1-5 were applied as racemates. 
Literature values are available for OP compounds 2, 4, 6 and 7 (Li et al., 2001; Omburo et al., 1992; 
Chen-Goodspeed et al., 2001a/b). The determined kinetic parameters for OPH of wild-type PTE are in 
good agreement with published values. Literature values published for GD p-NP (Li et al., 2001) differ 
slightly from values determined here in duplicates. The published parameters determined at 25 °C in 
50 mM CHES, pH 9.0, 10% MeOH are as follows: kcat = 44 s-1, KM = 1.1 mM, kcat/KM = 4.0 × 104 M-1s-1.  
 
 The bar diagram in Figure 27 illustrates the range of catalytic efficiencies of wild-
type Dr0930 and wild-type PTE for OP compounds 1-7. 
 
 
Figure 27: Catalytic efficiencies of wild-type Co/Co-Dr0930 (A) and wild-type Co/Co-PTE (B) for 
OPs 1-7. 
 
 Wild-type Dr0930 exhibits overall low promiscuous activity for the hydrolysis of 
phosphotriesters and methylphosphonates, with best activities for the hydrolysis of 
OPs with small substituents at the P-center (OPs 1+6). The KM values are in the mM 
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range. The catalytic efficiency of wild-type Dr0930 is four (OP 4) to seven (OPs 2+7) 
orders of magnitude lower when compared to wild-type PTE. 
 Wild-type PTE exhibits a broad range of activity for the hydrolysis of OPs 1-7. 
PTE most efficiently hydrolyzes phosphotriesters (OPs 6+7) and 
methylphosphonates with small substituents at the P-center (OPs 1-3), exhibiting 
extremely high kcat values, but also relative high KM values. The remarkably high 
catalytic efficiency for EPXN (OP 7) approaches the diffusion controlled limit (Dumas 
et al., 1989). The OPs 4 and 5, comprising bulky substituents at the P-center, are 
hydrolyzed at significantly lower rates.  
 In summary, the efficiencies of the promiscuous and native activities differ, for 
both Dr0930 and PTE, by several orders of magnitude. Moreover, both enzymes 
exhibit high KM and low kcat values for the promiscuous substrates. This may result 
from improper substrate binding interaction and positioning relative to the catalytic 
machinery (Khersonsky & Tawfik, 2010).  
 However, the mutually identified enzymatic activities in wild-type Dr0930 and wild-
type PTE further support their evolutionary relationship. As wild-type Dr0930 exhibits 
activity against a broad spectrum of OP compounds, it is an ideal scaffold to enhance 
its OPH activity using laboratory evolution and studying rapid molecular evolution in 
the laboratory.  
 
4.3 Laboratory evolution of wild-type Dr0930 for OPH activity 
 Earlier attempts to increase the OPH activity of the promiscuous Dr0930 enzyme 
have been performed. The eight substrate specificity determining βα-loops of PTE 
were transplanted to Dr0930 in order to generate a chimeric Dr0930-PTE protein with 
enhanced OPH activity, however without success. Moreover, a limited number of 
site-directed mutants were generated by rational design to mimick the hydrophobic 
substrate binding pocket of wild-type PTE in Dr0930 (Xiang et al., 2009). The rational 
design aimed to enlarge the small substrate binding pocket of Dr0930 (F26G and 
C72I), and to implement the residues important for proton shuttling in PTE in Dr0930 
(R228H and G207D). The best rationally designed variant Dr0930-F26G+C72I 
yielded only a 10-fold improvement in catalytic efficiency for EPXN. The kinetic 
constants kcat, KM and kcat/KM of the zinc-substituted Dr0930-F26G+C72I for EPXN 
are 1.9 × 10-2 s-1, 2.7 mM and 7.7 × 100 M-1 s-1 (Xiang et al., 2009).  
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 As the results of the rational design approach were limited, a random-based 
approach was used in order to further increase the OPH activity of wild-type Dr0930. 
The design applied several rounds of mutagenesis in an iterative process. The 
individual steps of laboratory evolution are described in the following.  
 First experiments were performed with ZnCl2 until the strong positive effect of 
CoCl2 on the catalytic activity was identified. The metal contents for the Dr0930 
variants are summarized in the appendix. Variants generated in the course of 
laboratory evolution are termed Dr0930_# using consecutive numbers.  
 
4.3.1 Randomization of wild-type Dr0930 by error-prone PCR (epPCR) 
4.3.1.1 Characterization of the epPCR library 
 At the start of the work, the generation and characterization of the epPCR library 
was completed. The results are briefly described in the following. 
 A plasmid-based gene library (pTNA-dr0930-epPCR), containing 2.7 × 107 
independent clones, was generated by error-prone PCR (Meier, 2008). The library 
(Ts/Tv ratio of 1.9) contained 6 nucleotide exchanges/gene, which corresponds to 2-
5 aa exchanges/protein. About 2.0 × 103 clones were assayed for the hydrolysis of 
EPXN using an in vitro activity screening. The experimental approach is illustrated in 
Figure 28. 
 
 
Figure 28: In vitro activity screening for Dr0930 variants with improved OPH activity.  
A plasmid-based gene library was generated by epPCR on the wild-type Dr0930 scaffold. E.	  coli cells 
were transformed with the library, individual colonies were grown in 96-well blocks, and the enzymatic 
activity of the crude extract was assayed.  
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 The plasmids of the best clones were isolated and their dr0930 inserts were 
sequenced to identify the incorporated mutations. The 12 most promising variants 
are listed in Table 7. 
 
Table 7: Dr0930 variants isolated from in vitro activity screening of the epPCR library. 
Dr0930_#: mutations  
1: G30D+V235M+G316V   7: Y28C+L57Q+F107Y+E122D 
2: V35E+A103V   8: N208I 
3: G38V+E51A   9: L157Q+D299G 
4: P39L+D71N+A163V 10: A103T+A280T 
5: D71N+E179D+L270M 11: A3T+G38R+T105S+P274L 
6: S48R+A145V+R148H 12: R272C 
Dr0930 variants contain the T2Q mutation, as the dr0930 gene library was constructed in the pTNA 
vector using a SphI restriction site at the 5’-end. For further details see Meier (2008). 
 
 Most mutations are localized in the βα-loops in the active site (Figure 29). Most 
noteworthy is the exchange D71N, on the basis of its proximity to the active site and 
its dual occurance in the variants Dr0930_4 and Dr0930_5. 
 
 
 
Figure 29: Localization of mutations identified in Dr0930_1 - Dr0930_12. 
Side view (A) and top view (B). Most mutations were localized in the βα-loops. The mutations in the 
βα-loops are colored by loop number: 1 (green), 2 (orange), 3 (purple), 4 (cyan), 5 (light pink), 6 (light 
blue), 7 (red), and 8 (dark blue). The β-sheets and α and β zinc ions are depicted in dark grey.  
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4.3.1.2 Verification of epPCR hits by in vitro activity screening with EPXN 
 Due to the low activity and consecutive weak signal in the in vitro activity screen, 
the isolated hits were re-screened to verify and priorize the hits for subsequent in 
vitro characterization by steady-state enzyme kinetics. In order to analyze the effect 
of the single mutation D71N, the construct Dr0930-D71N (Dr0930_13) was 
generated by OE-PCR (3.3.7.4) on the template pTNA-dr0930-T2Q using the 
mutagenic primers 5’- and 3’-dr0930-D71N and the terminal gene primers 5’-dr0930-
SphI-T2Q and 3’-dr0930-HindIII.  
 The Dr0930_1 - Dr0930_12 variants were analyzed by in vitro activity screening 
(3.2.8). To this end, E. coli T7 Express Rosetta cells transformed with the pTNA 
constructs were grown in 96-well blocks, containing 1.5 ml SuperBroth medium 
supplemented with 1.0 mM ZnCl2. The cells were lysed by incubation with 
1 x BugBuster in 50 mM HEPES pH 8.5, and the activity of the crude lysate was 
assayed using 0.5 mM EPXN. Figure 30 shows the result of the re-screen. 
 
 
Figure 30: In vitro activity screening of the epPCR variants Dr0930_1 - Dr0930_12 using 
0.5 mM EPXN. 
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.5 mM EPXN at 405 nm 
and 30 °C. The average values of triplicate measurements are shown. The signal of spontaneous 
background hydrolysis was subtracted from all values (empty pTNA vector was used as negative 
control). Wild-type Dr0930, the rational designed variant Dr0930-F26G+C72I, Dr0930_13 (Dr0930-
D71N) and wild-type PTE (positive control) were used as controls. The reaction of wild-type PTE 
completed within the deadtime of the experiment.  
 
 The positive effect of the single mutation D71N on the catalytic activity is 
significant. The best hits, Dr0930_2, Dr0930_5, Dr0930_11, and Dr0930_12, were 
selected for in vitro characterization in order to quantify the effect of the identified 
mutations by steady-state enzyme kinetics.  
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4.3.1.3 Heterologous expression, purification and in vitro characterization of 
the epPCR hits 
 The inserts of dr0930_2, dr0930_5, dr0930_11, and dr0930_12 were subcloned 
in pET24a expression plasmid using NdeI and NotI restriction sites. To this end, the 
inserts were amplified by standard PCR (3.3.5) using the terminal gene primers 
5’dr0930-NdeI-T2Q (or 5’dr0930-NdeI-T2Q+A3T) and 3’dr0930-NotI. The full-length 
fragments were digested with NdeI and NotI restriction enzymes, and ligated with 
equally digested pET24a. 
 E. coli T7 Express Rosetta cells were transformed with the pET24a-dr0930 
constructs, and a single colony was used to inoculate 2 l LB medium, supplemented 
with 1.0 mM ZnCl2. Following induction of gene expression with 0.5 mM IPTG, the 
cell suspension was incubated overnight at 37 °C. The cells were harvested, 
resuspended in 20 mM HEPES, pH 7.5, disrupted by sonication, and centrifuged. 
The recombinant proteins were purified from the soluble fraction by combinations of 
anion exchange chromatography using QSepharoseFF and MonoQ columns 
(3.4.1.2 & 3.4.2.2). Combined protein fractions were dialyzed overnight against 5 l of 
20 mM HEPES, pH 7.5. The Dr0930 variants were characterized for the hydrolysis of 
EPXN, in 50 mM CHES pH 9.0 at 400 nm and 30 °C (3.5.4.1). Saturation curves in 
comparison to wild-type Dr0930 are shown in Figure 31. 
 
 
Figure 31: Saturation curves of wild-type Zn/Zn-Dr0930 and Zn/Zn-Dr0930_2, Zn/Zn-Dr0930_5, 
Zn/Zn-Dr0930_11, and Zn/Zn-Dr0930_12 variants for the hydrolysis of EPXN.  
Dr0930 wild-type (), Dr0930_2 (¢), Dr0930_5 (p), Dr0930_11 (), Dr0930_12 (q). The reactions 
were performed in 50 mM CHES, pH 9.0 and a variable concentration of EPXN (0-5 mM). The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed 
using 10 µM enzyme concentration. The initial velocity vi is plotted versus the concentration of 
substrate. The solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). 
 
RESULTS AND DISCUSSION 107 	  
 The steady-state kinetic parameters, turnover number (kcat), Michaelis constant 
(KM), and the catalytic efficiency (kcat/KM), determined from the fit of the saturation 
curve to the Michealis-Menten equation (Equation 11) are summarized in Table 8. 
 
Table 8: Steady-state kinetic constants of wild-type Zn/Zn-Dr0930 and variants for the 
hydrolysis of EPXN. 
  EPXN 
  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
Zn/Zn-Dr0930_2 V35E+A103V 1.2 × 10-2 2.5 4.8 × 100 
Zn/Zn-Dr0930_5 D71N+E179D+L270M 2.3 × 10-2 1.3 1.8 × 101 
Zn/Zn-Dr0930_11 A3T+G38R+T105S+P274L 5.7 × 10-3 1.2 4.8 × 100 
Zn/Zn-Dr0930_12 R272C 6.8 × 10-3 2.2 3.1 × 100 
wild-type Zn/Zn-Dr0930a 1.2 × 10-3 1.4 8.3 × 10-1 
Dr0930 variants contain the T2Q mutation. a: data taken from Xiang et al. (2009). 
 
 The four characterized Dr0930 variants exhibited a 4-22 fold improvement in 
catalytic efficiency, with the best variant being Dr0930_5. 
 In an attempt to further increase the OPH activity of Dr0930_5, the beneficial 
mutation F26G of the rationally designed variant Dr0930-F26G+C72I (Xiang et al., 
2009) was added onto the Dr0930_5 construct. The pET24a-dr0930-
F26G+D71N+E179D+L270M (Dr0930_14) construct was generated by OE-PCR 
(3.3.7.4) on the template pET24a-dr0930_5 using the mutagenic primers 
5’(3’)dr0930-F26G and the terminal gene primers 5’dr0930-NdeI and 3’dr0930-NotI. 
The variant was heterologously expressed and purified as described in 4.3.1.3. 
Steady-state enzyme kinetic characterization of Zn/Zn-Dr0930_14 gave a reduced 
catalytic efficiency of 6.5 × 100 M-1s-1 (data not shown), confirming no additive effect 
of the beneficial mutations. 
 
4.3.1.4 Metal-dependency of the OPH activity 
 The metal dependency of wild-type Dr0930 for the hydrolysis of EPXN was 
investigated. Zn, Co and Mn were tested as active site metals. In order to allow for 
the incorporation of these metals upon protein production, the expression medium 
was supplemented with 1.0 mM of either ZnCl2, CoCl2 or MnCl2. The kinetic 
parameters for the purified recombinant proteins are summarized in Table 9. 
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Table 9: Metal-dependency (Zn, Co, Mn) of the kinetic constants for wild-type Dr0930 for the 
hydrolysis of EPXN. 
 EPXN 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
wild-type Zn/Zn-Dr0930a 1.2 × 10-3 1.4 8.3 × 10-1 
wild-type Mn/Mn-Dr0930b 1.0 × 10-2 6.8 1.5 × 100 
wild-type Co/Co-Dr0930b 5.7 × 10-2 2.0 2.9 × 101 
a: data taken from Xiang et al. (2009). The reactions were performed at 400 nm (ɛ400 = 1.7 × 104        
M-1cm-1) and 30 °C in 50 mM CHES, pH 9.0 b: The reactions were performed at 400 nm and 30 °C in 
50 mM CHES, pH 9.0, 100 µM CoCl2 and MnCl2, respectively.  
 
 Wild-type Dr0930 exhibits a strong metal dependency for the hydrolysis of EPXN 
with approximately 35-fold (20-fold) preference in catalytic efficiency for Co over Zn 
(Mn). Xiang et al. (2009) investigated the metal-dependency of wild-type Dr0930 for 
the hydrolysis of δ-nonanoic lactone. The catalytic efficiencies for Mn and Co-
substituted enzymes were found to be similar, with the Co/Co- or Mn/Mn-substituted 
enzymes being slightly more active than the Zn-substituted enzyme (4-fold). The 
OPH activity of Co-, Mn-, and Zn-substituted wild-type PTE was found to be overall 
similar (Omburo et al., 1992). All subsequent experiments were performed with 
CoCl2. 
 
4.3.1.5 Steady-state kinetic characterization of Co/Co-Dr0930_5 for the 
hydrolysis of OPs 1-7  
 The variant Dr0930_5 was isolated by in vitro activity screening with EPXN. In 
order to quantify the effect of the identified mutations on the impact of OPH in 
general, the cobalt-substituted variant was characterized for the hydrolysis of OPs 1-
7. 
 Dr0930_5 was heterologously expressed as described in medium supplemented 
with 1.0 mM CoCl2 (3.4.1.2). The protein was purified by protamine sulfate and 
ammonium sulfate precipitation, and anion exchange chromatography using a 
QSepharoseFF column (3.4.2.1 & 3.4.2.2). The saturation curves of purified 
Dr0930_5 for OPs 1-7 are shown in Figure 32. 
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Figure 32: Saturation curves of Dr0930_5 for the hydrolysis of OPs 1-7. 
A: Saturation curves for OP 1 (), 2 () and 5 (). B: Saturation curves for OP 3 (), 4 (), 6 () 
and 7 (). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed 
with 0.2 µM Dr0930_5. The initial velocity vi is plotted versus the concentration of substrate. The solid 
line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). Dr0930_5: Dr0930-
T2Q+D71N+E179D+L270M. 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curve are summarized in Table 10. 
 
Table 10:   Steady-state kinetic constants of Co/Co-Dr0930_5 for the hydrolysis of OPs 1-7. 
 Co/Co-Dr0930_5 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP - - 5.0 × 102 
2: GB p-NP 2.4 × 100 1.74 1.38 × 103 
3: VR p-NP 3.6 × 100 3.54 1.0 × 103 
4: GD p-NP 2.1 × 100 5.83 3.7 × 102 
5: GF p-NP - - 4.4 × 102 
6: MPXN 7.5 × 10-1 11.4 6.6 × 101 
7: EPXN 4.7 × 100 6.5 7.2 × 102 
–: kcat/KM was determined from non-saturating concentrations by a fit of the initial part of the saturation 
curve. Compounds 1-5 were applied as racemates. Dr0930_5: Dr0930-T2Q+D71N+E179D+L270M. 
 
 Figure 33A illustrates the absolute values of the catalytic efficiencies of Dr0930_5 
for OPs 1-7 in comparison to wild-type Dr0930. Figure 33B summarizes the fold 
improvement for the respective OP compounds relative to wild-type Dr0930. 
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Figure 33: Catalytic efficiencies of Dr0930_5 (open bars) in comparison to wild-type Dr0930 
(filled bars) (A) and deduced fold improvement of Dr0930_5 relative to wild-type Dr0930 (B).  
Compared to wild-type Dr0930, the catalytic efficiencies of Dr0930_5 for GB p-NP (OP 2), VR p-NP 
(OP 3), GD p-NP (OP 4), GF p-NP (OP 5), and EPXN (OP 7) are enhanced by up to 2.1 × 102 fold, at 
the expense of slightly reduced catalytic efficiencies for VX p-NP (OP 1) (0.82 fold) and MPXN (OP 6) 
(0.33 fold).  
 
 The highest catalytic efficiencies of Dr0930_5 are achieved for GB p-NP (OP 2) 
and VR p-NP (OP 3), obtaining kcat/KM values of up to 1.4 × 103.  The improvement in 
catalytic efficiency is mainly due to an increased kcat value. The catalytic efficiencies 
for VX p-NP (OP 1) and MPXN (OP 6) are slightly diminished compared to wild-type 
Dr0930. Dr0930_5 achieves a substantial fold improvement of up to two orders of 
magnitude for GB p-NP (OP 2), VR p-NP (OP 3) and GF p-NP (OP 5).  
 Dr0930_5 exhibits a similar metal dependency as wild-type Dr0930: the catalytic 
efficiency of the Co-substituted enzyme for the hydrolysis of EPXN is 40-fold higher 
than for the Zn-substituted enzyme (see Table 8 and Table 10). 
 
4.3.2 In vitro recombination of beneficial 1st generation variants by StEP 
 Homologous template sequences are recombined by the StEP method (Zhao et 
al., 1998) that allows for the efficient in vitro recombination of closely spaced 
mutations. The technique was applied to rapidly recombine beneficial mutations from 
the positive-first generation variants acquired in separate variants while deleterious 
mutations should be removed due to backcrossing with the wild-type sequence.  
 
4.3.2.1 Generation and characterization of a pTNA-dr0930-StEP library 
 Using StEP, the Dr0930_2, Dr0930_5, Dr0930_11 and Dr0930_12 variants were 
recombined with the rationally designed variant Dr0930-F26G+C72I and wild-type 
Dr0930.  
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 To this end, the dr0930 inserts were amplified under StEP conditions (3.3.8), 
which contained the mixture of pTNA-dr0930 templates (10 ng each), GoTaq DNA 
polymerase (2.5 U; Promega), 0.2 mM dNTP, 1.5 mM MnCl2, and 0.15 µM plasmid 
primers (5’- and 3’pTNA-F-MCS). The PCR was performed at an experimentally 
determined optimum annealing temperature of 50 °C and 130 abbreviated 
amplification cycles. Subsequently, nested PCR was performed under standard 
conditions on the gel-purified PCR-product to amplify the yield of full-length product 
using the terminal gene primer 5’pTNA-SphI and 3’pTNA-HindIII (3.3.5). The 
amplification products were purified from a 1% agarose gel and pooled 
(3.3.3 & 3.3.3.1). The mixture of in vitro recombined dr0930 genes was then digested 
with SphI and HindIII (3.3.4.1), and the purified reaction products were ligated into 
(equally digested) pTNA plasmid (3.3.4.2), yielding pTNA-dr0930-StEP. The dialyzed 
ligation reactions were used to transform electrocompetent E. coli ΔhisA-ΔhisF cells 
(3.2.5 & 3.2.6). In total 16 transformations were carried out. The preparation of the 
pTNA-dr0930-StEP gene library and the calculation of the library size were 
performed as described in 3.3.10 and 3.3.10.1. 
 The ligation efficiency of the StEP library was estimated to be 94% by colony 
PCR of 50 clones. The library contained about 7 × 107 independent variants. 
Assuming that all mutations are recombined in a random fashion, the theoretical 
library size contains 4.1 × 103 variants. Sequencing of the dr0930 inserts of 10 
randomly selected clones showed that the StEP protocol resulted in 3.8 nucleotide 
exchanges per gene that corresponded to 2.2 aa exchanges/protein. The high 
number of amplification cycles lead to the introduction of new mutations (on average 
0.5 additional mutations per gene). The maximum number of tracable cross-overs 
was three.  
 
4.3.2.2 In vitro activity screening of the pTNA-dr0930-StEP library 
 In vitro activity screening of the pTNA-dr0930-StEP library for the hydrolysis of 
EPXN was performed essentially as described (3.2.8). The colorimetric signal 
improved due to supplementation of the medium with 1.0 mM CoCl2 instead of 
1.0 mM ZnCl2, and optimized expression due to the usage of E. coli BL21-
CodonPlus(DE3) cells. Plasmids of the most active colonies were extracted and 
analyzed by sequencing. The 15 most significantly improved variants identified are 
listed in Table 11. 
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Table 11: Dr0930 variants isolated from in vitro activity screening of the StEP library. 
Dr0930_#: mutations  
15: D71N+T105S+L270M 23: A3T+G38R+T105S+E179D+P274L 
16: A3T+G38R+T105S 24: G38R+T105S+E179D+G194S 
17: G38R+T105S+L270M 25: D71N+L270M 
18: E101G+R272C 26: A3T+G38R+T105S+V141A 
19: G38R+T105S 27: A3T+G38R+T105S+L270M 
20: A3T+G38R+A43T+T105S+L270M 28: G38R+T105S+P274L 
21: A3T+G38R+T105S+R272C 29: A3T+D71N+T105S+E179D+L270M 
22: E101K+T105S  
Dr0930 variants contain the T2Q mutation. In addition to the shown variants, the template variant 
Dr0930_11 was also isolated.  
 
 The results of the in vitro activity screening with 0.5 mM EPXN are shown in 
Figure 34. 
 
 
Figure 34: In vitro activity screening of the StEP variants Dr0930_15 - Dr0930_29 using 0.5 mM 
EPXN. 
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.5 mM EPXN at 405 nm 
and 30 °C. The average values of triplicate measurements are shown. The signal of spontaneous 
background hydrolysis was subtracted from all values (empty pTNA vector was used as negative 
control). The first generation variant, Dr0930_5, and a PTE variant engineered for soluble expression 
(positive control; PTE-S2Q+K185R+I274N; the S2Q mutation is due to the insertion in the pTNA 
vector using SphI restriction site at the 5’-end) were used as controls. The reaction of the latter 
completed within the deadtime of the experiment.  
 
 Most isolated variants contained the mutations G38R (βα-loop 1) and T105S (βα-
loop 3). Two new mutations (G/K) were identified at position E101 (βα-loop 3). The 
best variants Dr0930_16 and Dr0930_22, which contains an exchange at the recently 
identified position E101 (βα-loop 3), were selected for in vitro characterization in 
order to quantify the activity improvement by steady-state enzyme kinetics.  
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4.3.2.3 Heterologous expression, purification and in vitro characterization of 
hits isolated from the StEP library 
 The dr0930_16 and dr0930_22 inserts were subcloned in the pET24a expression 
plasmid using NdeI and NotI restriction sites. The inserts were amplified using 
terminal gene primers 5’dr0930-NdeI and 5’dr0930-NdeI-A3T in combination with 
3’dr0930-NotI, and the full-length fragment was digested via NdeI and NotI 
restrictions enzymes, and ligated with equally digested pET24a. Heterologous 
expression in E. coli T7 Express Rosetta was performed in media supplemented with 
1.0 mM CoCl2, and the recombinant proteins were purified by a combination of anion 
exchange (QSepharoseFF) and gel filtration chromatography (Superdex 200) 
(3.4.1.2, 3.4.2.2 & 3.4.2.3). The steady-state kinetic parameters for the hydrolysis of 
EPXN determined from the fit of the saturation curves of purified Dr0930_16 and 
Dr0930_22 (data not shown) are summarized in Table 12 in comparison to wild-type 
Dr0930 and Dr0930_5. 
 
Table 12: Steady-state kinetic constants of Co/Co-Dr0930_16 and Co/Co-Dr0930_22 for the 
hydrolysis of EPXN.  
  EPXN 
  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
Co/Co-Dr0930_16a A3T+G38R+T105S 3.7 × 10-1 0.7 5.2 × 102 
Co/Co-Dr0930_22a E101K+T105S 5.5 × 10-1 2.2 2.5 × 102 
wild-type Co/Co-Dr0930b  5.7 × 10-2 2.0 2.9 × 101 
Co/Co-Dr0930_5c D71N+E179D+L270M 4.7 × 100 6.5 7.2 × 102 
a:The reactions were performed at 30 °C in 50 mM CHES, pH 9.0 and monitored at 400 nm 
(ɛ400 = 1.7 × 104 M-1cm-1). b: The reactions were performed at 30 °C in 50 mM CHES, pH 9.0, 100 µM 
CoCl2 and monitored at 400 nm. c: Dr0930_5 contains an additional T2Q mutation. 
 
 Compared to the first generation variant Dr0930_5, the variants Dr0930_16 and 
Dr0930_22 showed improved KM values, but also reduced kcat values. The catalytic 
efficiencies are similar to Dr0930_5, and 18- and 9-fold increase compared to wild-
type Dr0930. In the crude extract screen both variants showed higher catalytic 
activity than Dr0930_5, which might be due to a positive effect of the mutations on 
protein stability and/or solubility.  
 The variants Dr0930_16 and Dr0930_22 were isolated by in vitro activity 
screening with EPXN. In order to quantify the effect of the identified mutations on the 
impact of OPH in general, the variants were characterized for the hydrolysis of OPs 
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1-7. However, the variants showed only minor improvements compared to wild-type 
Dr0930 (data not shown). 
 
4.3.3 Simultaneous hot spot mutagenesis (SHM) 
 In the following a focused library was generated by targeted randomization of 
selected hot spots. We aimed to optimize key-active site residues mutated earlier by 
our group and others (Hawwa et al., 2009b) using simultaneous hot spot 
mutagenesis (SHM). 
 
4.3.3.1 Generation and characterization of a SHM library  
 Ten prominent positions identified in our previously described experiments 
(4.3.1 & 4.3.2) and positions identified by Mesecar and co-workers (most important 
identified mutations: D71G, E101G, M234I, V235L; Hawwa et al., 2009b) with a 
maximum distance of 13 Å between the Cα-atom of the active site residue of Dr0930 
and the phosphorus atom of the superimposed DIMP inhibitor bound to PTE were 
selected for site-directed mutagenesis using partially degenerated codons. The main 
criteria for the type of mutation choosen, was the generation of a hydrophobic active 
site containing smaller amino acids in order to reduce the steric hindrance to 
accommodate the larger OP substrates (see Figure 22).  
 The following positions were mutated in the SHM library: F26, Y28, D71, C72, 
E101, Q178, E179, R228, V235, and L270. The position R228 in Dr0930 
corresponds to H254 in P. diminuta PTE, and R254 in A. radiobacter OpdA. Together 
with the active-site aspartate, which deprotonates the pentacoordinated intermediate, 
this residue is important for proton shuttling. Although we knew that the mutation of 
the corresponding active site R223 to His in S. solfataricus SsoPox resulted in a 
large descrease in activity (Elias et al., 2008) we introduced smaller and polar amino 
acids (Cys, Tyr, Ser, Asn, His) at position R228 in order to provide space for the 
accommodation of the ligand. A broad set of mutations was allowed at positions 71 
and 101. Figure 35 shows the selected positions. The set of introduced mutations is 
given in Table 13.  
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Figure 35: Positions selected for simultaneous hot spot mutagenesis (SHM; same view as in 
Figure 18A). 
Structural superposition of wild-type Dr0930 (PDB ID 3FDK; grey) and wild-type PTE with co-
crystallized DIMP ligand (PDB ID 1EZ2; depicted in green). The labeled positions F26 (βα-loop 1), 
Y28 (βα-loop 1), D71 (βα-loop 2), C72 (βα-loop 2), E101 (βα-loop 3), Q178 (βα-loop 5), E179 (βα-loop 
5), R228 (βα-loop 7), V235 (βα-loop 7), and L270 (βα-loop 8) were selected for simultaneous hot-spot 
mutagenesis. The equivalent PTE residues (see Figure 17) are shown but not labeld. 
 
Table 13: Selected positions for SHM mutagenesis and introduced set of mutations. 
F26: G, V, I Q178: N, A, L, M, S, R 
Y28: A, V, L E179: E, D 
D71: N, G, Q, A, V, L, M R228: C, Y, S, N, H 
C72: C, I V235: L, M 
E101: G, A, V, L, M, C, S, N, D, K L270: A, V, L, M 
The positions F26, C72, and R228 have been mutated earlier in a rational design approach (Xiang et 
al., 2009). The positions Y28, D71, E101, E179, V235, and L270 have been identified in variants 
isolated from the epPCR and StEP library. Except for positions Q178 and L270 all positions have also 
been mutated by Mesecar and co-workers (Hawwa et al., 2009b). 
 
 The partially degenerated codons were selected regarding the E. coli codon 
usage. Adjacent positions with less than 6 amino acid distance were mutagenized 
using one primer. The theoretical library size was calculated to contain 8.6 × 107 
independent variants. The mutations were introduced by sequential OE-PCR 
(3.3.7.4) on the pTNA-dr0390 template. The primers used are listed in 2.8.2. In the 
first step the DNA fragments were amplified under standard PCR conditions (3.3.5) 
by using a set of neighboring primers in various combinations. The respective 
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amplified fragments were mixed in stoichiometric ratios, and used to amplify 
5’ (3’) megaprimers with the gene flanking primer 5’pTNA-SphI (3’pTNA-HindIII) 
primer in combination with the 3’ (5’) dr0930-101GBS, 3’ (5’) dr0930-101MTG, 
3’ (5’) dr0930-101WGC, and 3’ (5’) dr0930-101RAH mutagenic primers in a Phusion 
gradient PCR (3.3.5). Amplified 5’ and 3’ megaprimer fragments were mixed in 
stoichiometric ratios, and the full-length genes were generated using the gene 
flanking primers 5’pTNA-SphI and 3’pTNA-HindIII in a Phusion gradient PCR. 
Processing of the pTNA-dr0930-SHM library and plasmid preparation was performed 
essentially as described in 4.3.2.1. The ligation efficiency was estimated to be 82% 
by colony PCR of 50 clones. The library contained about 4 × 108 independent 
variants, covering the theoretical library size of 8.6 × 107. Altogether, 52 clones were 
analyzed by sequencing, of which 7 constructs contained a frame shift. Sequencing 
of the dr0930 inserts of the 45 in-frame clones confirmed that the protocol resulted in 
overall very homogeneous randomization (data not shown) and the introduction of an 
average of additional 0.4 aa exchanges/protein.  
 
4.3.3.2 In vitro activity screening of the pTNA-dr0930-SHM library using a 
combination of filter paper and 96-well block activity screen  
 Due to the large library size a DEAE-filter paper activity screen was used as a 
pretest to discriminate active and inactive colonies of the pTNA-dr0930-SHM library 
(3.2.8). To this end, E. coli BL21-CodonPlus(DE3) cells transformed with the pTNA-
dr0930-SHM library were plated on large square LB agar plates. Enzyme activities of 
lysed colony replicates on DEAE-filter paper were assayed using 0.5 mM EPXN in 
50 mM CHES pH 9.0. Active colonies turned yellow upon substrate hydrolysis and 
were identified visually or by digital imaging. 100,000 colonies were screened in total, 
of which approximately 30% were active. An exemplary plate excerpt of the DEAE 
filter paper screen is shown in Figure 36.  
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Figure 36: DEAE filter paper activity screen of the SHM library: identification of active colonies 
by digital imaging using a band pass filter. 
E. coli BL21-CodonPlus(DE3) cells transformed with the pTNA-dr0930-SHM library were plated on 
large square LB agar plates. Colony replicates on the DEAE-filter paper were lysed by incubation with 
a second Whatman filter paper soaked with 1 × BugBuster in 50 mM HEPES pH 8.5, 100 µM CoCl2, 
and incubated for 15 min. The activity was assayed by subsequent incubating of the replicate filter 
paper with Whatman filter paper soaked with 0.5 mM EPXN in 50 mM CHES pH 9.0. Active colonies 
turned yellow upon substrate hydrolysis and were identified visually or by digital imaging (using a band 
pass filter 406.5-8.1 nm) and further analyzed using 96-well block screening.  
 
 Isolated hits were verified by in vitro activity screening of the crude extracts (96-
well block activity screen; 3.2.8). A representative result of the screen with 0.5 mM 
EPXN is shown in Figure 37. 
 
 
Figure 37: Representative in vitro activity screen of a 96-well plate using 0.25 mM EPXN. 
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.25 mM EPXN at 400 nm 
and 30 °C. The average values of triplicate measurements with standard deviations are shown. The 
signal of spontaneous background hydrolysis was subtracted from all values (empty pTNA vector was 
used as negative control). The first generation variant, Dr0930_5, and wild-type PTE (positive control; 
containing the S2Q mutation) were used as controls. The reaction of the latter completed within the 
deadtime of the experiment. The best hit of this plate is Dr0930_31 (Dr0930-T2Q+F26C+Y28I+ 
D71A+E101N+Q178S+E179D+V235I). 
 
 Plasmids of the 28 most active colonies (Dr0930_30 - Dr0930_57) were extracted 
and analyzed by sequencing. A complete list of constructs is listed in the appendix 
(Table 33). Table 14 summarizes the percentage alteration of mutations at each 
position, calculated from the 28 most active variants from the SHM library. 
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Table 14: Percentage alteration of mutations at each position. 
position aa/position (%) 
F26  C (61%), I/V (18% each), F (3%) 
Y28  I (75%), T (14%), V (7%), A (4%) 
D71  G (32%), N (22%), L (18%), M (14%), A/V (7% each) 
C72 C (68%), I (32%) 
E101 N/S (18% each), G (13%), M/V (11% each), L/C/D (7% each), A/K (4% each) 
Q178 S (71%), Q (25%), T (4%) 
E179 D (50%), E (50%) 
R228 R (100%) 
V235 I (54%), L (36%), M (10%) 
L270 V (43%), L (29%), I (18%), A (7%), R (3%) 
 
 Some positions exhibited a strong amino acid preference (Ile at position Y28, Cys 
at position 72, Ser at position Q178, Arg at position 228), whereas others showed a 
rather broad residue distribution (positions D71 and E101). Most noteworthy, each hit 
contained amino acids other than wild-type amino acids at position 28, 71, 101, and 
235. Furthermore, the results indicated that R228 is essential for the activity, as it 
was identified in all isolated hits (see also 4.4.5.2). Deleterious mutations, such as 
mutations other than Arg at position 228, lead to a high percentage of inactive and 
weaky active clones. 
 The three most active variants, Dr0930_30, Dr0930_31 and Dr0930_32 were 
selected for in vitro characterization in order to quantify the activity improvement by 
steady-state enzyme kinetics. 
 
4.3.3.3 Heterologous expression, purification and steady-state enzyme kinetic 
characterization of hits from the SHM library  
 The dr0930_30, dr0930_31, and dr0930_32 inserts were subcloned in the 
pET24a expression plasmid using NdeI and XhoI restriction sites. To this end, the 
inserts were amplified using terminal gene primers 5’dr0930-NdeI and 3’dr0930-XhoI 
(3.3.5), the full-length fragment was digested with NdeI and XhoI restrictions 
enzymes, and ligated with equally digested pET24a.  
 Heterologous expression in E. coli BL21(DE3) Rosetta 2 was performed in media 
supplemented with 1.0 mM CoCl2 (3.4.1.2), and the recombinant proteins were 
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purified by protamine sulfate and ammonium sulfate precipitation (3.4.2.1) and a 
combination of anion exchange (QSepharoseFF) and gel filtration chromatography 
(Superdex 200) (3.4.2.2 & 3.4.2.3). The saturation curves of purified Dr0930_30, 
Dr0930_31 and Dr0930_32 for EPXN are shown in Figure 38. 
 
 
Figure 38: Saturation curves of Dr0930_30, Dr0930_31 and Dr0930_32 for the hydrolysis of 
EPXN.  
Dr0930_30 (), Dr0930_31 (¢), Dr0930_32 (p).  
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed 
with an enzyme concentration of 75 nM. The initial velocity vi is ploted versus the concentration of 
substrate. The solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). 
Dr0930_30: F26V+Y28I+D71G+C72I+E101M+Q178S+V235L+L270I, Dr0930_31: F26C+Y28I+D71A+ 
E101N+Q178S+E179D+V235I, Dr0930_32: F26C+Y28I+D71G+E101D+Q178S+V235L+L270V. 
 
 The steady-state kinetic parameters (kcat/KM only) determined from the fit of the 
saturation curves for OPs 1-7 are summarized in Table 15. 
 
Table 15: Catalytic efficiencies of Dr0930 variants in comparison to wild-type Dr0930 and 
Dr0930_5 for the hydrolysis of OPs 1-7. 
 Dr0930 WT Dr0930_5 Dr0930_30 Dr0930_31 Dr0930_32 
 kcat/KM [M-1s-1] kcat/KM [M-1s-1] kcat/KM [M-1s-1] kcat/KM [M-1s-1] kcat/KM [M-1s-1] 
OP 1 6.1 × 102 5.0 × 102 4.0 × 102 3.3 × 102 1.2 × 102 
OP 2 9.8 × 100 1.38 × 103 8.4 × 102 4.7 × 102 3.3 × 102 
OP 3 5.1 × 100 1.0 × 103 6.9 × 102 4.5 × 102 2.5 × 102 
OP 4 6.8 × 100 3.7 × 102 4.0 × 102 6.7 × 102 2.2 × 102 
OP 5 2.1 × 100 4.4 × 102 1.3 × 103 5.6 × 102 2.3 × 102 
OP 6 2.0 × 102 6.6 × 101 4.3 × 102 2.0 × 102 4.6 × 102 
OP 7 2.9 × 101 7.2 × 102 3.45 × 103 1.8 × 103 3.9 × 103 
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Dr0930_30: F26V+Y28I+D71G+C72I+E101M+Q178S+V235L+L270I, Dr0930_31: F26C+Y28I+D71A+ 
E101N+Q178S+E179D+V235I, Dr0930_32: F26C+Y28I+D71G+E101D+Q178S+V235L+L270V. 
 
 The three characterized variants exhibited up to 135-fold increased activity for 
EPXN compared to wild-type Dr0930 and a 2.5-5.4-fold increased activity relative to 
Dr0930_5. The activity for the hydrolysis of MXPN was increased by a factor of 3-7 
relative to Dr0930_5. 
 Remarkably, most variants exhibited overall high KM values and the catalytic 
efficiencies were determined from a linear fit of the data points. Moreover, although 
the characterized variants contain 7-8 mutations, the catalytic efficiencies for OPs 1-5 
are not at all or only slightly improved compared to Dr0930_5, which carries only 3 
mutations. 
 
4.3.3.4 Generation and characterization of consensus variants 
 In order to further increase the OPH activity, 12 consensus variants were 
generated based on the frequently encountered exchanges listed in Table 14. The 
total number of mutations in each consensus variant was limited to six, keeping wild-
type amino acids at position E179, R228, and L270. The exchanges 
Y28I+Q178S+V235I were fixed, whereas positions 26 (C, V), 71 (N, G) and 101 (G, 
S, N) were kept variable. 
 The megaprimer fragments were amplified from constructs listed in the appendix 
(Table 33) using mutagenic primers listed in 2.8.2 and the terminal gene primers 
5’dr0930-SphI-T2Q and 3’dr0930-HindIII. The megaprimers were combined by OE-
PCR (3.3.7.4) using terminal gene primers 5’dr0930-SphI-T2Q and 3’dr0930-HindIII 
in a Phusion gradient PCR (3.3.5). The full-length fragments were digested with SphI 
and HindIII restriction enzymes, and ligated with equally digested pTNA vector. The 
generated consensus variants are listed in Table 16. 
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Table 16: Consensus Variants Dr0930_58 - Dr0930_69. 
Dr0930_#: Y28I+Q178S+V235I 
58: +F26C+D71N+E101G 64: +F26V+D71N+E101G 
59: +F26C+D71N+E101S 65: +F26V+D71N+E101S 
60: +F26C+D71N+E101N 66: +F26V+D71N+E101N 
61: +F26C+D71G+E101G 67: +F26V+D71G+E101G 
62: +F26C+D71G+E101S 68: +F26V+D71G+E101S 
63: +F26C+D71G+E101N 69: +F26V+D71G+E101N 
Dr0930 variants contain the T2Q mutation. 
 
 In vitro activity screening of Dr0930_58 - Dr0930_69 was performed as described 
(3.2.8) using 0.15 mM EPXN as substrate. The result is illustrated in Figure 39. 
 
 
Figure 39: In vitro activity screening for consensus variants Dr0930_58 - Dr0930_69 using 
0.15 mM EPXN. 
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.15 mM EPXN at 400 nm 
and 30 °C. The average values of triplicate measurements with standard deviations are shown. The 
signal of spontaneous background hydrolysis was subtracted from all values (empty pTNA vector was 
used as negative control). The first generation variant, Dr0930_5, and hits isolated from the SHM 
library (Dr0930_30 and Dr0930_32), and wild-type PTE (positive control; containing the S2Q mutation) 
were used as controls. The reaction of the latter completed within the deadtime of the experiment. 
Dr0930_58 - Dr0930_63 contain the F26C mutation, Dr0930_64 - Dr0930_69 contain the F26V 
mutation. Dr0930_61: Dr0930-F26C+Y28I+D71G+E101G+Q178S+V235I. 
 
 Compared to Dr0930_30 and Dr0930_32, none of the consensus variants 
showed enhanced activity for the hydrolysis of EPXN. Moreover, variants containing 
the F26V mutation showed overall diminished activity, compared to consensus 
variants containing the F26C mutation.  
 In order to verify the result in vitro, the consensus variant Dr0930_61 was 
exemplarily selected for characterization. To this end, the construct was subcloned in 
the pET24a vector using NdeI and XhoI restriction sites. The inserts were amplified 
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using terminal gene primers 5’dr0930-NdeI and 3’dr0930-XhoI (3.3.5), and the full-
length fragment was digested with NdeI and XhoI restrictions enzymes, and ligated 
with equally digested pET24a.  
 The variant was heterologusly expressed, purified and steady-state kinetically 
characterized for the hydrolysis of EPXN as described (4.3.3.3). The kinetic constant 
kcat/KM of the cobalt-substituted Dr0930_61 for EPXN was determined from a linerar 
fit of the data and is 3.1 × 103 M-1s-1. The kinetic parameters for OP compounds 1-6 
were not determined. The approach was not further pursued as no significant 
enhancement in activity was achieved. 
 As the in vitro screen of the SHM library was only performed with EPXN (OP 7), 
the improvements were limited to increased hydrolytic activity for the 
phosphotriesters MPXN (OP 6) and EPXN (OP 7) (see Table 15) when compared to 
Dr0930_5. Moreover, all isolated variants contained the wild-type amino acid a 
position R228 (see Table 14); mutations other than R228 lead to inactive variants. 
Hence, this position seems to be critical for the OPH activity. 
 
4.3.4 Sequential site-directed, site-saturation and combinatorial 
mutagenesis 
 In the following smaller focused libraries were generated in order to reduce the 
screening effort. This included targeted randomization of single hot spots by site-
directed or site-saturation mutagenesis in an interactive process of combinatorial 
mutagenesis. Key active site residues mutated earlier were re-optimized gradually. 
Positions were selected based on their proximity to the active site and a structure-
guided approach comparing differences between Dr0930 and PTE. In contrast to the 
SHM approach the positions were mutated consecutively instead of simultaneously. 
 Moreover, in vitro activity screening was performed under more stringent 
screening conditions. As the activity increased, the signal became more sensitive 
and enabled the substrate concentration to be reduced to specifically screen for 
improvements in kcat/KM. Small library sizes (less than 1000 variants) enabled 
simulatenously to screen for OP compounds 1-7, instead of only EPXN (OP 7) and 
the design of a multi-efficient OPH.  
 Starting from template Dr0930_5 (Dr0930-T2Q+D71N+E179D+L270M) selected 
active active site positions were successively targeted. The semi-rational design 
approach aimed to generate a larger hydrophobic active site. Mutagenesis focused 
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on residues located predominately in βα-loops 1, 3, 7, and 8. The most important 
positions are illustrated in Figure 40. 
 
 
Figure 40: Selected positions for sequential site-directed and site-saturation mutagenesis 
(same view as in Figure 18A). 
Structural superposition of wild-type Dr0930 (grey) and wild-type PTE (greeen) with co-crystallized 
substrate analogue DIMP (PDB ID 1EZ2). The most important positions selected for mutagenesis 
(F26, Y28, G38, D71, Y97, E101, T105, M234, V235, R272 and P274) are highlighted in grey. The βα-
loops 1, 2, 3, 7, and 8 are shown. The positions Phe26 (βα-loop 1), Tyr28 (βα-loop 1), Phe97 (βα-loop 
3), were subjected to detailed analysis using site-saturation mutagenesis. The mutations identified by 
Mesecar and co-workers (D71G, E101G, M234I, and V235L; Hawwa et al., 2009b) and mutations 
identified in hits isolated from the epPCR library (G38R, T105S, R272C, P274L) were analyzed by 
combinatorial mutagenesis. As major structural differences between Dr0930 and PTE are in the length 
and conformation of βα-loops, deletion and insertion (scanning) mutagenesis was also performed. 
 
4.3.4.1 Combinatorial mutagenesis on template Dr0930_5 
 Mesecar and co-workers discovered Dr0930 variants with enhanced activity for 
MPXN and EPXN (Hawwa et al., 2009b). By site-saturation mutagenesis of active 
site residues they obtained two variants, Dr0930-D71G+E101G+V235L and Dr0930-
D71G+E101G+M234I, with catalytic efficiencies for EPXN of 7.7 × 102 M-1s-1 and 
2.1 × 102 M-1s-1, respectively. These variants contained mutations at positions 
previously identified by our group: Dr0930_4 and Dr0930_5 contain the mutation 
D71N, Dr0930_1 the mutation V235M, and Dr0930_18 and Dr0930_22 contain the 
mutations E101G and E101K, respectively. 
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 The kinetic constants of wild-type Dr0930 reported in Hawwa et al. (kcat/KM for 
EPXN and MPXN: 1.4 × 100 M-1s-1 and 5.8 × 10-1 M-1s-1) vary considerably from the 
values determined here; apparently Mesecar and co-workers did not add metal to the 
growth medium; they only incubated the enzyme with CoSO4 prior to steady-state 
enzyme kinetics.  
 For comparative analysis, their best variant Dr0930-D71G+E101G+V235L 
(Dr0930_70) was in vitro characterized for the hydrolysis of OPs 1-7 under the same 
conditions used here. The pET24a-dr0930_70 construct was generated on the 
dr0930 template. Initially four megaprimers were generated by standard PCR (3.3.5) 
using the following combinations of primers: 5’T7P and 3’dr0930-D71G, 5’dr0930-
D71G and 3’dr0930-E101G, 5’dr0930-E101G and 3’dr0930-V235L, 5’dr0930-V235L 
and 3’T7T. In a second step the four megaprimer fragments were assembled by 
Phusion gradient PCR (3.3.5) using gene flanking primers 5’T7P and 3’T7T for 
amplification. The full-length fragment was digested with NdeI and XhoI restriction 
enzymes and ligated with equally digested pET24a. Heterologous expression in 
E. coli BL21(DE3) Rosetta 2 was performed in media supplemented with 1.0 mM 
CoCl2 (3.4.1.2), and the recombinant protein was purified by protamine and 
ammonium sulfate precipitation and a combination of anion exchange 
(QSepharoseFF) and gel filtration chromatography (Superdex 200) 
(3.4.2.1 & 3.4.2.2 & 3.4.2.3). The steady-state kinetic parameters of the purified 
protein determined from the fit of the saturation curves with OPs 1-7 (data not shown) 
are summarized in Table 17. 
 
Table 17: Steady-state kinetic parameters of Co/Co-Dr0930_70 for the hydrolysis of OPs 1-7. 
 Co/Co-Dr0930_70 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP - - 5.6 × 102 
2: GB p-NP - - 1.0 × 103 
3: VR p-NP - - 9.8 × 102 
4: GD p-NP - - 3.1 × 102 
5: GF p-NP - - 3.2 × 102 
6: MPXN 4.5 × 100 9.0 5.0 × 102 
7: EPXN 4.4 × 100 2.3 1.9 × 103 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
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reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. -: kcat/KM was determined from 
non-saturating concentrations by a fit of the initial part of the saturation curve. Compounds 1-5 were 
applied as racemates. Dr0930_70: Dr0930-D71G+E101G+V235L. 
 
 The catalytic efficiencies obtained here were somewhat elevated compared to 
those published in Hawwa et al. (2009b). However, as the kinetic constants for wild-
type Co/Co-Dr0930 determined here are much higher than those published, the 
variant achieves only a 65-fold improvement in kcat/KM for EPXN compared to the 
published 560-fold improvement. When compared to Dr0930_5, Dr0930_70 achieves 
higher catalytic efficiencies for EPXN (2.6 fold) and MPXN (7.6 fold); the catalytic 
efficiencies for OPs 1-5 are similar to Dr0930_5 (see Table 10 and Table 17).  
 In order to further increase the OPH activity of Dr0930_5, the mutations D71G, 
E101G, M234I, and V235L, were added in various combinations. The variants were 
generated by sequential OE-PCR on the template pET24a-dr0930_5 using gene 
flanking primers 5’T7P and 3’T7T in various combinations with the mutagenic primers 
5’(3’)dr0930-D71G, 5’(3’)dr0930-E101G, 5’(3’)dr0930-M234I and 5’(3’)dr0930-V235L. 
In a second step the megaprimer fragments were assembled by Phusion gradient 
PCR (3.3.5) using terminal gene primers 5’dr0930-NdeI and 3’dr0930-XhoI as nested 
primers for amplification. The full-length fragment was digested with NdeI and XhoI 
restriction enzymes and ligated with equally digested pET24a. The generated 
variants are listed in Table 18. 
 
Table 18: Variants generated by combinatorial mutagenesis on template Dr0930_5 
(D71N+E179D+L270M): Dr0930_71 - Dr0930_80. 
Dr0930_#: E179D+L270M  
71: +D71N+E101G 76: +D71G+E101G 
72: +D71N+V235L 77: +D71G+V235L 
73: +D71N+E101G+V235L 78: +D71G+E101G+V235L 
74: +D71N+M234I 79: +D71G+M234I 
75: +D71N+E101G+M234I 80: +D71G+E101G+M234I 
 
 The variants were characterized by in vitro activity screening (3.2.8). To this end, 
E. coli BL21(DE3) Rosetta 2 cells transformed with the constructs were grown in 
media supplemented with 0.5 mM CoCl2, lysed, and assayed using 0.5 mM EPXN. 
The results are shown in Figure 41. 
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Figure 41: In vitro activity screening of combinatorial variants Dr0930_71 - Dr0930_80 using 
0.5 mM EPXN.  
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.5 mM EPXN at 400 nm 
and 30 °C. The average values of triplicate measurements with standard deviations are shown. The 
signal of spontaneous background hydrolysis was subtracted from all values (empty pTNA vector was 
used as negative control). Wild-type Dr0930 and the Dr0930_5 template were used as controls. 
Dr0930_71 - Dr0930_75 contain the D71N mutation, Dr0930_76 - Dr0930_80 contain the D71G 
mutation. Dr0930_73: Dr0930-D71N+E101G+E179D+V235L+L270M. 
 
 All variants show significantly enhanced activity compared to Dr0930_5. Overall 
the Dr0930_71 - Dr0930_75 variants, containing the D71N mutation, were more 
active than variants containing D71G mutation (Dr0930_76 - Dr0930_80). The best 
variant Dr093_73 was selected for steady-state enzyme kinetic characterization. The 
variant was heterologously expressed and purified as decribed (4.2.1), and 
characterized for the hydrolysis of OPs 1-7. The saturation curves are shown in 
Figure 42. 
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Figure 42: Saturation curves of Dr0930_73 for the hydrolysis of OPs 1-7. 
Saturation curves for OP 1 () + 4 () (A), OP 3 () (B), OP 2 () +5 () (C), OP 6 () + 7 () (D). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed at 
150 nM enzyme concentration. The initial velocity vi is plotted versus the concentration of substrate. 
The solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). Dr0930_73: 
Dr0930-D71N+E101G+E179D+ V235L+L270M. 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curves are summarized in Table 19. 
 
Table 19: Steady-state kinetic constants of Co/Co-Dr0930_73 for the hydrolysis of OPs 1-7. 
 Co/Co-Dr0930_73 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP - - 6.7 × 102 
2: GB p-NP 3.6 × 100 3.2 1.1 × 103a 
3: VR p-NP 3.0 × 100 2.6 1.2 × 103 
4: GD p-NP - - 2.4 × 102 
5: GF p-NP - - 2.4 × 102 
6: MPXN 4.4 × 100 15.4 2.8 × 102 
7: EPXN 5.4 × 100 1.5 3.6 × 103 
-: kcat/KM was determined from non-saturating concentrations by a fit of the initial part of the saturation 
curve. a: data reproduced with same enzyme preparation; average value of three measurements 
given. Compounds 1-5 were applied as racemates. Dr0930_73: Dr0930-D71N+E101G+E179D+ 
V235L+L270M. 
 
 Compared to Dr0930_5, Dr0930_73 exhibits a 4-5 fold improvement in kcat/KM for 
EPXN and MPXN. The catalytic efficiencies for OPs 1-5 are not improved and similar 
to parameters obtained for the Dr0930_5 template (see Table 10). 
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4.3.4.2 Site-saturation mutagenesis at position Tyr28 
 Site-saturation mutagenesis at position Tyr28 was performed due to its proximity 
to the active site (Figure 40). The Y28NNS site-saturation mutagenesis was 
performed on two different templates: Dr0930_73 (D71N+E101G+E179D+V235L+ 
L270M) and Dr0930_75 (D71N+E101G+E179D+M234I+L270M).  
 In most cases, in vitro activity screening with EPXN resulted in improvement in 
OPH activity for only phosphotriester compounds (see Table 15 and 4.3.2.3). To 
ensure, that the design resulted in a simultaneous increase of the catalytic 
efficiencies towards all substrates, the smaller and targeted libraries were screened 
with all 7 OP compounds.  
 Plasmid-based gene libraries, pET24a-dr0930_73-Y28NNS and pET24a(+)-
dr0930_75-Y28NNS, on the templates pTNA-dr0930_73 and pTNA-dr0930_75 were 
generated by Phusion PCR (3.3.5) using the mutagenic primers 5’(3’)dr0930-
Y28NNS in combination with the terminal gene primers 5’dr0930-NdeI and 3’dr0930-
XhoI. The full-length fragments were digested with NdeI and XhoI, and inserted in 
equally digested pET24a vector. BL21(DE3) Rosetta 2 cells were directly 
transformed with the ligated library. In vitro activity screening with 8-fold library 
coverage was performed as described (3.2.8). Single colonies were grown in 96-well 
blocks, containing 0.75 ml SuperBroth medium supplemented with 0.5 mM CoCl2. 
Cells were lysed, and the activity of the crude lysate was assayed simultaneously for 
the hydrolysis of OPs 1-7. The best 70 hits were re-screened with 0.25 mM substrate 
in 50 mM CHES pH 9.0. The most proficient clones with increased activity for all OPs 
were isolated and analyzed by sequencing. The constructs are listed in Table 20.  
 
Table 20: Hits isolated from Y28NNS screen on templates Dr0930_73 and Dr0930_75. 
Dr0930_#: D71N+E101G+E179D+L270M 
81: +V235L+Y28L 83: +M234I+Y28L 
82: +V235L+Y28W 84: +M234I+Y28I 
 85: +M234I+Y28M 
The hits Dr0930_81 and Dr0930_82 were isolated from the pTNA-dr0930_73-Y28NNS library. The 
hits Dr0930_83, Dr0930_84 and Dr0930_85 were isolated from the pTNA-dr0930_75-Y28NNS library. 
 
 Results of the in vitro activity screening with GF p-NP (OP 5) and MPXN (OP 6) 
are exemplarily shown in Figure 43. 
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Figure 43: In vitro activity screening of the 28NNS library variants Dr0930_81 - Dr0930_85 
using 0.25 mM GF p-NP (OP 5) (A) and 0.25 mM MPXN (OP 6) (B). 
The activity of the lysed crude extract was assayed in 50 mM CHES pH 9.0, and 0.25 mM substrate at 
400 nm and 30 °C. The A400 values of the controls were measured in triplicates, single values are 
given for Dr0930_81 - Dr0930_85. The signal of spontaneous background hydrolysis was subtracted 
from all values (empty pTNA vector was used as negative control). Dr0930_73, Dr0930_75 and wild-
type PTE were used as controls.  
 
 From the Y28NNS libraries, hits containing a hydrophobic amino acid (Leu, Ile, 
Met and Trp mutation) at position 28 were isolated. Dr0930_83 - Dr0930_85, 
(containing M234I and Y28L/I/M mutations), appeared to be more active in the crude 
extract screening for methylphosphonates GF p-NP (OP 5) and GD p-NP (OP 4; data 
not shown) than Dr0930_81 and Dr0930_82 (containing V235L+Y28L/W). On the 
other hand, Dr0930_81 appeared to be slightly more active for MPXN (OP 6) than 
Dr0930_83. 
 Dr0930_81 and Dr0930_83, both containing a Leu at position 28, were selected 
for steady-state kinetic characterization. Both variants were heterologously 
expressed in media supplemented with 1.0 mM CoCl2, purified by protamine sulfate 
and ammonium sulfate precipitation in combination with anion exchange 
chromatrography (4.2.1). Steady-state kinetic characterization was performed as 
described (3.5.4.1). The saturation curves of Dr0930_81 for the hydrolysis of OPs 1-7 
are shown in Figure 44. 
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Figure 44: Saturation curves of Dr0930_81 for the hydrolysis of OPs 1-7. 
Saturation curves for OP 1 (), 2 (), 3 (), 4 () and 5 () (A), and OP 6 () + 7 () (B). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed at 
100 nM enzyme concentration. The initial velocity vi is plotted versus the concentration of substrate. 
The solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). Dr0930_81: 
Dr0930-Y28L+D71N+E101G+ E179D+V235L+L270M. 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curves are summarized in Table 21. 
 
Table 21: Steady-state kinetic constants of Co/Co-Dr0930_81 and Co/Co-Dr0930_83 for the 
hydrolysis of OPs 1-7. 
 Co/Co-Dr0930_81  Co/Co-Dr0930_83 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1]  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP 3.1 × 100 0.39 7.9 × 103  - - 1.3 × 103 
2: GB p-NP 3.1 × 100 0.5 6.2 × 103  3.1 × 100 1.23 2.5 × 103 
3: VR p-NP 2.6 × 100 0.42 6.2 × 103  - - 1.5 × 103 
4: GD p-NP 1.15 × 100 1.42 8.1 × 102  - - 5.6 × 102 
5: GF p-NP 1.4 × 100 1.2 1.17 × 103  - - 1.2 × 103 
6: MPXN 2.3 × 100 1.46 1.58 × 103  3.0 × 100 12.1 2.5 × 102 
7: EPXN 2.9 × 100 0.38 7.6 × 103  7.1 × 100 3.1 2.3 × 103 
-: kcat/KM was determined from non-saturating concentrations by a fit of the initial part of the saturation 
curve. Compounds 1-5 were applied as racemates. Dr0930_81: Dr0930-Y28L+D71N+E101G+ 
E179D+V235L+L270M. Dr0930_83: Dr0930-Y28L+D71N+E101G+E179D+M234I+L270M. 
 
 Relative to the Dr0930_73 template (Table 19), Dr0930_81 obtained improved 
catalytic efficiencies for all 7 OPs, exhibiting up to 12-fold higher catalytic efficiencies 
relative to the template Dr0930_73, and absolute kcat/KM values of 103 M-1s-1. 
Compared to wild-type Dr0930, Dr0930_81 obtains a fold improvement of up to 
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1.2 × 103, with the highest improvement being obtained for VR p-NP (OP 3). 
Dr0930_81 (containing V235L) was used as template for the next round of 
mutagenesis as it exhibits slightly higher kcat/KM values for OPs 1-4 and OPs 6+7 (up 
to 6-fold), and overall lower KM values than Dr0930_83 (containing M234I). 
 
4.3.4.3 Combinatorial and insertion/deletion scanning mutagenesis on 
template Dr0930_81 
4.3.4.3.1 Generation of insertion and deletion variants  
 PTE and Dr0930 differ in the length and conformation of βα-loops, in particular 
βα-loops 1, 3, 7, and 8. The βα-loop 7 of PTE is 11 amino acids longer than the βα-
loop 7 in Dr0930, and contains an extra helix; βα-loops 3 and 8 of Dr0930 and PTE 
adopt different conformations. In order to adjust Dr0930 to the PTE structure, 
variants containing multiple amino acid deletions in βα-loop 3 and a five amino acid 
insertion library were generated on the Dr0930_81 template. 
 
4.3.4.3.1.1 Multiple amino acid deletion variants of βα-loop 3  
 Hawwa et al. (2009b) discovered Dr0930 variants that contained in addition to the 
mutation Y97L, amino acid deletions in βα-loop 3 (deletion of G100 and E101). The 
variants exhibited enhanced catalytic efficiency for the hydrolysis of MPXN (OP 6) 
and EPXN (OP 7) of approximately 20-fold. Here, the deletion variants Dr0930_86, 
Dr0930_87, and Dr0930_88 were generated, where the amino acids at positions 99-
101, 100+101, and 101 were deleted. The variants were generated on the template 
pTNA-dr0930_81 using the Phusing® Site-Directed Mutagenesis Kit according to the 
protocol supplied by the manufacturer (3.3.7.2) and the primer 5’dr0930_Δincl101 in 
combination with 3’dr0930_Δ99+100+101, 3’dr0930_Δ100+101, 3’dr0930_Δ101. The 
variants were analyzed by in vitro activity screening with OPs 1-7 (3.2.8), and 
exhibited slightly diminished activity (data not shown). The variants Dr0930_86 -
Dr0930_88 were not further characterized. 
 
4.3.4.3.1.2 Transposon-mediated insertion scanning mutagenesis 
 A 5 in-frame amino acid insertion library was generated on the template 
Dr0930_81 using a commercially available transposon-mediated insertion scanning 
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mutagenesis kit (MGSTM Kit). The library (theoretical library size of 103 individual 
variants) was generated in the pTNA vector using SphI and HindIII restriction sites 
according to the protocol supplied by the manufacturer (3.3.9). Sequencing of the 
dr0930 inserts of 10 clones showed that 9 clones contained the 15 bp insertion. The 
insertions were homogeneously distributed (data not shown). Approximately 700 
clones were analyzed by in vitro activity screening using GB p-NP (OP 2), GD p-NP 
(OP 4) and EPXN (OP 7) (3.2.8). Two variants with similar activity for GB p-NP and 
GD p-NP, but with diminished activity for EPXN, were isolated (data not shown). Both 
variants contained the insertion of an alanine stretch in βα-loop 7: Dr0930_89 
(GAAAQ insertion following Q232) and Dr0930_90 (GAAAL insertion at following 
V235). The result of the experiment confirmed the potential of insertion scanning 
mutagenesis, and indicates that the βα-loop 7 might be important for substrate 
specificity. Dr0930_81 tolerated 5 amino acid insertions without inactivation. Due to 
time constraints randomization of the inserts in the βα-loop 7 was not performed.  
 
4.3.4.3.2 Site-saturation mutagenesis of Tyr97 on template Dr0930_81 
 Site-saturation mutagenesis at position Tyr97 was performed due to the 
proximity of the residue to the active site (Figure 40). Tyr97 is conserved within the 
PLL enzymes (Figure 17); at the equivalent position in P. diminuta PTE is a Trp 
(Trp131). In order to obtain Dr0930 variants with enhanced OPH activity, Y97 has 
been mutagenized earlier in D. radiodurans Dr0930 (Xiang et al., 2009; Hawwa et al., 
2009b) and S. solfataricus SsoPox (Elias et al., 2008). In order to quantify the effect 
of all 19 single mutations in a systematic manner, and to make a detailed analysis, 
the variants were generated individually.  
 The constructs were generated by OE-PCR (3.3.7.4) on the template dr0930_81 
using the mutagenic NNS primers 5’(3’)dr0930-Y97NNS-E101G or the single 
mutagenic primers 5’(3’)dr0930-Y97Q, 5’(3’)dr0930-Y97W and 5’(3’)dr0930-Y97C in 
combination with the 5’(3’)dr0930-V235L+ΔSphI primers (simultaneously deleted the 
internal SphI restriction site) and terminal gene primers 5’dr0930-SphI and 3’dr0930-
HindIII. The full-length fragments were digested with SphI and HindIII restriction 
enzymes and ligated with equally digested pTNA. The inserts of the 19 individual 
constructs were verified by sequencing. The generated variants are listed in Table 
22.  
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Table 22: Y97NNS variants generated on the Dr0930_81 template: Dr0930_91 - Dr0930_109. 
Dr0930_#: Y28L+D71N+E101G+E179D+V235L+L270M 
91: +Y97M   96: +Y97P 101: +Y97R 106: +Y97F 
92: +Y97V   97: +Y97H 102: +Y97N 107: +Y97C 
93: +Y97I   98: +Y97S 103: +Y97G 108: +Y97Q 
94: +Y97D   99: +Y97A 104: +Y97T 109: +Y97W 
95: +Y97L 100: +Y97E 105: +Y97K  
Dr0930 variants contain the T2Q mutation. 
 
 E. coli BL21-CodonPlus(DE3) cells transformed with the pTNA-dr0930_91 - 
pTNA-dr0930_109 constructs were grown in media supplemented with 1.0 mM 
CoCl2. The crude extract was screened for the hydrolysis of OPs 1-7 (0.15 mM for 
OPs 1-3 and OPs 6+7; 0.25 mM for OPs 4+5). In vitro activity screening results for 
OPs 4 and 7 are exemplarily shown in Figure 45. 
 
 
Figure 45: In vitro activity screening of the Y97NNS variants using 0.25 mM GD p-NP (OP 4) (A) 
and 0.15 mM EPXN (OP 7) (B). 
The activity of the lysed crude extract was assayed in 50 mM CHES pH 9.0, and 0.25/0.15 mM 
substrate at 400 nm and 30 °C. The A400 values were measured in triplicates, the standard deviation is 
given. The signal of spontaneous background hydrolysis was subtracted from all values (empty pTNA 
vector was used as negative control). Dr0930_81 (template; Dr0930-Y28L+D71N+E101G+E179D+ 
V235L+L270M) and wild-type PTE (positive control) were used as controls. Although, wild-type PTE 
exhibits a higher catalytic efficiency for GD p-NP than Dr0930_81 (see Table 6 and Table 21), in the 
crude extract screen it showed lower activity relative to Dr0930_81 due to a lower expression level.  
 
 Dr0930 variants containing hydrophobic amino acids (Ile, Leu, Phe, Trp) at 
position 97 showed increased activity for the hydrolysis of OPs. Dr0930_93 (Y97I) 
and Dr0930_106 (Y97F) exhibited significantly increased activity for the hydrolysis of 
GD p-NP (OP 4; Figure 45A) and GF p-NP (OP 5; data not shown). Dr0930_106 and 
Dr0930_109 (Y97W) were the most active variants for EPXN (OP 6; Figure 45B) and 
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MPXN (OP 6; data not shown). However, the improvements of the variant 
Dr0930_109 (Y97W) were only significant for the hydrolysis of MPXN and EPXN. 
 Dr0930_93 and Dr0930_106, showing increased activity for all seven OPs, were 
subjected to in vitro characterization in order to quantify the effect of the identified 
mutations by steady-state enzyme kinetics. The constructs dr0930_93 and 
dr0930_106 were subcloned into the pET24a expression vector. The inserts were 
amplified by Phusion PCR (3.3.5) using the terminal amplification primers 5’dr0930-
NdeI and 3’dr0930-XhoI. The full-length fragments were digested with NdeI and XhoI 
restriction enzymes, ligated with equally digested pET24a vector. 
 Dr0930_93 (Y97I) and Dr0930_106 (Y97F) were heterologously expressed in 
media supplemented with 1.0 mM CoCl2, and purified as described (4.2.1). The 
saturation curves of Dr0930_106 for OPs 1-7 are shown in Figure 46.  
 
 
Figure 46: Saturation curves of Co/Co-Dr0930_106 for the hydrolysis of OPs 1-7.  
Saturation curves for OP 1 (), 2 (), 3 (), 4 () and 5 () (A), and OP 6 () + 7 () (B). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Reactions were performed at 
25 nM enzyme concentration. The initial velocity vi is plotted versus the concentration of substrate. 
The solid line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). 
Dr0930_106: Dr0930-Y28L+D71N+Y97F+E101G+E179D+V235L+L270M. 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curves are summarized in Table 23. 
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Table 23: Steady-state kinetic constants of Co/Co-Dr0930_93 and Co/Co-Dr0930_106 for the 
hydrolysis of OPs 1-7.  
 Co/Co-Dr0930_93  Co/Co-Dr0930_106 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1]  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP - - 1.2 × 104  - - 2.2 × 104  
2: GB p-NP 3.73 × 101 1.5 2.5 × 104  2.19 × 101 0.51 4.3 × 104 
3: VR p-NP 1.47 × 101 0.39 3.8 × 104  1.9 × 101 0.48 4.0 × 104 
4: GD p-NP 1.63 × 101 3.8 4.3 × 103  7.51 × 100 2.15 3.5 × 103 
5: GF p-NP 2.96 × 101 4.9 6.0 × 103  1.27 × 101 2.13 6.0 × 103 
6: MPXN n.a. n.a. n.a.  8.0 × 100 1.0 8.0 × 103 
7: EPXN 9.2 × 100 1.5 6.1 × 103  1.3 × 101 0.8 1.6 × 104 
-: kcat/KM was determined from non-saturating concentrations by a fit of the initial part of the saturation 
curve. n.a.: not analyzed. Compounds 1-5 were applied as racemates. Dr0930_93: Dr0930-Y28L+ 
D71N+Y97I+E101G+E179D+V235L+L270M. Dr0930_106: Dr0930-Y28L+D71N+Y97F+E101G+ 
E179D+V235L+L270M. 
 
 The catalytic efficiencies of Dr0930_93 and Dr0930_106 are overall very similar. 
The absolute values of kcat/KM of approach 104 M-1s-1. Compared to Dr0930_106, 
Dr0930_93 exhibits approximately two fold higher kcat values for GD p-NP (OP 4) and 
GF p-NP (OP 5), but also slightly higher KM values. Dr0930_106 was used as 
template for further combinatorial mutagenesis due to its lower KM value. When 
compared to the template Dr0930_81, Dr0930_106 obtains a 2-7-fold improvement in 
kcat/KM. Relative to wild-type Dr0930, Dr0930_106 obtains highest fold improvements 
for GB p-NP (OP 2) (4.4 × 103) and VR p-NP (OP 3) (7.8 × 103). 
 
4.3.4.4 Mutagenesis on template Dr0930_106 
4.3.4.4.1 Site-saturation mutagenesis at position Phe26 
 Site-saturation mutagenesis at position Phe26 was performed due to the 
proximity of the residue to the active site (Figure 40). The corresponding residue in 
PTE, G60, is crucial for the OPH activity (Chen-Goodspeed et al., 2001a/b). 
Although, the position was mutagenized earlier (Xiang et al., 2009; Hawwa et al., 
2009b), the position was subjected to detailed characterization in order to quantify 
the effect of the single mutations. The 19 variants (Dr0930_110 - Dr0930_128) were 
generated by QuikChange mutagenesis (3.3.7.1) on the template pTNA-dr0930_106 
using single primers listed in 2.8.2. In vitro activity screening with 0.15 mM OPs 1-7 
was performed as described (3.2.8). All 19 variants were essentially inactive for OPs 
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1-6, and showed significantly diminished activity for OP 7 (data not shown). Thus, 
residue F26 seems to be critical for substrate positioning (see also 4.4.5.2).  
 
4.3.4.4.2 Combinatorial site-directed mutagenesis on template Dr0930_106 
 Beneficial mutations identified in the first-generation variants Dr0930_11 and 
Dr0930_12 isolated from the epPCR library (Figure 30; Table 8) were added in 
various combinations onto the best variant Dr0930_106. The mutations are localized 
in βα-loops 1, 3 and 8: G38R (βα-loop 1), T105S (βα-loop 3), P274L (βα-loop 8), 
R272C (βα-loop 8) (Figure 40). Likewise, combinatorial variants were generated with 
Met or Leu (wild-type amino acid) at position 270 (βα-loop 8) to analyze the effect of 
the more distant mutation. 
 Constructs containing single or double mutations were generated by 
(consecutive) QuikChange mutagenesis (3.3.7.1) on the template pTNA-dr0930_106 
using primers listed in 2.8.2. Constructs containing three or four mutations were 
generated by QuikChange mutagenesis (3.3.7.1) or OE-PCR (3.3.7.4) using the 
constructs generated earlier. The primers used are listed in 2.8.2, 5’dr0930-SphI-T2Q 
and 3’dr0930-HindIII were used as terminal gene primers. Genes were inserted in the 
pTNA vector using SphI and HindIII restriction sites. The generated variants are 
listed in Table 24. 
 
Table 24: Variants generated by combinatorial mutagenesis on template Dr0930_106: 
Dr0930_129 - Dr0930_143. 
Dr0930_#: Y28L+D71N+Y97F+E101G+E179D+V235L+L270M 
129: +G38R 137: +G38R+P274L 
130: +T105S 138: +G38R+M270L+P274L 
131: +R272C 139: +G38R+T105S+R272C 
132: +P274L 140: +G38R+T105S+P274L 
133: +M270L+R272C 141: +G38R+M270L+R272C 
134: +M270L+P274L 142: +G38R+T105S+M270L+R272C 
135: +G38R+T105S 143: +G38R+T105S+M270L+P274L 
136: +G38R+R272C  
Dr0930 variants contain the T2Q mutation. 
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 E. coli BL21-CodonPlus(DE3) cells transformed with the pTNA-dr0930_129 -
pTNA-dr0930_143 constructs were grown in media supplemented with 1.0 mM 
CoCl2. The lysed and diluted crude extract was screened for the hydrolysis of OPs 1-
7 (0.15 mM for OPs 1-3 and OPs 6+7; 0.2 mM for OPs 4+5). In vitro activity 
screening results for GB p-NP (OP 2) and GD p-NP (OP 4) are exemplarily shown in 
Figure 47. 
 
 
Figure 47: In vitro activity screening of Dr0930_129 - Dr0930_143 using 0.15 mM GB p-NP (OP 
2) (A) and 0.2 mM GD p-NP (OP 4) (B).  
The activity of the crude lysate was assayed in 50 mM CHES pH 9.0, and 0.15/0.2 mM substrate at 
400 nm and 30 °C. The A400 values were measured in triplicates and the standard deviation is given. 
The signal of spontaneous background hydrolysis was subtracted from all values (empty pTNA vector 
was used as negative control). Dr0930_106 (template; Dr0930-Y28L+D71N+Y97F+E101G+E179D+ 
V235L+L270M) and wild-type PTE (positive control) were used as controls. Although wild-type PTE 
exhibits a higher catalytic efficiency for GB p-NP than Dr0930_106 (Table 6; Table 23), in the crude 
extract screen it showed lower activity relative to Dr0930_106 due to a lower expression level. Due to 
the high activity, the lysed crude extract was diluted in 50 mM HEPES pH 8.5, 100 µM CoCl2 prior to 
the screen.  
 
 The best variants Dr0930_132 and Dr0930_134 contain the P274L mutation and 
differ at position 270 (Met versus wild-type Leu). The other mutations (G38R, T105S, 
and R272C) had no beneficial effect on the activity. The Dr0930_132 and 
Dr0930_134 variants showed comparable solubility (data not shown); hence 
Dr0930_134 was selected for in vitro characterization as it shows slightly higher 
activity and contains one less mutation. 
 The construct dr0930_134 was subcloned in the pET24a expression plasmid. The 
insert was amplified using terminal gene primers 5’dr0930-NdeI and 3’dr0930-XhoI. 
The full-length fragment was digested with NdeI and XhoI restriction enzymes, and 
ligated with equally digested pET24a. The variant was heterologously expressed and 
purified as described (4.2.1). Saturation curves from steady-state kinetic 
characterization of Co/Co-Dr0930_134 with OPs 1-7 are shown in Figure 48. 
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Figure 48: Saturation curves of Co/Co-Dr0930_134 for the hydrolysis of OPs 1-7. 
Saturation curves for OP 1 (), 2 (), 3 () (A), and 4 (), 5 (), 6 (), 7 () (B). 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. The saturation curves were 
determined in triplicates; exemplary curves are shown. Dr0930_136 was diluted in 20 mM HEPES 
pH 7.5, 100 µM CoCl2 buffer supplemented with 1 mg/ml BSA in order to stabilize the protein at high 
dilutions. BSA has no influence on activity (data not shown). Reactions were performed with 5 nM 
enzyme concentration. The initial velocity vi is plotted versus the concentration of substrate. The solid 
line shows the result of the hyperbolic or linear fit of the data points (SigmaPlot). Dr0930_134: Dr0930-
Y28L+D71N+Y97F+E101G+E179D+V235L+P274L. 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curves are summarized in Table 25. 
 
Table 25: Steady-state kinetic parameters of Co/Co-Dr0930_134 for the hydrolysis of OPs 1-7. 
 Co/Co-Dr0930_134a 
 kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
1: VX p-NP - - 2.5 ± 0.7 × 105  
2: GB p-NP 6.8 ± 0.3 × 101 0.19 ± 0.01 3.6 ± 0.2 × 105 
3: VR p-NP 1.27 ± 0.04 × 102 0.36 ± 0.02 3.5 ± 0.2 × 105 
4: GD p-NP 9.4 ± 0.3 × 100 1.03 ± 0.08 9.2 ± 0.6 × 103 
5: GF p-NP 4.0 ± 0.4 × 101 1.1 ± 0.1 3.5 ± 0.1 × 104 
6: MPXN 4.2 ± 0.4 × 101 1.26 ± 0.07 3.4 ± 0.4 × 104 
7: EPXN 1.1 ± 0.1 × 101 0.53 ± 0.08 2.0 ± 0.1 × 104 
a: The kinetic constants were determined in three independent measurements. The standard deviation 
is given. -: kcat/KM was determined from non-saturating concentrations by a fit of the initial part of the 
saturation curve. Compounds 1-5 were applied as racemates. Dr0930_134: Dr0930-Y28L+D71N+ 
Y97F+E101G+E179D+V235L+P274L. 
 
 Figure 49A illustrates the catalytic efficiencies of Dr0930_134 for OPs 1-7, Figure 
49B provides the individual values of kcat and KM.  
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Figure 49: Catalytic efficiencies (kcat/KM) (A) and kcat (filled bars) and KM (open bars) values of 
Co/Co-Dr0930_134 for OPs 1-7. 
The kinetic constants were determined in three independent measurements. The standard deviation is 
given. For OP 1: only kcat/KM was determined from non-saturating concentrations by a fit of the initial 
part of the saturation curve. 
 
 Dr0930_134 is most efficient for the hydrolysis of methylphosphonates with a 
small substituent at the P-center (OPs 1-3), achieving high catalytic efficiencies of 
105 M-1s-1. Highest kcat values were achieved for OPs 2 and 3. The KM values within 
methylphosphonate compounds 2-5 increase with the size of the substituent at the P-
center. Moreover, Dr0930_134 achieves a fold improvement in kcat/KM ranging from 
1.3 for EPXN (OP 7) to more than one order of magnitude (11.4-fold) for VX p-NP 
(OP 1), when compared to the previous variant Dr0930_106. 
 Figure 50A illustrates the fold activity improvement of Dr0930_134 compared to 
the starting template wild-type Dr0930. The fold improvement in kcat/KM is substantial, 
ranging from two (VX p-NP (OP 1), MPXN (OP 6), EPXN (OP 7)) to four (GB p-NP 
(OP 2), VR p-NP (OP 3), GF p-NP (OP 5)) orders of magnitude. The fold 
improvement is mainly due to an enhancement in kcat. When compared to wild-type 
Dr0930, the KM values are, except for MPXN, only slightly reduced (not shown). 
Compared to wild-type PTE, the catalytic efficiencies of Dr0930_134, are lower by 
one to two orders of magnitude for methylphosphonates (OPs 1-5) and three to four 
orders of magnitude for phosphotriesters (MPXN and EPXN) (not shown). However, 
the catalytic efficiency for GD p-NP (OP 4) is essentially identical to that obtained by 
wild-type PTE (Figure 50B). 
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Figure 50: Comparison of Dr0930_134 with wild-type Dr0930 (A) and wild-type PTE (B). 
A: Fold improvements of Dr0930_134 in kcat/KM compared to wild-type Dr0930: 4.1 × 102 (OP 1), 
3.7 × 104 (OP 2), 6.9 × 104 (OP 3), 1.4 × 103 (OP 4), 1.7 × 104 (OP 5), 1.7 × 102 (OP 6), 6.9 × 102 (OP 
7). B: Comparison of absolute values of kcat/KM, kcat, and KM of Dr0930_134 (filled bars) and wild-type 
PTE (open bars) for GD p-NP (OP 4).  
 
 The catalytic efficiency for the hydrolysis of VR p-NP (OP 3) by Dr0930_134 has 
been improved by 6.9 × 104-fold thereby reaching kcat/KM values that approach the 
level of natural enyzmes (see Table 25: kcat/KM > 105 M-1s-1; Bar-Even et al., 2011). 
Moreover, the results support the notion that broad substrate specificity does not 
necessarily trade-off with catalytic efficiency (Goldsmith et al., 2012). 
 
4.3.5 Summary: Design of a multi-efficient OPH  
 Figure 51 summarizes the crucial evolved Dr0930 variants most important for in 
the design for a multi-efficient OPH.  
 
 
Figure 51: Overview on the enzyme design approach. 
The engineered Dr0930 variants crucial in the design for a multi-efficient OPH are summarized. 
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 Most noteworthy, the first generation variant, Dr0930_5, yielded the highest 
improvement of up to 2.1 × 102 -fold in kcat/KM. The fold improvements of the 
consecutive evolved variants were no more than one order of magnitude.  
 
4.4 Detailed Characterization of best engineered Dr0930 variants 
 Next, the engineered Dr0930 variants listed in Figure 51 were kinetically 
characterized for the hydrolysis of δ-nonanoic lactone (native activity) and the 
hydrolysis of the phosphorothiolate DEVX (OP 8). Moreover, the stereopreference for 
OPs 1-5 of wild-type Dr0930 and the best variant Dr0930_134 were analyzed. The 
crystal structures of three engineered Dr0930 variants were solved, and ligand 
docking was performed to explain the structural basis for the enhanced OPH activity.  
 
4.4.1 Steady-state kinetic characterization for the hydrolysis of δ-
nonanoic lactone (native activity) 
 In order to relate the trade-off between native and engineered promiscuous 
activity, the Dr0930 variants, Dr0930_5, Dr0930_73, Dr0930_81, Dr0930_106, and 
Dr0930_134, were characterized for the hydrolysis of δ-nonanoic lactone (δ-NL) 
using a pH-sensitive colorimetric assay (3.5.4.3). The saturation curves are shown in 
Figure 52 in comparison to wild-type Dr0930.  
 
 
Figure 52: Saturation curves of wild-type Dr0930 and variants for the hydrolysis of δ-nonanoic 
lactone. 
A: wild-type Dr0930 (), Dr0930_73 (p), Dr0930_81 (). B: Dr0930_5 (u), Dr0930_106 (q), 
Dr0930_134 (¢).  
The reactions were performed in 2.5 mM BICINE (initial pH: 8.3), 0.1 mM CoCl2, 1.4% DMSO, 0.1 mM 
m-cresol purple, 0.2 M NaCl and variable concentration of δ-nonanoic lactone (0-2 mM). The reaction 
was monitored at 577 nm (ɛ577 = 1.17 × 103 M-1cm-1) and 30 °C. Prior to use, the protein buffer was 
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exchanged to 10 mM bicine pH 8.3, 100 µM CoCl2 using a NAP-25 desalting column. Wild-type 
Dr0930 and Dr0930 variants were diluted in 10 mM bicine pH 8.3, 100 µM CoCl2, 1 mg/ml BSA. BSA 
has no influence on activity (data not shown). Reactions were performed at 10 nM (A) and 0.5 µM (B) 
enzyme concentration, respectively. The initial velocity vi is plotted versus the concentration of 
substrate. The solid line shows the result of the hyperbolic fit of the data points (SigmaPlot). 
 
 The steady-state kinetic parameters determined from the fit of the saturation 
curve are summarized in Table 26 and Figure 53. 
 
Table 26: Steady-state kinetic constants of wild-type Co/Co-Dr0930 and engineered Dr0930 
variants for the hydrolysis of δ-nonanoic lactone. 
  δ-NL 
  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
Dr0930 wild-type 2.2 × 102 0.028 7.9 × 106 
Dr0930_5a D71N+E179D+L270M 1.79 × 101 1.94 9.2 × 103 
Dr0930_73 D71N+E101G+E179D+V235L 
+L270M 
1.43 × 102 5.87 2.4 × 104 
Dr0930_81 Y28L+D71N+E101G+E179D 
+V235L+L270M 
8.59 × 101 4.23 2.0 × 104 
Dr0930_106 Y28L+D71N+Y97F+E101G 
+E179D+V235L+L270M 
2.4 × 100 1.42 1.7 × 103 
Dr0930_134 Y28L+D71N+Y97F+E101G 
+E179D+V235L+P274L 
4.4 × 100 1.59 2.8 × 103 
PTE wild-type 5.7 × 10-2 0.84 6.8 × 101 
a: Dr0930_5 contains an additional T2Q mutation, which is assumed to have no effect on activity. The 
saturation curve of wild-type PTE for the hydrolysis of δ-nonanoic lactone is shown in Figure 24B. 
 
 
Figure 53: Catalytic efficiencies (A) and kcat (filled bars) and KM (open bars) parameters (B) of 
wild-type Co/Co-Dr0930 and Co/Co-Dr0930 variants for the hydrolysis of δ-nonanoic lactone.  
A: The catalytic efficiencies of Dr0930_5, Dr0930_73, Dr0930_81, Dr0930_106 and Dr0930_134 
compared to wild-type Dr0930 are reduced by 8.6 × 102, 3.3 × 102, 4.0 × 102, 4.7 × 103, and 2.8 × 103 
-fold, respectively. B: The engineered variants exhibit significantly increased KM values (in the mM 
range) and decreased kcat values compared to wild-type Dr0930. 
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 Compared to wild-type Dr0930, the catalytic efficiency for the hydrolysis of δ-
nonanoic lactone by the best engineered variant, Dr0930_134 (fold improvement in 
kcat/KM for the hydrolysis of OPs 1-7 is 1.7 × 102 - 6.9 × 104), is diminished by three 
orders of magnitude (absolute value of catalytic efficiency of 2.8 × 103 M-1s-1), due to 
an approximately 50-fold increase in KM and a 50-fold decrease in kcat. Hence, the 
increase in promiscuous OPH activity is accompanied by an equal decrease in the 
original function. Despite the partial trade-off, Dr0930_134 is a truly bifunctional 
enzyme exhibiting broad substrate specificity. The catalytic efficiencies of lactone 
and OP hydrolysis are in the range of 103 - 105 M-1s-1.  
 Interestingly, the catalytic efficiency for δ-nonanoic lactone did not continuously 
decrease in the course of the design. The kcat/KM value drops by two orders of 
magnitude with the first variant, whereas the two subsequent variants show slightly 
increased activity compared to Dr0930_5. With the introduction of the Y97F mutation 
the activity drops by another order of magnitude. The effect of the mutation of the 
PLL-conserved residue Y97 to Phe on the δ-nonanoic lactone activity has been 
investigated earlier in Xiang et al. (2009): the activity for Zn/Zn-Dr0930-Y97F was 
lower by a factor of approximately 2.5 × 102 compared to wild-type Dr0930.  
 Overall, our results confirm that the engineered OPH activity can be extremely 
high while retaining a kcat/KM of 103 M-1s-1 for the native activity, the hydrolysis of δ-
nonanoic lactone.  
 
4.4.2 Steady-state kinetic characterization for the hydrolysis of DEVX 
 To investigate the extended substrate specificity for the phosphorothiolate bond 
cleavage, the activity of wild-type Dr0930 and the engineered variants was 
investigated for the hydrolysis of DEVX (OP 8) and the kinetic parameters were 
compared to those for wild-type PTE. Wild-type Dr0930 and Dr0930 variants were 
characterized by steady-state enzyme kinetics using a DTNB coupled assay 
(3.5.4.2). The kinetic parameters determined form saturation curves (data not shown) 
are summarized in Table 27. 
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Table 27: Steady-state kinetic constants of wild-type Co/Co-Dr0930 and engineered variants 
for the hydrolysis of DEVX. 
  DEVX 
  kcat [s-1] KM [mM] kcat/KM [M-1s-1] 
Dr0930 wild-typea n.d. n.d. n.d. 
Dr0930_5b D71N+E179D+L270M 7.3 × 10-3 5.5 1.3 × 100 
Dr0930_73 D71N+E101G+E179D+V235L 
+L270M 
1.5 × 10-2 7.7 1.9 × 100c 
Dr0930_81 Y28L+D71N+E101G+E179D 
+V235L+L270M 
6.5 × 10-3 9.5 6.8 × 10-1 
Dr0930_106 Y28L+D71N+Y97F+E101G 
+E179D+V235L+L270M 
6.7 × 10-3 3.48 2.0 × 100 
Dr0930_134a Y28L+D71N+Y97F+E101G 
+E179D+V235L+P274L 
n.d. n.d. n.d. 
PTE wild-typec 5.6 × 10-1 10.6 5.3 × 101 
The reactions were performed in 50 mM HEPES pH 8.0, 0.3 mM DTNB, 100 µM CoCl2, 12% MeOH 
and variable concentrations of DEVX (0-3.5 mM). The reaction was monitored at 412 nm 
(ɛ412 = 1.415 × 104 M-1cm-1) and 30 °C. n.d.: not detected. a: No activity was detected for wild-type 
Dr0930 and Dr0930_134 for the hydrolysis of DEVX up to 50 µM enzyme concentration. b: Dr0930_5 
contains an additional T2Q mutation, which is assumed to have no effect on activity. c: Kinetic 
parameters for DEVX differ from previous measured parameters (kcat = 1 s-1, KM = 0.8 mM, 
kcat/KM = 1.2 × 103 M-1s-1; personal communication Dr. A. Bigley), predominantly in KM. 
 
 The kinetic parameters for wild-type PTE with DEVX determined here differ from 
previously determined values by one order of magnitude in KM (kcat is essentially 
identical). The reason for this remains unclear. Overall, phosphorothiolates are 
hydrolyzed by wild-type PTE at significantly lower rates compared to OPs 1-7. The 
catalytic efficiencies of the engineered Dr0930 variants are low, and 1-2 fold reduced 
compared to wild-type PTE. Moreover, wild-type Dr0930 and the best engineered 
variant exhibit no measureable activity at 50 µM enzyme concentration. 
 Our results show that although Dr0930_134 is extremely efficient for the 
hydrolysis of P-O bond within VX p-NP, no activity for the hydrolysis of P-S bond 
within structurally similar DEVX is observable.  
 
4.4.3 Stereopreference analysis of wild-type Dr0930 and Dr0930_134 
 The design of Dr0930 for enhanced OPH activity was performed applying racemic 
OPs. To assess the stereopreference and analyze potential changes during the 
design approach the stereoselectivity of wild-type Dr0930 and the best evolved 
variant, Dr090_134, were investigated for the methylphosphonates OPs 1-5.  
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 The strategy to elucidate the stereopreference is exemplarily illustrated for VR p-
NP (OP 3) in Figure 54 and briefly described in the following. Chemical and 
enzymatic hydrolysis of OP is monitored as a function of time, and the change in A400 
over time is an exponential time course. Initially, the total concentration of VR p-NP 
([S]<KM) and the resulting amplitude corresponding to 100% hydrolysis is determined 
by chemical hydrolysis of VR p-NP using KOH (Figure 54A). The time courses for the 
enzymatic hydrolysis of OP 3 by wild-type Dr0930 (blue curve) and Dr0930_134 (red 
curve) are presented in Figure 54B. The time course of wild-type Dr0930 exhibits a 
double exponential curve shape. A double exponential fit of the data (Equation 13) 
provides the rate constants for the two enantiomers using a single concentration of 
enzyme. The obtained rate constants divided by the enzyme concentration yields 
kcat/KM. The time course for Dr0930_134 indicates, that the two enantiomers are 
hydrolyzed at significantly different rates, since only one-half of the total substrate is 
hydrolyzed within 30 min. A higher concentration of enzyme is added to hydrolyze 
the remaining enantiomer. Both phases are analyzed by single exponential fits. To 
assign the configuration of the non-hydrolyzed isomer in solution after the reaction 
has approximately reached an end point at half amplitude, wild-type PTE or 
engineered PTE variants, PTE-G60A and PTE-H254G+H257W+L303T, with 
assigned stereopreference (Tsai et al., 2010a) were added to the reaction mixture. 
The rate assignment is exemplarily shown for Dr0930_134 in Figure 54C and D. An 
appropriate amount of Dr0930_134 is added to 50 µM VR p-NP, inducing the 
hydrolysis of one enantiomer. After one-half of the total substrate is hydrolyzed (50% 
amplitude), PTE-G60A (high enantiomeric preference for RP) is added to hydrolyze 
the RP enantiomer. As no change in absorbance is observed, the hydrolyzed 
stereoisomer has RP configuration, indicating the fast phase of racemate hydrolysis 
corresponds to the RP-isomer. As additional control PTE-H254G+H257W+L303T, 
with high enantiomeric preference for SP, was added to the reaction mixture to 
hydrolyze the remaining SP enantiomer resulting in fast hydrolysis. The catalytic 
efficiency determined for the phase of PTE-H254G+H257W+L303T in Figure 54C is 
equal to the catalytic efficiency determined for the first phase of PTE-H254G+H257W 
+L303T in Figure 54D, confirming the conformational assignment.  
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Figure 54: Time courses for the chemical (A) and enzymatic hydrolysis (B, C, D) of 
approximately 50 µM racemic VR p-NP (OP 3). 
The stereopreference of wild-type Dr0930 and Dr0930_134 was assigned using previously reported 
stereopreferences of wild-type PTE and PTE variants for p-acetylphenyl substituted OPs (Tsai et al., 
2010a). The PTE variants, PTE-G60A and PTE-H254G+H257W+L303T, were kindly provided by Dr. 
A. Bigley (group of Prof. Dr. F. M. Raushel). 
A: Hydrolysis of racemic VR p-NP by 75 mM KOH as a function of time. The total concentration of VR 
p-NP was determined by complete chemical hydrolysis.  
B: Time courses for the hydrolysis of racemic VR p-NP using 110 µM wild-type Dr0930 (blue) and 
4.9 nM Dr0930_134 (red). Dr0930_134 hydrolyzes both enantiomers at significantly different rates. 
After 30 minutes one half of the substrate was hydrolyzed by Dr0930_134, and 4.8 µM Dr0930_134 
was added to the reaction to hydrolyze the remaining enantiomer. The hydrolysis profile data for wild-
type Dr0930 fits to the sum of two exponentials. For Dr0930_134 the data of the individual phases fits 
to a single exponential fit each.  
C: The hydrolysis of the RP enantiomer of racemic VR p-NP was initiated with 4.9 nM Dr0930_134. 
After 27 minutes 0.65 nM PTE-G60A variant (dark cyan) was added (enantiomeric preference for RP; 
ratio RP:SP (VR p-acetylphenyl) = 7600:1) and no further hydrolysis was observed. At 30 minutes 
4.1 nM PTE-H254G+H257W+L303T variant (dark purple; enantiomeric preference for SP, ratio RP:SP 
(VR p-acetylphenyl) = 1:120) was added to hydrolyze the remaining SP enantiomer. The kcat/KM value 
determined from the fit of the time course of PTE-H254G+H257W+L303T is equal to the kcat/KM value 
determined for the first phase of PTE-H254G+H257W+L303T in Figure 54D. 
D: Hydrolysis of racemic VR p-NP by 4.1 nM PTE-H254G+H257W+L303T (dark purple) and 0.65 nM 
PTE-G60A (dark cyan) as a function of time. At 23 and 32 minutes respectively, higher concentrations 
of enzyme (0.28 µM and 3 µM) were added for complete hydrolysis. The data for the first phase of 
PTE-G60A and both second phases is fit by a single exponential fit. The data of the first phase for 
H254G+H257W+L303T fits to the sum of two exponentials.  
 
 Dr0930_134 hydrolyzes RP-VR p-NP with a 6.5 × 103 fold preference over SP-VR 
p-NP. The values of kcat/KM (1) for the fast phase (RP) are in good agreement with 
values determined by steady-state enzyme kinetics. 
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 Racemic GD p-NP (OP 4) contains four diastereomers. In the enzymatic time 
courses for wild-type Dr0930 and Dr0930_134, only one or three phases, 
respectively, could be clearly distinguished from one another (data not shown). The 
conformational assignment was performed as described earlier. For wild-type 
Dr0930, the only phase amounted to 50% of the signal amplitude observed upon 
chemical hydrolysis, corresponding to the degradation of the two RP enantiomers. 
For Dr0930_134 one fast phase (50% amplitude, fit by single exponential fit) and a 
significantly slower phase (double exponential curve shape) were obtained. The fast 
phase corresponds primarily to the degradation of the two RP enantiomers, while the 
SP enantiomers only began to degrade in the second phase. The SPSC or SPRC 
stereoisomer cannot be assigned by comparative analysis.  
 The values of kcat/KM (1) and (2) determined from the fit of the exponential phases 
for the hydrolysis of the racemic compounds are reported in Table 28.  
 
Table 28: Summary of kcat/KM (M-1s-1) parameters deduced from the analysis of individual 
phases (1-3) observed upon the hydrolysis of racemic substrates by wild-type Dr0930 and 
Dr0930_134.  
  wild-type Co/Co-Dr0930  Co/Co-Dr0930_134 
1: VX p-NP kcat/KM (1) [M-1s-1] 1.9 × 103 1.1 ± 0.1 × 106 
 kcat/KM (2) [M-1s-1] 1.0 × 100 1.3 ± 0.4 × 103 
2: GB p-NP kcat/KM (1) [M-1s-1] 5.6 × 101 9.6 ± 0.3 × 105 
 kcat/KM (2) [M-1s-1] 3.0 × 10-1 6.3 ± 0.7 × 101 
3: VR p-NP kcat/KM (1) [M-1s-1] 3.0 × 101 1.1 ± 0.1 × 106 
 kcat/KM (2) [M-1s-1] 2.0 × 100 1.7 ± 0.1 × 102 
4: GD p-NP kcat/KM (1) [M-1s-1] 6.2 × 100 1.3 ± 0.1 × 104 
 kcat/KM (2) [M-1s-1]  2.5 ± 0.5 × 100 
 kcat/KM (3) [M-1s-1]  3.4 ± 0.8 × 10-1 
5: GF p-NP kcat/KM (1) [M-1s-1] 7.1 × 100 8 ± 1 × 104 
 kcat/KM (2) [M-1s-1] 2.0 × 10-1 1.7 ± 0.3 × 101 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2 and variable concentration of 
OPs. For OP compounds 4 and 5 the reaction assay was supplemented with 12% MeOH. The 
reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) and 30 °C. Wild-type Dr0930 and 
Dr0930_134 were diluted in 20 mM HEPES pH 7.5, 100 µM CoCl2, and 1 mg/ml BSA, 20 mM HEPES 
pH 7.5, 100 µM CoCl2, respectively. BSA has no influence on activity (data not shown). Values for 
Dr0930_134 were determined in triplicates; the standard deviations are given.  
The enantiomeric preference was assigned by addition of wild-type PTE and variants when the 
hydrolysis profile had reached approximately an end point at half amplitude. The enantiomeric 
preference for both wild-type Dr0930 and Dr0930_134 is RP > SP for OPs 1-3 and OP 5. The 
enantiomeric preference for OP 4 is RPRC + RPSC > SPRC or SPSC. For wild-type Dr0930 only one 
phase of 50% amplitude was determined. Addition of PTE-G60A and PTE-H254G+H257W+L303T 
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confirmed that the phase corresponds to the hydrolysis of RPRC + RPSC. For Dr0930_134 one fast 
phase of 50% amplitude was determined corresponding to the hydrolysis of RPRC + RPSC. The second 
phase was fit by double exponential fit yielding two rate constants corresponding to rates for SPRC and 
SPSC. However, the rate constant cannot be assigned to either SPRC or SPSC. 
The values of kcat/KM (1) for the fast phase are in good agreement with values determined by steady-
state enzyme kinetics (see Table 6 and Table 25). For comparative analysis, the values determined by 
steady-state enzyme kinetics need to be multiplied by a factor of two as the effective substrate 
concentration is half, as only the hydrolysis of the RP isomer is followed under steady-state enzyme 
conditions. 
 
 The enantiomeric preference of wild-type Dr0930 and Dr0930_134 is for the less 
toxic RP isomers of OPs 1-5 (OP 4: RPRC + RPSC > SPRC or SPSC). The ratios of 
kcat/KM (RP) / kcat/KM (SP) are summarized in Table 29.  
 
Table 29: Ratios of kcat/KM (RP) / kcat/KM (SP) for the hydrolysis of chiral OPs 1-5 by wild-type 
Dr0930 and Dr0930_134. 
 RP/SP for 1 RP/SP for 2 RP/SP for 3 RP/SP for 4a RP/SP for 5 
wild-type Dr0930  1.9 × 103:1 1.9 × 102:1 1.5 × 101:1 n.d. 3.6 × 101:1 
Dr0930_134 8.5 × 102:1 1.5 × 104:1 6.5 × 103:1 5.2 × 103:1 4.7 × 103:1 
n.d.: not determined. a: RP:SP for OP 4 is equal to kcat/KM (1) / kcat/KM (2), presumably 
(RPRC + RPSC) / SPRC or SPSC. 
 
 The kcat/KM (RP) / kcat/KM (SP) ratios for wild-type Dr0930 and Dr0930_134 are 
illustrated comparatively in Figure 55. 
 
 
Figure 55: Ratios of kcat/KM (RP) / kcat/KM (SP) for the hydrolysis of chiral OPs 1-5 by wild-type 
Dr0930 (A) and Dr0930_134 (B).  
 
 Wild-type Dr0930 and Dr0930_134 both exhibit a stereopreference for the less 
toxic RP-OPs 1-5. The sterepreference for wild-type Dr0930 is only pronounced for 
VX p-NP (OP 1) and GB p-NP (OP 2), the two methylphosphonate compounds with 
small substituents at the P-center. Dr0930_134 hydrolyzes RP-OPs with up to 
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1.5 × 104-fold preference over SP-OPs, with the highest discrimination being 
observed for GB p-NP (OP 2). Compared to wild-type Dr0930 the stereopreference 
of Dr0930_134 for VX p-NP (OP 1) is slightly diminished. The stereopreference of 
Dr0930_134 for the OPs 2-5 is significantly enhanced, resulting in a shift in 
enantiomeric preference between wild-type Dr0930 and Dr0930_134 as high as 
4.3 × 102-fold for VR p-NP (OP 3). Altogether, the results demonstrate that the 
enhanced OPH activity of Dr0930_134 is associated with an enhancement in its 
inherent stereoselectivity for OPs 2-5.  
 The stereopreference of PTE is also for RP. However, its stereopreference is less 
pronounced and increasing with the size of the substituent on the P-center 
(kcat/KM (RP) / kcat/KM (SP) for GF p-acetylphenyl is 7.6 × 102:1). Both, Dr0930 and 
PTE exhibit high stereopreference for RP, indicating that the relative orientation of the 
OP substrates in the substrate binding pockets of PTE and Dr0930 are identical (see 
also Figure 63). 
 
4.4.4 Structural analysis of engineered Dr0930 variants 
4.4.4.1 Crystallization and X-ray structure determination of evolved Dr0930 
variants 
 To elucidate the structural basis of the enhanced OPH activity of the evolved 
Dr0930 variants, we attempted to co-crystallize the three best Dr0930 variants, 
Dr0930_81, Dr0930_106 and Dr0930_134, with substrate analogues (DIMP, 
DE4MBP) and product analogues (DEP, CAC) of PTE. The structures of the 
inhibitors used are shown in Figure 56. By analogy to crystallization experiments with 
PTE, the ligands were assumed not to be very potent inhibitors; consequently, high 
amounts of compound were added to the crystal set-ups. The amounts used were 
identical or higher to conditions used to obtain complexed PTE structures (Benning et 
al., 2000; Vanhooke et al., 1996; Kim et al., 2008). However, the concentration of 
substrate analogues added was limited by the solubility of the compounds, 
particularly for DE4MP. 
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Figure 56: Structures of substrate analogues (DIMP, DE4MBP) and product analogues (DEP, 
CAC) used for co-crystallization. 
DIMP: diisopropyl methylphosphonate. DE4MBP: diethyl 4-methylbenzylphosphonate. DEP: 
diethylphosphate. CAC: sodium cacodylate.  
The ligands were assumed not to be very potent inhibitors and hence added in high concentrations. 
For co-crystallization set-ups the following amounts were used: 3% (v/v) DIMP, 1% (v/v) DE4MBP 
(limited solubility), 100 mM DEP, 100 mM CAC. DMSO and MeOH were added to increase the limited 
solubility of the substrate analogues, particularly for DE4MBP. For soaking studies, preformed crystals 
were soaked in reservoir solution supplemented with higher concentrations of ligand. 
DIMP is a competitive inhibitor for GB p-NP (OP 2). Initial velocity of GB p-NP hydrolysis ([S]=KMGB p-
NP=0.19mM) recorded in presence of various concentrations of DIMP yielded a competitive inhibition 
constant, Ki, for Dr0930_136 of 9.5 mM (see 7.6 for details). 
 
 Initially commercially available crystallization kits (see 3.6.1 for details) were used 
to screen for suitable crystallization conditions, as published crystallization conditions 
for wild-type Dr0930 and Dr0930 variants (Xiang et al., 2009; Hawwa et al., 2009b) 
gave no hits. Attempts to obtain complexed Dr0930 structures by co-crystallization or 
soaking of ligands into preformed crystals were performed. Streak- and macro-
seeding experiments with product analogues gave no suitable crystals. Promising 
crystallization conditions obtained were manually refined in a grid screen, modifying 
precipitant concentration, additives, pH and protein concentration.  
 Efforts to obtain crystals for Dr0930_81, Dr0930_106, and Dr0930_134 were 
successful. The crystallization conditions are summarized in Table 30.  
 
Table 30: Crystallization conditions for Dr0930 variants. 
Dr0930 variant crystallization conditons 
Dr0930_81 10% (w/v) PEG-8000, 0.1 M imidazole pH 8.0, 0.2 M Ca(OAc)2, 3% (v/v) DIMP; 14% ethylene glycol 
Dr0930_106  0.01 M NiCl2, 0.1 M Tris pH 8.5, 8% PEG MME 2000, 3% (v/v) DIMP, 3% (v/v) MeOH; 25% ethylene glycol 
Dr0930_134  0.1 M MES pH 6.5, 1.3 M MgSO4, 1% (v/v) DE4MBP; 25% ethylene glycol 
The crystals were obtained by sitting- (Dr0930_81) and hanging-drop vapor (Dr0930_106, 
Dr0930_134) diffusion methods. For some crystal set-ups, MeOH and DMSO were added to the 
protein ligand mix in order to increase the solubility of DIMP and DE4MBP compounds. Dr0930_81: 
Dr0930-Y28L+D71N+E101G+E179D+V235L+L270M. Dr0930_106: Dr0930-Y28L+D71N+Y97F+ 
E101G+E179D+V235L+L270M. Dr0930_134: Dr0930-Y28L+D71N+Y97F+E101G+E179D+V235L+ 
P274L. 
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 The crystals were flash-frozen in reservoir solution supplemented with ethylene 
glycol as a cryo-protectant (see Figure 57).  
 
 
Figure 57: Crystal of a Dr0930 variant frozen in ethylene glycol.  
Ethylen glycol was used as a cryo-protectant. In ethylene glycol frozen crystals showed no ice on the 
crystals and no ice rings in the diffraction pattern. 
 
 The diffraction data was collected at the Stanford Synchrotron Radiation 
Lightsource (SSRL BL7-1, Stanford, USA; Dr0930_81) and the Swiss Light source 
(SLS PXII, Villigen, Switzerland; Dr0930_106 and Dr0930_134). Data processing and 
structure determination was performed as described in 3.6.3 together with Nicholas 
Fox (group of Prof. Dr. David Barondeau, Texas A&M University, College Station, 
USA) or by Dr. Chitra Rajendran (group of Prof. Dr. Christine Ziegler, University of 
Regensburg). 
 The data sets had a resolution of 1.78-2.05 Å, and cell dimensions were as 
follows: a = 62 Å, b = 62 Å, c = 204 Å, α = β = 90°, γ = 120°. The primitive trigonal 
space group was P3121. The crystals contained one molecule in the asymmetric unit 
yielding a VM of approximately 3.24 A3/Da. Final Rcryst and Rfree values for all 
structures were below 23.5% and 26.1%, respectively. The data collection and 
refinement statistics are summarized in Table 31.  
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Table 31: Data collection and refinement statistics for Dr0930_81, Dr0930_106 and 
Dr0930_134. 
 Dr0930_81 Dr0930_106 Dr0930_134 
 native, pH 8.0 native, pH 8.5 native, pH 6.5 
    
Data collection    
beamline SSRL BL 7-1 SLS PXII SLS PXII 
wavelength (Å) 0.9794 1.0 1.0 
space group P 31 21 P 31 21 P 31 21 
unit cell dimensions a=61.655Å a=61.78Å a=61.853Å 
 b=61.655Å b=61.78Å b=61.853Å 
 c=203.670Å c=203.71Å c=204.786Å 
 α=β=90°, γ=120° α=β=90°, γ=120° α=β=90°, γ=120° 
resolution range (Å) 50.0-2.05 (2.09-2.05) 47.37-1.79 (1.88-1.79) 47.46-1.78 (1.88-1.78) 
no. of observed reflections 540199 233864 231779 
no. of unique reflections 29424 43548 44209 
redundancy 18.4 (19.1) 5.4 (5.2) 5.3 
mosaicity 0.351 0.249 0.110 
I (%) 100 (100) 99.1 (97.7) 99.44 
I/σI 36.5 (7.8) 13.60 9.83 
Rmerge (%)† - 0.050 (0.492) 0.075 (0.505) 
Rsym (%) 13.7 (55.8) - - 
    
Refinement    
residues in molecule T2-G323 T2-G323 T2-G323 
Rcryst (%)‡ 23.5 21.9 20.13 
Rfree (%)‡ 26.1 25.05 22.61 
no. of protein non-hydrogen 
atoms  2702 2592 
no. of water molecules 209 273 173 
average B factor (Å2) 18.9 38 46.7 
rmsd bond length (Å) 0.012 0.012 0.015 
rmsd angles (deg) 1.60 1.337 1.477 
Ramachandran plot (%)    
   favored regions 92.5 97.20 98.12 
   allowed regions 7.5 2.18 1.88 
   disallowed regions 0.00 0.62 0.00 
rmsd: root mean square deviation.  
Values in parenthesis indicate statistics for the highest resolution shell. 
†Rmerge = ∑∑j |Ij (hkl) - ‹I (hkl)›| / ∑∑j |‹I (hkl)›|, where Ij is the intensity measurement for reflection j and  
‹I› is the mean intensity over j reflections. 
‡R
cryst
 or R
free
 = ∑ ||Fo (hkl)| - |Fc (hkl)|| / ∑ |Fo (hkl)|, where Fo and Fc are the observed and calculated 
structure factors, respectively. 5% of the reflections were excluded from the refinement and used to 
calculate Rfree. 
*In the structure of Dr0930_106 an additional density distant from the active site was identified that 
could not be assigned. The additional density had no influence on crystal packing or dimerization. 
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4.4.4.2 Analysis of beneficial mutations in engineered variants 
 Structural analysis showed that the 6-7 mutations located in the βα-loops 1-3, 5, 7 
and 8 of Dr0930_81, Dr0930_106, and Dr0930_134 did not lead to a change of the 
overall backbone conformation (average backbone r.m.s.d = 0.43 Å) compared to 
wild-type Dr0930 (PDB IDs: 3FDK and 2ZC1). A structural superposition of the wild-
type Dr0930 and Dr0930_134 backbones is shown in Figure 58A. 
 The two cobalt-binding sites and the metal-coordinating residues (bridging 
carboxylated lysine; α-metal coordinating: His21, His23, Asp264, His176, β-metal 
coordinating: His176, His204) were retained in the designed proteins and maintained 
their wild-type conformation. A density was observed that indicated the bridging 
hydroxide. The side chain of the active site residue Arg228, potentially involved in 
proton shuttling, was found to be flexible and adopts an alternate conformation 
relative to wild-type Dr0930 (see Figure 58B). 
 
 
Figure 58: Structural superpositions of the engineered Dr0930_134 variant and wild-type 
Dr0930 (PDB ID 3FDK).  
A: Overal structural superposition of Dr0930_134 and wild-type Dr0930. The ribbon backbones of 
Dr0930_134 and wild-type Dr0930 (both depicted in grey) superimpose with an r.m.s.d deviation of 
only 0.43 Å. The 7 mutations are indicated (blue sticks: wild-type Dr0930 residues; red sticks: 
Dr0930_134 residues). The largest backbone differences are observed in βα-loops 3 (comprises the 
mutations Y97F and E101G) and 8 (comprises the mutation P274L). Some variation can also be seen 
in βα-loop 7 (comprises the mutation V235L). 
B: Active site superposition of wild-type Dr0930 (depicted in grey) and Dr0930_134 (depicted in blue). 
The metal coordinating His and Asp residues maintain their wild-type conformation. The active site 
residue R228 adopts an alternate conformation. The Y97F mutation does not alter the side chain 
conformation.  
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 Except for residues W269 (βα-loop 8) and M234 (βα-loop 7), all invariable 
residues in the substrate binding pocket of Dr0930, align well with the residues in the 
wild-type enzyme (data not shown). 
 The structural changes around the mutated positions are illustrated in Figure 59. 
 
 
Figure 59: Structural superpositions of Dr0930_134 and wild-type Dr0930. 
Wild-type Dr0930 (PDB ID 3FDK) and Dr0930_134 are depicted in grey and blue, respectively. 
A: Excerpts of structural superpositions of βα-loops 1, 2 and 3. The βα-loop 3, comprising the 
mutations Y97F and E101G, is shifted by 3 Å at positions A99-A103, due to the elimination of a 
hydrogen bond between D71 and the backbone nitrogen of A103 (dashed line). The loop has a high 
B-factor, suggesting that it may be flexible. The mutations Y28L in βα-loop 1 and Y97F and E101G in 
βα-loop 3, caused an enlargement of the substrate binding pocket.  
B: Excerpts of structural superpositions of βα-loops 5, 7 and 8 of wild-type Dr0930 and Dr0930_134. 
The βα-loop 7, harboring the V235L mutation, is flexible. D179 (βα-loop 5) adopts an alternate 
conformation. The βα-loop 8, harboring the mutation P274L, is shifted by 1.7 Å. 
 
 The βα-loop 1 comprises the mutation Y28L; by introducing a smaller, 
hydrophobic amino acid the size of the active site is increased, providing more space 
for the accommodation of the OP substrates. The βα-loop 3, composed of residues 
F96-E117, is more flexible in the engineered variants and was displaced by 
approximately 3 Å at positions A99-A103, due to the elimination of a hydrogen bond 
between the side chain of D71 (βα-loop 2) and the backbone nitrogen of A103. The 
E101G mutation enlarges the OP substrate binding pocket. The side chain of F97, 
present in Dr0930_106 and Dr0930_134, overall resembles the Y97 side chain in the 
wild-type enzyme (Figure 59A).  
 The D179 amino acid in βα-loop 5 is found in alternate conformations within the 
engineered variants. In Dr0930_134 the residue D179 forms no hydrogen bond to the 
neighboring R148 in βα-loop 4 (not shown), probably resulting in more flexibility. The 
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βα-loop 7 is composed of residues R228-T239. This loop is flexible but in a similar 
conformation as in the wild-type structure (PDB ID 2ZC1), hence providing no 
obvious explanation for the considerable increase in activity caused by the V235L 
mutation. The mutation L270M (βα-loop 8), present in Dr0930_81 and Dr0930_106, 
is found in a location remote from the active site (data not shown). It has not been 
demonstrated that this distant mutation has a beneficial effect by itself. The P274L 
mutation, present only in Dr0930_134, causes a shift of the backbone by 1.7 Å 
(Figure 59B). 
 The X-ray structures of the engineered variants helped to explain the partial 
trade-off between the native lactonase and the engineered OPH activities. 
Elimination of a crucial electrostatic interaction by the Y97F mutation and an 
enlargement of the active site lead to less effective binding and positioning of the 
lactone substate relative to the catalytic machinery; at the same time the latter only 
then allowed for improved binding of OPs. 
 
4.4.5 Ligand docking studies with engineered Dr0930 variants 
 Attempts to obtain complexed structures of engineered Dr0930 variants by co-
crystallization with substrate and product analogues or soaking of preformed crystals 
failed. Therefore, we docked the substrate EPXN into the active site of Dr0930_134 
to assess its configurational and spatial orientation.  
 Docking of ligands into the active site of wild-type PTE and Dr0930_134 was 
performed by Christoph Malisi (group of Dr. Birte Höcker, MPI Tübingen) using the 
RosettaLigand program (Davis	  &	  Baker, 2009). RosettaLigand docking and the 
analysis of docking results were performed as described in 3.7. The RosettaLigand 
program allows for ligand and receptor backbone flexibility and has been used 
previously for several successful computational designs and ligand docking 
experiments, including the docking of OPs and lactones (Khare et al., 2012; Ben-
David et al., 2012). 
 
4.4.5.1 Retroperspective ligand docking 
 To test the validity of the docking models, the output of the RosettaLigand 
docking was evaluated using the DIMP-complexed crystal structure of wild-type PTE 
(PDB ID 1EZ2) from which the inhibitor was removed. DIMP (Figure 56) and EPXN 
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(OP 7; Figure 22) were docked into the active site of PTE, and the 10 top-scoring 
ligand poses each were analyzed. The poses obtained for the docked DIMP are 
essentially identical to the one obtained by X-ray crystallography. For the best two 
scoring poses, DIMP is positioned within 0.5-0.8 Å r.m.s.d., when compared to the 
DIMP pose in the crystal structure (Figure 60A). Furthermore, docking of EPXN into 
the active site of PTE yielded essentially identical binding modes. The phosphoryl 
oxygen of the DIMP ligand is coordinated by the β-metal, and the substituents at the 
P-center fit the assigned substrate binding pockets: the O-ethyl substituents fit the 
small and large subsites, and the p-NP ring fits the leaving group subsite in PTE 
(Figure 60B). The best two poses for DIMP and EPXN, superimposed with the native 
DIMP pose, are shown in the insets. Although, RosettaLigand allows for backbone 
flexibility, the side chains in the substrate binding pocket experienced neglectable 
conformational changes. 
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Figure 60: Docking poses of DIMP (A) and EPXN (B) in the crystal structure of wild-type PTE, 
obtained using the RosettaLigand program.  
PTE (PDB ID 1EZ2) and the co-crystallized DIMP ligand are depicted in grey and dark grey, 
respectively. The docking poses are depicted in green and purple. 
A: Active site and substrate binding pocket of PTE. One top-scoring docking pose of DIMP is 
superimposed with the native DIMP pose observed in the crystal structure. The two best docking 
poses of DIMP, superimposed with the native DIMP ligand, are shown in the inset in a different view. 
The docked DIMP ligands superimpose with an r.m.s.d of 0.5-0.8 Å with the native DIMP pose. 
B: Active site and substrate binding pocket of PTE. One top-scoring docking pose of EPXN is 
superimposed with the native DIMP pose observed in the crystal structure. The phosphoryl oxygen of 
EPXN is coordinated by the β-metal. The O-ethyl substituents at the phosphorous center of EPXN fit 
the small (G60, S308, I106 and L303; I106 and L303 are not shown; overlined) and large (H254, 
H257, L271, M317; underlined) substrate binding pockets. The p-NP moiety occupies the leaving 
group pocket (W131, F132, F306, Y309; boxed) of PTE. The residues of the small, large and leaving 
group subsite are marked the same as in Figure 19B. The two best docking poses of EPXN, 
superimposed with the native DIMP ligand, are shown in the inset in a different view. 
 
4.4.5.2 Docking of EPXN in the active site of Dr0930_134 
 Subsequently, EPXN was docked into the active site of Dr0930_134. In all poses 
obtained the phosphoryl oxygen of EPXN is hydrogen bonded to the R228 side chain 
(see Figure 61). 
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Figure 61: Docking poses of EPXN in the crystal structure of Dr0930_134, obtained by docking 
using the RosettaLigand program.  
The EPXN docking poses are depicted in green and purple. The phosphoryl oxygen of EPXN is 
hydrogen bonded to the R228 side chain (dashed lines) instead of coordinating the β-metal as 
observed in the modelled PTE-EPXN complex (Figure 60B). The p-NP ring in the EPXN docking 
poses is orientated towards βα-loops 1 and 3. The residue R228 in the docked structure is shifted 
compared to the conformation obtained by crystallization.  
 
 The results indicate that R228 might be important for electrostatic coordination or 
activation of the substrate and/or stabilization of the intermediate (see also 4.3.3). 
However, as the RosettaLigand docking program allows only for small backbone 
flexibility, the electrostatic interaction between R228 and the phosphoryl oxygen of 
the EPXN ligand might be overestimated in the docking (personal communication C. 
Malisi). 
 Therefore, in an additional series of docking studies, the complexation of EPXN 
by the β-metal was enforced by introducing geometric constraints. The phosphoryl 
oxygen of the ligand was restricted to stay within 2.5 ± 0.4 Å to the β-metal. 
Moreover, the β-metal - O=P angle was set to 140° ± 30°. The docking poses 
obtained using these constraints were reasonable. The 20 top-scoring docking poses 
were analyzed and yielded essentially two clusters of poses. In the highest scoring 
and most frequently occupied poses the p-NP ring is oriented towards the βα-loop 3 
(equivalent to leaving group subsite in PTE), the O-ethyl substituents both fit the 
large pocket generated by βα-loop 7 and 8 in Dr0930_134. In the second pose 
obtained, the p-NP moiety and one O-ethyl substituent fit the large pocket; the 
second O-ethyl substituent is oriented towards the βα-loop 3. The orientation of the 
EPXN docking poses in the substrate binding pocket of Dr0930_134 in cartoon and 
stick representation is shown in Figure 62A, the surface representation is shown in 
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Figure 62B. For each of the two clusters one representative docking pose is shown in 
green and purple, respectively. The insets illustrate the variation within the two 
clusters of docking poses. 
 
 
Figure 62: Docking poses of EPXN in the crystal structure of Dr0930_134, obtained by docking 
using the RosettaLigand program applying distance and angle constraints.  
A: Active site and substrate binding pocket of Dr0930_134 in cartoon and stick representation. One 
representative of each cluster of docking poses of EPXN is shown in green and purple. The docking 
pose depicted in green belongs to the group of highest scoring and most frequently occupied cluster of 
docking poses, the docking pose in purple belongs to the second cluster of docking poses obtained. 
The variation within each cluster of docking poses is indicated in the insets. Docking poses for the first 
cluster are illustrated in green and cyan; the second cluster of docking poses is depicted in purple and 
light pink. Residue R228 is shifted compared to the conformation obtained by crystallization in order to 
accommodate the ligand (only one R228 side chain conformation is shown). 
B: Active site and substrate binding pocket of Dr0930_134 in surface representation. Important active 
site residues are labeled. 
 
 In order to compare the configurational and spatial orientation of EPXN in 
Dr0930_134 and PTE, and in order to identify residues involved in substrate 
positioning for Dr0930_134, one top scoring EPXN-docking pose for Dr0930_134 
was superimposed with the EPXN-docking pose obtained for PTE (Figure 63). 
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Figure 63: Structural superposition of the active sites of Dr0930_134 and PTE with the top 
scoring docking poses for EPXN each. 
Dr0930_134 and wild-type PTE are depicted in grey and green, respectively. One top scoring EPXN 
docking pose is shown each. The docking poses for EPXN are identical with respect to the p-NP 
moiety, but differ in orientation of O-ethyl substituents. The O-ethyl substituents of the docked EPXN 
in Dr0930_134 are shifted to avoid a steric clash with the F26 side chain. The residue R228 in the 
docked structure of Dr0930_134 is shifted relative to the conformation obtained by crystallization (not 
shown). 
 
 Docking of EPXN yields similar binding modes in Dr0930_134 and PTE with 
respect to the orientation of the p-NP ring. The results of the stereopreference 
studies also indicated that the relative orientation of the substrates in Dr0930 and 
PTE are identical (4.4.3). However, the orientation of the O-ethyl substituents differs. 
The O-ethyl substituents cannot accommodate the same orientation as in PTE due to 
a steric clash of one O-ethyl substituent with F26 (βα-loop1). Hence, F26 seems to 
be important for substrate positioning (Figure 63). Site-saturation mutagenesis 
studies (see 4.3.4.4.1) also confirmed that this residue is important for the activity. 
The equivalent residue in PTE (G60) is also a crucial residue for the OPH activity 
(Chen-Goodspeed et al., 2001a/b).  
 In all docked structures R228 is shifted compared to the conformation obtained by 
crystallization in order to accommodate the ligand. R228 is an essential residue for 
the OPH activity (see also 4.3.3), potentially being part of proton shuttling and 
coordination or activation of the substrate and/or stabilization of the intermediate. In 
order to entirely characterize the amino acid R228, the position might be analyzed by 
site-saturation mutagenesis.  
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5 FINAL DISCUSSION 
 
5.1 Divergent and convergent evolution of enzymes 
 Enzymes are characterized by a remarkable adaptability and evolvability 
(Khersonsky et al., 2006). Prominent examples are atrazine chlorhydrolases (AtzA, 
AtzB, AtzC) and the OP hydrolases, which degrade man-made chemicals such as 
the xenobiotic organohalogen herbicide atrazine and organophosphate compounds. 
These enzymes are thought to have evolved rapidly as they provide a novel nitrogen 
and phosphate source for the affected organisms (Aharoni et al., 2005a; Khersonsky 
et al., 2006; Janssen et al., 2005; Wackett, 2004; de Souza et al., 1998). In any case, 
the adaptility and evolvability depends on two criteria: (i) a high tolerance against 
destabilizing mutations (robustness) and (ii) the introduction of new phenotypic traits 
by a relatively low number of mutations (plasticity) (Glansdorff et al., 2008; 
Kirschner & Gerhart, 1998). 
 Two mechanisms for the generation of diversity of protein folds and functions can 
be distinguished: convergent and divergent evolution. Enzymes that share the same 
function and have similar active sites but differ in overall structure and exhibit 
unrelated sequences have emerged independently from different precursors by 
convergent evolution (Hegyi & Gerstein, 1999). Prominent examples for convergent 
evolution are the mammalian chymotrypsin and the bacterial subtilisin. These 
enzymes share no sequence or fold similarity but function as serine proteases and 
use the same active site triad for catalysis (Neurath, 1984). In divergent evolution, 
proteins have evolved from a common ancestor by gene duplication and 
diversification (Aharoni et al., 2005a). Divergent evolution can be traced through 
sequence and fold similarity, and conserved motifs such as key active site residues. 
Noteworthy, sequence diverges far more rapidly than structure (Elias & Tawfik, 
2012), which is clearly illustrated for example by chymotrypsin and trypsin, prominent 
examples for divergent evolution (Neurath, 1967). Most noteworty, promiscuous 
activities (weak secondary or side activities) often serve as evolutionary starting 
points for the divergence of new functions (Khersonsky et al., 2006). This notion is 
important to understand the divergent evolution of enzyme superfamilies in which 
catalytic chemistry is conserved while substrate specificity varies (Gerlt & Raushel, 
2003; O’Brien & Herschlag, 1999). 
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5.2 D. radiodurans Dr0930: a promiscuous OP hydrolyzing enzyme 
 The bacterial phosphotriesterase (PTE) from P. diminuta PTE is by far the most 
efficient and best characterized OP hydrolyzing enzyme. A close homologue of PTE 
is the phosphotriesterase-like-lactonase Dr0930 from D. radiodurans. Both enzymes 
share the same TIM-barrel fold, approximately 31% sequence identity, and key active 
site features (Xiang et al., 2009). PTE is thought to have evolved rapidly from a PLL 
precursor by gene duplication and diversification (Raushel & Holden, 2000; Afriat et 
al., 2006).  
 Dr0930 efficiently hydrolyzes γ- and δ-lactones, and promiscuous activity for the 
hydrolysis of the phosphotriesters methyl- and ethyl-paraoxon has been reported 
(Xiang et al., 2009; Hawwa et al., 2009b). The promiscuous OPH activity of Dr0930 is 
thought to be due to physical similarities between the intermediate for the native 
lactonase reaction and the ground/intermediate state for the promiscuous OPH 
reaction (Elias et al., 2008; Ben-David et al., 2012). As a C-O bond within lactones 
versus a P-O bond within organophosphates is cleaved and the reactions proceed 
via a tetrahedral versus a pentavalent oxyanionic intermediate (Figure 23), Dr0930 
exhibits both catalytic and substrate promiscuity.  
 In the framework of this thesis, the cobalt-substituted wild-type Dr0930 was 
characterized for its promiscuous OPH activity using a broad spectrum of OPs that 
vary in the size of the substituent at the P-center. Mutually, wild-type PTE was 
assayed for its hydrolysis activity against δ-nonanoic lactone (Figure 22; 4.2.3). It 
was found, that wild-type Dr0930 exhibits overall low promiscuous activities for the 
hydrolysis of phosphotriesters and methylphosphonates, with best activities for 
methylphosphonates comprising small substituents at the P-center (VX p-NP and 
MPXN). The catalytic efficiency of wild-type Dr0930 is in the range of 2.1 M-1s-1 to 
6.1 × 102 M-1s-1 and hence four to seven orders of magnitude lower when compared 
to wild-type Co/Co-PTE. Wild-type PTE hydrolyzes – in addition to a broad range of 
OPs – δ-nonanoic lactone with a catalytic efficiency of 6.8 × 101 M-1s-1, which is five 
orders of magnitude lower compared to the lactonase activity of wild-type Dr0930. In 
summary, the efficiencies of the promiscuous and native activities differ, for both 
Dr0930 and PTE, by several orders of magnitude (Table 5; Table 6). Moreover, both 
enzymes exhibit high KM and low kcat values for the promiscuous substrates. This 
may result from improper substrate binding interaction and positioning relative to the 
catalytic machinery (Khersonsky & Tawfik, 2010). However, the mutually identified 
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enzymatic activities in wild-type Dr0930 and wild-type PTE in concert with the 
observed similarities of their sequences, structures and active site features support a 
common evolutionary relationship and reinforce that PTE evolved from a PLL 
precursor by gene duplication and diversification.  
 
5.3 Laboratory evolution of Dr0930 for OP hydrolysis 
 The molecular evolution of organophosphate hydrolysis by the bacterial PTE was 
reconstructed in the laboratory by engineering Dr0930 for enhanced OPH activity, 
thereby changing its substrate specificity. Dr0930 is an ideal target for laboratory 
evolution as it is a robust and thermostable (βα)8-barrel protein (Hawwa et al., 
2009b). High protein stability enables a large number of destabilizing mutations to be 
accommodated while protein fitness is retained (Tokuriki & Tawfik, 2009). Moreover, 
thermostable (βα)8-barrels have been used earlier for the design of the non-natural 
retro-aldol (indole-3-glycerol phosphate synthase scaffold) and Kemp-elimination 
reactions (phosphoribosyl anthranilate isomerase scaffold) (Jiang et al., 2008; 
Röthlisberger et al., 2008).	   
 
5.3.1 Design of an efficient and multi-functional OP hydrolyzing Dr0930 
variant  
 Using random mutagenesis, site-directed and site-saturation mutagenesis in 
combination with in vitro activity screening of E. coli crude extracts, Dr0930 variants 
were identified showing significantly enhanced catalytic efficiencies for the hydrolysis 
of OPs. In each round of mutagenesis the most active variants were purified and 
characterized by steady-state kinetics using a broad-spectrum of racemic p-NP 
analogues of G- and V-type nerve agents (VX, GB, VR, GD, GF) and 
phosphotriesters (MPXN, EPXN). An overview of the experimental workflow is given 
in Figure 64. 
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Figure 64: Overview of the experimental workflow. 
The boxes illustrate the engineered Dr0930 variants. Amino acid exchanges in red are mutations that 
were newly identified in the individual steps. The applied mutagenesis technique is stated above the 
arrow; the corresponding chapters of this thesis are given in brackets. Three independent techniques 
are mentioned for the generation of the Dr0930_73 variant. The StEP technique identified the new 
mutations E101G/K. The SHM and consensus approach resulted in no variants that positively 
influenced the design. The mutations E101G and V235L identified by Hawwa et al., (2009b) 
highlighted the importance of the previously identified E101G mutation in the StEP design and the 
V235M mutation identified by epPCR and screening. Bona fide beneficial exchanges were combined. 
The Dr0930_5 variant contains the additional mutation T2Q, which is thought to have no influence on 
the activity. 
 
 Initially, a random based error-prone PCR approach was performed on the 
starting template wild-type Dr0930 and screened for improved catalytic activity with 
EPXN (4.3.1). The best isolated Dr0930 variant, Co/Co-Dr0930_5 
(D71N+E179D+L270M), exhibited a 25-fold increased catalytic efficiency of 
7.2 × 102 M-1s-1. Although the library was not screened for MPXN and the 
methylphosphonates VX p-NP, GB p-NP, VR p-NP, GD p-NP, and GD p-NP, the 
evolved variants also efficiently hydrolyzed these compounds. The highest catalytic 
efficiency of 1.4 × 103 M-1s-1 observed for GB p-NP corresponds to a fold 
improvement of two orders of magnitude when compared to wild-type Dr0930. The 
best first generation variant not only showed the highest improvement in catalytic 
efficiency obtained in any single step of the total design, but – together with other 
variants isolated from the error-prone PCR library – also identified many positions 
(Y28, D71, E179, V235, L270, P274) essential for OPH activity (Table 7). This result 
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demonstrates the power of random mutagenesis although only a small fraction of the 
library was screened (7.4 × 10-3%).  
 The four best isolated variants with elevated activity for the target substrate EPXN 
were recombined in vitro with wild-type Dr0930 and a previously designed variant 
(Dr0930-F26G+C72I; Xiang et al., 2009) using the StEP protocol (4.3.2). The 
second-generation gene library was subsequently screened with EPXN and two new 
residues (G, K) were identified at position E101. However, no substantial increase in 
activity for EPXN was obtained for the variants isolated from the StEP approach. 
Steady-state enzyme kinetic characterization of purified variants that appeared to 
have higher activity in the crude extract screen were presumably isolated due to a 
higher expression level rather than improved enzymatic activity. 
 Subsequently, a SHM-library was generated by simultaneous targeted 
mutagenesis of ten defined residues, introducing a selected set of amino acids at 
each position (4.3.3). A newly developed DEAE filter paper screen enabled the pre-
screen of 100,000 colonies. As the in vitro screen of the SHM library was only 
performed with the EPXN, the improvements were limited to increased hydrolytic 
activity for the phosphotriesters MPXN and EPXN (see Table 15) when compared to 
Dr0930_5. Moreover, all isolated variants contained the wild-type amino acid at 
position R228 (see Table 14), indicating that this residue is critical for the OPH 
activity. As the ten sites were mutagenized simultaneously, one single deleterious 
mutation leading to residues other than Arg at position 228, lead to a high number of 
inactive variants in the library. Moreover, variants contained mutations at position 
F26, while site-saturation mutagenesis confirmed that F26 residue is essential for 
activity (4.3.4.4.1). This disadvantage could not be compensated by increasing the 
screening throughput. Thus, also the consensus approach resulted in no variants that 
positively influenced the design (4.3.3.4).  
 The mutations E101G and V235L identified by Hawwa et al. (2009b) highlighted 
the importance of the previous identified E101G mutation in the StEP design (Table 
11) and the V235M mutation identified in the epPCR (Table 7). The bona fide 
beneficial exchanges were combined on the Dr0930_5 template yielding Dr0930_73. 
The catalytic efficiencies for MPXN and EPXN improved by 4-5 fold, while the 
catalytic parameters for OPs 1-5 remained unchanged. 
 As the StEP and SHM approaches did not yield further improved variants, in the 
following based on Dr0930_73 smaller and more focused libraries were generated. In 
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general, focused, high quality libraries are advantageous as they require less 
screening effort (Reetz et al., 2010; Lutz & Patrick, 2004). Single hot spots were 
consecutively mutagenized by site-directed or site-saturation mutagenesis with the 
goal to re-optimize previously identified key active-site residues located in βα-loops: 
Y28, D71, Y97, E101, M234, V235 (for Dr0930: Hawwa et al., 2009b; for SsoPox: 
Elias et al., 2008). 
 To ensure, that the design resulted in a simultaneous increase of the catalytic 
efficiencies towards all substrates, the smaller and more focused libraries were 
screened with all 7 OP compounds, while gradually reducing the substrate 
concentrations to screen specifically for improvements in kcat/KM. The more advanced 
rounds need to be performed at higher stringency to ensure the enrichment of 
significantly enhanced variants (Aharoni et al., 2005b). 
 Site saturation mutagenesis at positions Y28 (4.3.4.2) and Y97 (4.3.4.3.2) and 
combinatorial mutagenesis with mutations obtained by epPCR hits (4.3.4.4.2) was 
performed. The individual variants contained only a single or a few exchanges, and 
gave fold improvements at a maximum of one order of magnitude. The beneficial 
mutations were then combined in an iterative design process. 
 Following several rounds of mutagenesis the variant Dr0930_134 was obtained 
which showed 1.7 × 102 (MPXN) to 6.9 × 104 (VR p-NP) fold higher catalytic 
efficiencies relative to wild-type Dr0930 for the hydrolysis of p-NP analogues of G- 
and V-type nerve agents and phosphotriesters (Figure 50A). The catalytic efficiencies 
of Dr0930_134 ranged from 104-105 M-1s-1 and attributed to a slight decrease in the 
KM value for OP compounds and a substantial increase in kcat (Table 6; Table 25). 
The kcat/KM values for the hydrolysis of methylphosphonates VX p-NP, GB p-NP and 
VR p-NP are particularly high (>2 × 105 M-1s-1), and the catalytic efficiencies with 
phosphotriesters and methylphosphonates containing a bulky substituent (GD p-NP 
and GF p-NP) are only lower by one order of magnitude. Moreover, Dr0930_134 
approaches wild-type catalytic efficiencies for the GD p-NP substrate (approximately 
104 M-1s-1; Figure 50B). The result proves that the Dr0930 enzyme exhibits great 
plasticity and evolvability. 
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5.3.2 Detailed characterization of engineered Dr0930 variants 
 The engineered variants were characterized for their residual native lactonase 
activity (4.4.1), their ability to hydrolyze P-S in addition to P-O bonds (4.4.2), and the 
stereoselectivity of the OP hydrolysis (4.4.3). 
 The results showed that the substantial increase in promiscuous OPH activity is 
accompanied by an equally strong decrease of the native lactonase activity (4.4.1). 
Dr0930_134 retains a kcat/KM for the hydrolysis of δ-nonanoic lactone of 2.8 × 103    
M-1s-1, which corresponds to a fold decrease of 2.8 × 103 (Table 26; Figure 53), while 
the catalytic efficiencies for the hydrolysis of OPs increased by up to 6.9 × 104-fold, 
achieving absolute values of 105 M-1s-1 (Table 25; Figure 50A). Despite the partial 
trade-off, Dr0930_134 is a truly bifunctional enzyme exhibiting broad substrate 
specificity. Protein designs with both, weak and strong, trade-off have been reported 
(Aharoni et al., 2005a and references therein; Seebeck & Hilvert, 2003; Claren at al., 
2009). Noteworthy, the conservation of the native function was not a constraint of the 
screen, which only searched for improved OPH activity. Most likely, in the case 
reported here the structural flexibility of the βα-loops and the conservation of most 
residues important for positioning for the native substrate (R228, D264, F26, L231, 
V235, W287) allowed for the conservation of the native function (Figure 19A); 
however, the elimination of a crucial electrostatic interaction by the Y97F mutation 
and an enlargement of the active site lead to reduced catalytic efficiencies relative to 
the wild-type enzyme as binding and positioning of the lactone substate relative to 
the catalytic machinery might be less effective; at the same time the latter only then 
allowed for improved binding of OPs (4.4.4.2). 
 The dramatic improvement of the promiscuous OPH activity for a broad range of 
OPs prompted us to further investigate the substrate specificity of the engineered 
Dr0930 variants. They were tested for their ability to degrade the phosphorothiolate 
DEVX (Diethyl-VX), a close analogue of the real nerve agent VX (4.4.2). In spite of 
their high catalytic efficiencies for the hydrolysis of P-O bonds within the p-
nitrophenol analogues of VX, the kcat/KM values for the hydrolysis of the P-S bond of 
DEVX was only 1 M-1s-1. Noteworthy, the hydrolytic activity for DEVX did not increase 
in the course of the design. Although, phosphorothiolates are also hydrolyzed by PTE 
at significantly lower rates than methylphosphonates and phosphotriesters, the 
results also demonstrate, that p-nitrophenol analogues of VX and presumably also 
VR (P-O bond) are no faithful analgoues for the V-type nerve agents VX and VR (P-S 
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bond). In contrast, it has been demonstrated earlier, that activities with p-
acetylphenyl substituted analogues of GB and GD nerve agents (containing P-O 
bonds) and the original GB and GD nerve agents (containing P-F bonds) are 
comparable, confirming the analogues of G-type nerve agents to be faithful 
substrates (Tsai et al., 2010a). 
 Investigating the stereoselectivity of enzymes is particularly interesting, and 
several studies have been performed to enhance and inverse the inherent 
stereoselectivities of PTE (Tsai et al., 2010a/b; Nowlan et al., 2006; Hill et al., 2003; 
Chen-Goodspeed et al., 2001a/b; Li et al., 2001) and PON1 (Goldsmith et al., 2012). 
Hence, the stereoselectivities of wild-type Dr0930 and Dr0930_134 were monitored 
and compared with the stereoselectivity of PTE (4.4.3). The results showed that the 
Dr0930 variants exhibit the same stereopreference for the less toxic RP isomers of 
OPs 1-5 as wild-type PTE (Table 28), indicating that the relative orientation of the OP 
substrates in the substrate binding pocket is identical. Remarkably, the evolution of 
higher detoxification rates for the p-NP analogues of G- and V-type nerve agents was 
accompanied by an enhancement in Dr0930’s stereoselectivity (Table 29; Figure 55). 
The shift in enantiomeric preference [ratio kcat/KM (RP) / kcat/KM (SP)] between the 
wild-type enzyme and Dr0930_134 was high as 4.3 × 102-fold in the case of VR p-
NP. The highest enantiomeric preference of 1.5 × 104-fold was observed for GB p-
NP. Since the OP compounds were synthesized as racemates, their SP isomers were 
also present during screening. However, we observed no inhibition by the SP 
isomers.  
 Structural and computational analysis was performed to identify the structural 
basis for the enhanced OPH activity of the engineered Dr0930 variants. 
 Three variants including Dr0930_134 were successfully crystallized and their X-
ray structures were solved to a resolution of 1.78-2.05 Å (4.4.4.1). However, ligand 
complexed structures were not obtained. The variants exhibited only minor structural 
differences relative to wild-type Dr0930 (Figure 58). By the introduction of 6-7 
mutations the active site was enlarged and its hydrophobic character was increased, 
providing more suitable space to accommodate the OP substrates (Figure 59). 
Moreover, additional flexibility was gained due to the elimination of a hydrogen bond 
between residues of the βα-loops 2 and 3. Mesecar and co-workers described similar 
effects with their OPH enhanced Dr0930 variants (Hawwa et al., 2009b). From all 
PLL enzymes, only wild-type Dr0930 has been crystallized in the complexed 
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structure with an OP analogue. However, the complexed structure contained the 
small product analogue cacodylate, and hence allowed only to make a limited 
statement about the configurational and spatial orientation of OP substrates in the 
active site of Dr0930 (Hawwa et al., 2009b). A strong shift in substrate specificity 
accompanied by only minor structural modifications in the active site has also been 
reported by Poelarends and co-workers. In their recent study they re-designed the 
substrate specificity of methylaspartate ammonia lyase from Clostridium 
tetanomorphum to accept a varity of amines and fumarates and to catalyze the 
asymmetric synthesis of aspartic acid derivatives. Using single amino acid 
substitutions that enlarged the substrate binding pocket they widened the substrate 
scope of the enzyme for both amine and fumarate derivatives, achieving an up to 
70,000-fold shift in specificity (Raj et al., 2012). 
 In order to identify the orientation of EPXN in the active site of Dr0930_134, the 
substrate was docked using the RosettaLigand program (Davis & Baker, 2009). The 
docking program has been successfully applied in earlier designs for the docking of 
OPs and lactones in the metallo-enzymes adenosine deaminase and PON1 (Khare 
et al., 2012; Ben-David et al., 2012). Initially, retroperspective docking experiments 
with wild-type PTE using DIMP and EPXN were performed yielding docking poses 
that were essentially identical to poses observed by crystallization, and hence 
confirmed the validity of the docking models (4.4.5.1). Then, EPXN was docked into 
the active site of Dr0930_134. When no constraints were set, the phosphoryl oxygen 
of EPXN hydrogen bonded to the side chain of R228, indicating a potential 
electrostatic interaction to the substrate/intermediate. Constraints were set to enforce 
a metal-complexed pose as observed in the PTE crystal structures. The best poses 
obtained were similar to the pose of EPXN when docked into the active site of PTE 
(Figure 63) and confirmed site-directed mutagenesis experiments that have indicated 
an important role of residues F26 and R228 for OPH activity (4.3.4.4.1 and 4.3.3). 
F26 might be important for substrate positioning and R228, potentially being part of 
proton shuttling, might be important for the coordination and/or activation of the 
substrate and/or stabilization of the intermediate.  
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5.3.3 Comparison of design achievemens to state-of-the-art designs for 
OPH activity 
 The catalytic efficiency of OP hydrolysis by Dr0930_134 is substantial in terms of 
absolute numbers and significantly better when compared to previous designs with 
PLL enyzmes (Hawwa et al., 2009b; Elias et al., 2008; Merone et al., 2010) and the 
de novo design for OPH activity (Khare et al., 2012). Moreover, the presented 
achievements are comparable to the designs made with a more efficient OP-
hydrolyzing enzyme such as the lactonase PON1 (see also 1.2.2; Gupta et al., 2011; 
Goldsmith et al., 2012). 
 Mesecar and co-workers and Chabriere and co-workers made only modest 
achievements with the design of the PLL enzymes, Dr0930 and SsoPox, for the 
hydrolysis of MPXN and EPXN (Hawwa et al., 2009b; Elias et al., 2008; Merone et 
al., 2010). The best published design for Dr0930 achieves a fold-improvement of only 
1.8 × 102 and 5.6 × 102 for MPXN and EPXN and absolute values of kcat/KM are 
1.1 × 102 M-1s-1 and 7.7 × 102 M-1s-1, respectively (Hawwa et al., 2009b; our data 
confirmed a fold-improvement of only 65-fold for EPXN for their best variant – see 
4.3.4.1). The highest fold improvement in kcat/KM published for SsoPox is 6.5-fold for 
EPXN (Elias et al., 2008; Merone et al., 2010). 
 The achievements made by Tawfik and Baker for the design of OPH activity of 
PON1 are more significant. Tawfik and co-workers optimized PON1 for hydrolysis of 
fluorogenic coumarinyl analogue of SP-GF and in-situ generated SP-GF. Excessive 
mutagenesis and a FACS-based high-throughput screen yielded a variant with a 
8.6 × 104-fold improvement in catalytic efficiency (kcat/KM increased from 3.3 M-1s-1 to 
2.9 × 105 M-1s-1) for the SP-isomer of the GF analogue. The fold improvement for SP-
GF was significantly lower with only 1.4 × 102 compared to wild-type-like PON1 
(Gupta et al., 2011). In their latest design, Tawfik and co-workers enhanced the 
activity of a PON1 variant by re-optimizing earlier identified active-site residues for 
the hydrolysis of in-situ generated GD isomers by up to 3.4 × 102 fold in kcat/KM 
compared to the starting variant and 3.4 × 103 fold compared to wild-type-like PON1. 
However, improvements for other G-type agents isomers, GA, GB, and GF were 
significantly smaller, achieving only one order of magnitude fold-improvement 
compared to the starting variant (Goldsmith et al., 2012).  
 Baker and co-workers computationally redesigned a mononuclear zinc metallo-
enzyme, the mouse adenine deaminase, for organophosphate hydrolysis. After 
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optimization by subsequent directed evolution they achieved a catalytic efficiency of 
9.8 × 103 M-1s-1 for one single substrate, the RP-isomer of the coumarinyl analogue of 
GF. However, the authors noticed that their designed variant hydrolyzes only 
substrates with coumarinyl leaving group but not p-NP substituted substrates (Khare 
et al., 2012). 
 In this work an extremely efficient OPH was designed, which hydrolyzes not only 
a broad spectrum of methylphosphonates (G and V-type nerve agent analogues), but 
also phosphotriesters. The catalytic efficiency for the hydrolysis of OPs by Dr0930 
has been improved by 1.7 × 102 to 6.9 × 104 -fold thereby reaching kcat/KM values of 
3.6 × 105 M-1s-1. The absolute values in kcat/KM approach the level of natural enzymes 
(Bar-Even et al., 2011) and wild-type PTE (Figure 50B). To the best of our 
knowledge, designs yielding comparable high fold improvements and catalytic 
efficiencies for multiple substrates have not been described previously. 
 
5.4 Implications for protein design and evolution 
 Taken together, the results of this thesis show that laboratory evolution can 
readily establish high OPH activity on the scaffold of Dr0930, providing strong 
evidence for the postulated natural evolution of PTE from members of the PLL family. 
Most noteworthy, only three mutations were sufficient to substantially alter the 
substrate specificity of Dr0930 and to achieve catalytic efficiencies as high as 
1.4 × 103 M-1s-1 (Dr0930_5; Table 10). Hence, the results underline the catalytic 
versatility of the ubiquitous (βα)8-barrel fold (Sterner & Höcker, 2005). However, the 
results here (4.3.4.3.1.1; 4.3.4.3.1.2; 4.3.4.4.1) and in Xiang et al. (2009) 
demonstrate that the efficient OPH activity cannot be increased by simply structurally 
miminking the active site and substrate binding pocket of PTE. 
 Analogously to the rapid molecular evolution of PTE from a PLL precursor, the 
methyl-parathion hydrolase (MPH) from Pseudomonas sp. WBC-3 (1.2.2; an OPH 
enzyme with a β-lactamase fold) is speculated to have evolved by divergent evolution 
from Bacillus thuringiensis AiiA, a metallo-β-lactamase-like lactonase. However, the 
postulated evolutionary origin of the MPH is as yet based soley on sequence 
similarity, and detailed kinetic studies for this case of divergent evolution remain to be 
done (Elias & Tawfik, 2012). 
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5.5 Outlook 
 Testing the engineered Dr0930 variants for a broader substrate scope using 
another class of OPs, such as thiophosphotriesters (e.g. diazinon, parathion and 
chlorpyrifos), would be interesting. Also, characterization of the most proficient 
Dr0930 variants for the true nerve agents using an assay developed by Tawfik and 
co-workers where nerve agents are generated in situ in dilute aqueous solutions 
(Gupta et al., 2011) or analysis by an accredited laboratory might be scientifically 
interesting. Moreover, reversing the stereoselectivity of the designed variants for the 
more toxic SP-isomers as described for PTE (Tsai et al., 2010a/b; Nowlan et al., 
2006; Hill et al., 2003; Chen-Goodspeed et al., 2001a/b; Li et al., 2001) and PON1 
(Gupta et al., 2011; Goldsmith et al., 2012) would be attractive. 
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7 APPENDIX 
 
7.1 DNA and protein sequences of wild-type Dr0930 and wild-type 
PTE  
7.1.1 DNA and protein sequences of Deinococcus radiodurans R1 
Dr0930 
 
dr0930 DNA sequence: 
  1 ATGACGGCAC AGACGGTGAC GGGCGCAGTC GCGGCGGCTC AACTCGGAGC 
 51 GACGCTGCCC CACGAACACG TGATTTTCGG CTACCCCGGC TACGCGGGCG 
101 ACGTGACGCT CGGGCCATTC GACCACGCGG CAGCGCTCGC AAGCTGCACC 
151 GAAACGGCGC GGGCGCTGCT GGCGCGCGGT ATTCAGACGG TGGTGGACGC 
201 CACCCCCAAC GACTGCGGAC GCAACCCGGC CTTCCTGCGC GAGGTGAGCG 
251 AGGCAACCGG CCTCCAGATT CTGTGCGCGA CCGGCTTTTA TTACGAGGGC 
301 GAGGGCGCCA CGACCTACTT CAAGTTCCGC GCTTCTCTGG GTGACGCCGA 
351 AAGCGAAATC TACGAGATGA TGCGGACCGA GGTGACCGAG GGCATCGCCG 
401 GCACCGGCAT CCGCGCCGGG GTCATCAAGC TGGCGAGCAG CCGCGACGCC 
451 ATCACCCCCT ACGAGCAACT GTTTTTCCGG GCGGCGGCGC GGGTGCAGCG 
501 CGAAACCGGC GTGCCGATCA TCACCCACAC TCAGGAAGGC CAGCAGGGAC 
551 CGCAGCAAGC CGAGCTGCTG ACCTCGCTCG GCGCGGACCC GGCGCGCATC 
601 ATGATCGGGC ACATGGACGG CAACACCGAC CCGGCCTACC ACCGCGAGAC 
651 GCTGCGCCAC GGCGTGAGCA TCGCCTTTGA CCGCATCGGC TTGCAGGGCA 
701 TGGTGGGCAC CCCCACCGAC GCCGAGCGGC TAAGCGTGCT GACCACGCTG 
751 CTCGGCGAGG GCTACGCCGA CCGGCTGCTG CTCTCGCACG ACAGCATCTG 
801 GCACTGGCTG GGACGCCCGC CGGCCATCCC CGAAGCCGCC TTGCCCGCCG 
851 TCAAGGACTG GCACCCTCTC CACATCTCCG ACGACATCTT GCCTGATCTG 
901 CGGCGCCGGG GCATCACCGA GGAGCAGGTG GGGCAGATGA CGGTGGGCAA 
951 CCCGGCCCGG CTGTTCGGGT AA 
 
Dr0930 protein sequence: 
  1 MTAQTVTGAV AAAQLGATLP HEHVIFGYPG YAGDVTLGPF DHAAALASCT 
 51 ETARALLARG IQTVVDATPN DCGRNPAFLR EVSEATGLQI LCATGFYYEG 
101 EGATTYFKFR ASLGDAESEI YEMMRTEVTE GIAGTGIRAG VIKLASSRDA 
151 ITPYEQLFFR AAARVQRETG VPIITHTQEG QQGPQQAELL TSLGADPARI 
201 MIGHMDGNTD PAYHRETLRH GVSIAFDRIG LQGMVGTPTD AERLSVLTTL 
251 LGEGYADRLL LSHDSIWHWL GRPPAIPEAA LPAVKDWHPL HISDDILPDL 
301 RRRGITEEQV GQMTVGNPAR LFG* 
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7.1.2 DNA and protein sequences of Pseudomonas diminuta PTE 
 
pte DNA sequence: 
   1 ATGTCCATCG GGACCGGTGA CCGTATCAAC ACCGTTCGTG GGCCCATCAC 
  51 CATCTCCGAA GCTGGTTTCA CCCTGACCCA CGAACACATC TGCGGTTCCT 
 101 CCGCGGGTTT CCTGCGTGCT TGGCCGGAGT TTTTCGGTTC CCGTAAAGCT 
 151 CTGGCTGAAA AAGCTGTTCG TGGTCTGCGT CGTGCTCGTG CTGCAGGTGT 
 201 TCGTACCATC GTTGACGTTT CCACCTTCGA CATCGGCCGT GACGTTTCCC 
 251 TGCTGGCTGA AGTTTCCCGT GCTGCTGATG TACACATCGT TGCTGCTACC 
 301 GGTCTGTGGT TCGACCCGCC GCTGAGCATG CGTCTGCGTT CCGTTGAAGA 
 351 ACTGACCCAG TTCTTCCTGC GTGAAATCCA GTACGGTATC GAAGACACCG 
 401 GGATCCGTGC TGGTATCATC AAAGTTGCTA CCACCGGTAA AGCTACCCCG 
 451 TTCCAGGAGC TCGTTCTGAA AGCTGCTGCT CGTGCTTCCC TGGCTACCGG 
 501 GGTCCCGGTT ACCACCCACA CCGCTGCTAG CCAGCGTGAC GGTGAACAGC 
 551 AGGCTGCTAT CTTCGAATCC GAAGGTCTGT CCCCGTCACG CGTTTGCATC 
 601 GGTCACTCCG ACGACACCGA CGACTTAAGC TACCTGACCG CTCTGGCTGC 
 651 TCGTGGGTAC CTGATCGGTC TGGACCACAT CCCGCACTCC GCTATCGGTC 
 701 TGGAAGACAA TGCATCCGCT TCCGCTCTGC TGGGTATCCG TTCCTGGCAG 
 751 ACCCGTGCTC TGCTGATCAA AGCTCTGATC GACCAGGGTT ACATGAAACA 
 801 GATCTTGGTT TCCAACGACT GGCTGTTCGG TTTCTCGAGC TACGTTACCA 
 851 ACATCATGGA CGTTATGGAC CGTGTTAACC CGGACGGTAT GGCTTTCATC 
 901 CCGCTGCGTG TTATCCCGTT CCTGCGTGAA AAAGGTGTTC CGCAGGAAAC 
 951 CCTGGCTGGT ATCACCGTTA CCAACCCGGC TCGTTTCCTG TCCCCGACCC 
1001 TGCGTGCTTC CTGA 
 
PTE protein sequence: 
   1 MSIGTGDRIN TVRGPITISE AGFTLTHEHI CGSSAGFLRA WPEFFGSRKA 
  51 LAEKAVRGLR RARAAGVRTI VDVSTFDIGR DVSLLAEVSR AADVHIVAAT 
 101 GLWFDPPLSM RLRSVEELTQ FFLREIQYGI EDTGIRAGII KVATTGKATP 
 151 FQELVLKAAA RASLATGVPV TTHTAASQRD GEQQAAIFES EGLSPSRVCI 
 201 GHSDDTDDLS YLTALAARGY LIGLDHIPHS AIGLEDNASA SALLGIRSWQ 
 251 TRALLIKALI DQGYMKQILV SNDWLFGFSS YVTNIMDVMD RVNPDGMAFI 
 301 PLRVIPFLRE KGVPQETLAG ITVTNPARFL SPTLRAS* 
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7.2 Structure of various substrates for PLL enzymes and PTE 
 The structures of substrates for PLL enzymes and PTE listed in Table 4 are 
shown in Figure 65. 
 
 
Figure 65: Structures of substrates of PLL enzymes and PTE: lactones and esters (A) and OPs 
(B).  
A: Structures of lactones and esters: γ-/δ-lactone (R: alkyl side chain), TBBL (5-thiobutyl-γ-
butyrolactone), HSL (homoserine lactone; R’: alkyl side chain with or without 3-oxo group), and 2NA 
(2-naphthyl acetate). The cleaved C-O bond is highlighted in red. 
B: Structures of OP compounds: diazinon, chlorpyrifos, methyl- and ethyl-parathion, methyl- and ethyl-
paraoxon (MPXN and EPXN), and coumaphos. The cleaved P-O bond is highlighted in red. 
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7.3 Determination of the conversion factor ɛ577 for the pH-
dependent colorimetric assay 
 The conversion factor ɛ577 (change of absorbance A577 per change in proton 
concentration, ɛ577 = 1.17 × 103 M-1cm-1) was determined by in-situ calibration with 
acetic acid (see Figure 66). 
 
 
Figure 66: Determination of the conversion factor ɛ577 for the pH-dependent colorimetric assay.  
In-situ calibration with acetic acid gave a conversion factor ɛ577 of 1.17 × 103 M-1cm-1 (linear fit). The 
reactions were performed in 2.5 mM BICINE (initial pH: 8.3), 0.1 mM CoCl2, 1.4% DMSO, 0.1 mM m-
cresol purple, 0.2 M NaCl and variable concentration of acetic acid (0-1 mM).  
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7.4 Determination of the enzyme metal content by ICP-MS 
 The metal content determined by ICP-MS for the Dr0930 and PTE enzyme 
preparations are listed in Table 32. 
 
Table 32:  Metal content determined by ICP-MS. 
variant metal content determined by ICP-MS 
wild-type Co/Co-PTE  1.2 eq. Co, 0.1 eq. Zn 
wild-type Co/Co-Dr0930  0.6-1.2 eq. Co, 0-0.12 eq. Zn, up to 0.23 eq. Fe 
wild-type Zn/Zn-Dr0930  0.71 eq. Zn, 0.52 eq. Fe  
wild-type Mn/Mn-Dr0930  2.15 eq. Mn, 0.14 eq. Zn, 0.28 eq. Fe 
Co/Co-Dr0930_5 0.85 eq. Co, 0.44 eq. Zn, 0.02 eq. Fe 
Co/Co-Dr0930_16 1.41 eq. Co, 0.28 eq. Zn, 0.02 eq. Fe 
Co/Co-Dr0930_22 1.1 eq. Co, 0.13 eq. Zn, 0.03 eq. Fe 
Co/Co-Dr0930_30 1.21 eq. Co 
Co/Co-Dr0930_31 1.22 eq. Co, 0.09 eq. Zn 
Co/Co-Dr0930_32 1.4 eq. Co, 0.06 eq Zn 
Co/Co-Dr0930_70 1.24 eq. Co, 0.1 eq. Zn 
Co/Co-Dr0930_73 1.33 eq. Co, 0.08 eq. Zn, 0.02 eq Fe 
Co/Co-Dr0930_81 1.07 eq. Co 
Co/Co-Dr0930_83 1.28 eq.Co 
Co/Co-Dr0930_93 1.39 eq. Co 
Co/Co-Dr0930_106 1.33-1.58 eq. Co 
Co/Co-Dr0930_134 1.05-1.44 eq. Co 
Abbreviation: eq.: equivalents of metal ion per enzyme subunit. An interval is given for multiple 
enzyme preparations. 
Dr0930_5: Dr0930-T2Q+D71N+E179D+L270M. Dr0930_16: Dr0930-A3T+G38R+T105S. Dr0930_22: 
Dr0930-E101K+T105S. Dr0930_30: Dr0930-F26V+Y28I+D71G+C72I+E101M+Q178S+V235L+L270I. 
Dr0930_31: Dr0930-F26C+Y28I+D71A+E101N+Q178S+E179D+V235I. Dr0930_32: Dr0930-F26C+ 
Y28I+D71G+E101D+Q178S+V235L+L270V. Dr0930_70: Dr0930-D71G+E101G+V235L. Dr0930_73: 
Dr0930-D71N+E101G+E179D+V235L+L270M. Dr0930_81: Dr0930-Y28L+D71N+E101G+E179D+ 
V235L+L270M. Dr0930_83: Dr0930-Y28L+D71N+E101G+E179D+M235I+L270M. Dr0930_93: 
Dr0930-Y28L+D71N+Y97I+E101G+E179D+V235L+L270M. Dr0930_106: Dr0930-Y28L+D71N+ 
Y97F+E101G+E179D+V235L+ L270M. Dr0930_134: Dr0930-Y28L+D71N+Y97F+E101G+E179D+ 
V235L+P274L. 
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7.5 Sequence of most active Dr0930 variants isolated from the 
pTNA-dr0930-SHM library 
 The Dr0930 variants isolated from the SHM library are listed in Table 33. 
 
Table 33: Most active variants isolated from pTNA-dr0930-SHM library. 
Dr0930_#: mutations 
30: F26V+Y28I+D71G+C72I+E101M+Q178S+V235L+L270I 
31: F26C+Y28I+D71A+E101N+Q178S+E179D+V235I 
32: F26C+Y28I+D71G+E101D+Q178S+V235L+L270V 
33: F26I+Y28I+D71G+C72I+E101N+Q178S+E179D+V235I+L270V 
34: F26V+Y28I+D71G+C72I+E101G+Q178S+E179D+V235M 
35: F26I+Y28I+D71N+ E101G+Q178T+E179D+V235I+L270R 
36: F26V+Y28A+D71L+E101G+Q178S+E179D+V235I+L270V 
37: F26C+Y28V+D71G+E101C+Q178S+V235I+L270V 
38: F26I+Y28T+D71N+C72I+E101N+V235L+L270V 
39: F26C+Y28T+D71G+C72I+E101S+E179D+V235L 
40: F26V+Y28I+D71G+C72I+E101V+Q178S+V235I+L270V 
41: F26C+Y28I+D71L+E101M+Q178S+E179D+V235I+L270V 
42: F26C+Y28V+D71N+C72I+E101N+E179D+V235I+L270V 
43: F26C+Y28I+D71M+C72I+E101S+E179D+V235L+L270I 
44: F26C+Y28T+D71N+E101S+E179D+V235L+L270V 
45: F26C+Y28I+D71V+E101A+V235L 
46: F26C+Y28T+D71N+E101K+Q178S+V235I 
47: F26I+Y28I+D71G+E101S+Q178S+V235I+L270V 
48: F26I+Y28I+D71N+E101G+Q178S+V235I+L270A 
49: F26C+Y28I+D71M+E101D+Q178S+E179D+V235M+L270V 
50: F26C+Y28I+D71V+E101C+Q178S+E179D+V235I 
51: F26C+Y28I+D71A+E101L+Q178S+E179D+V235L+L270A 
52: F26C+Y28I+D71L+E101V+Q178S+V235M+L270V 
53: Y28I+D71L+C72I+E101V+V235L+L270I 
54: F26V+Y28I+D71G+E101L+Q178S+V235I+L270I 
55: F26C+Y28I+D71M+E101N+Q178S+V235I+L270I 
56: F26C+Y28I+D71L+E101S+Q178S+E179D+V235L 
57: F26C+Y28I+D71M+E101M+Q178S+V235I 
Dr0930 variants contain the T2Q mutation.  
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7.6 Dixon Plot for determination of Ki 
 The Dixon plot is used to determine the dissociation constant (Ki) for an enzyme-
inhibitor complex. The substrate analogue DIMP is a competitive inhibitor for GB p-
NP (OP 2). The initial velocity of GB p-NP hydrolysis ([S] = KMGB p-NP = 0.19 mM) 
recorded in presence of various concentrations of DIMP (0-500 mM) yielded a 
competitive inhibition constant, Ki, for Dr0930_134 of 9.5 mM (Figure 67). 
 
 
Figure 67: Dixon plot to determine Ki for DIMP and Dr0930_134. 
The reactions were performed in 50 mM CHES, pH 9.0, 100 µM CoCl2, 0.19 mM GB p-NP and various 
concentrations of DIMP (0-500 mM). The reaction was monitored at 400 nm (ɛ400 = 1.7 × 104 M-1cm-1) 
and 30 °C. Dr0930_134 was diluted in 20 mM HEPES pH 7.5, 100 µM CoCl2 buffer supplemented with 
1 mg/ml BSA in order to stabilze the protein at high dilutions. BSA has no influence on activity (data 
not shown). Reactions were performed with 3 nM enzyme concentration. 
The solid line shows the result of a linear fit of the data points (SigmaPlot). The Ki value is determined 
using Equation 12, giving a value of 9.5 mM. The slope intersects at y=0 at a concentration of              
-15.6 mM DIMP (~Ki), confirming that DIMP is a competitive inhibitior for GB p-NP. Dr0930_134: 
Dr0930-Y28L+D71N+Y97F+E101G+E179D+V235L+P274L. 
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